<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="chapter-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><?noissn?><journal-meta><journal-id journal-id-type="nlm-ta">Stiehm's Immune Deficiencies</journal-id><journal-title-group><journal-title>Stiehm's Immune Deficiencies</journal-title></journal-title-group></journal-meta><article-meta><article-id pub-id-type="pmcid">7258708</article-id><article-id pub-id-type="publisher-id">B978-0-12-816768-7.00049-1</article-id><article-id pub-id-type="doi">10.1016/B978-0-12-816768-7.00049-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Infections that cause secondary immune deficiency</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Bonagura</surname><given-names>Vincent Robert</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Rosenthal</surname><given-names>David Walter</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><aff id="aff1"><label>a</label>Center for Immunology and Inflammation, The Feinstein Institute for Medical Research, NY, NY, United States</aff><aff id="aff2"><label>b</label>Departments of Pediatrics, Internal Medicine, and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, NY, NY, United States</aff><aff id="aff3"><label>c</label>Departments of Internal Medicine and Pediatrics, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, NY, NY, United States</aff></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Sullivan</surname><given-names>Kathleen E.</given-names></name></contrib><aff>Professor of Pediatrics, Division of Allergy Immunology, University of Pennsylvania School of Medicine, Children&#x02019;s Hospital of Philadelphia, Philadelphia, PA, United States</aff></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Stiehm</surname><given-names>E. Richard</given-names></name></contrib><aff>Chief, Division of Immunology/Allergy, UCLA Department of Pediatrics</aff><aff>Professor of Pediatrics, University of California School of Medicine, Los Angeles, CA, United States</aff></contrib-group><pub-date pub-type="pmc-release"><day>29</day><month>5</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><year>2020</year></pub-date><pub-date pub-type="epub"><day>29</day><month>5</month><year>2020</year></pub-date><fpage>1035</fpage><lpage>1058</lpage><permissions><copyright-statement>Copyright &#x000a9; 2020 Elsevier Inc. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier Inc.</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="abs0010"><p>Discriminating between patients with microbial infections that cause secondary immune effects from those with the same infection who have primary immune deficiency disease can be difficult. There are many microbes that temporarily &#x0201c;stun&#x0201d; innate and/or adaptive immunity during a primary infection. The common result of temporary inhibition, or permanent depletion of host immunity during some primary infections is the development of superinfections of other microbes that cause significant morbidity, and on occasion, mortality. In addition, microbes that cause persistent infection, such as the human immune deficiency virus, deplete effective immunity over time and can also lead to secondary infections with other microbes ultimately leading to death if not appropriately treated. In some cases, such as influenza virus infection, mortality can be dramatic due in large part to acquired secondary bacterial infections. Many microbes manipulate host immunity and thereby inhibit the ability of patients to combat secondary microbial infections. The overall survival of patients primarily infected with some viruses, parasites, or bacteria, is closely linked to the ability of secondary infections to take advantage of the immune modulation induced by the primary infection. Herein we discuss some of the secondary immune defects caused by select viruses (measles, influenza, HIV1, HTLV), parasites, (leishmania, malaria), and bacteria (<italic>Bordetella pertussis</italic>). Furthermore, the genetic susceptibility of a given host to become infected, or develop severe disease, also determines whether an infected individual who becomes infected with a secondary microbe survives. Future studies are needed to explore not only the immunomodulation caused by select microbes, but also the repertoire of immune responses expressed by infected individuals in order to predict clinical outcomes of these infections. Thus, understanding the delicate balance that exists between &#x0201c;immune altering&#x0201d; microbes that suppress immune responses during primary infections leading to severe secondary infections versus those infections found in patients with inborn errors of innate or adaptive immunity, is essential in predicting the clinical outcome and the appropriate treatment for these two different patient populations.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Secondary immune deficiency</kwd><kwd>Measles</kwd><kwd>Influenza</kwd><kwd>HIV</kwd><kwd>HTLV</kwd><kwd>Leishmania</kwd><kwd>Malaria</kwd><kwd>Pertussis</kwd><kwd>Sepsis</kwd><kwd>Infection</kwd><kwd>Infectious</kwd></kwd-group></article-meta></front><body><sec id="s0010"><title>Introduction</title><p id="p0295">Immune deficiencies can be subdivided into two categories: primary or secondary. This chapter describes secondary defects related to infection, and other forms of secondary immunodeficiency are described elsewhere in this book. Some microbes manipulate or exhaust effector immune responses, leading to secondary infections by other microbes. While the manipulation or exhaustion of immune responses is an important defense mechanism of some microbes to evade effective immune clearance, it is also likely that the genetic immune response repertoire that programs how an infected individual will respond to these microbes contributes significantly to whether the resulting immune responses will protect against, or facilitate, superinfection by other microbes. In this chapter, we discuss how some microbes manipulate or, in the case of the human immune deficiency virus (HIV), exhaust protective innate and/or adaptive immunity, ultimately leading to severe microbial superinfections by other infectious organisms that cause significant morbidity and, on occasion, mortality from secondary infections.</p><p id="p0300">A critical component of host defense includes the expression of immunosuppressive cytokines. IL-10, and TGF-&#x003b2;, and the generation of regulatory T&#x000a0;cells that can express these cytokines serve to limit the immune-mediated damage related to host defense. These same elements also cause secondary immune deficiency by suppressing or blocking effector Th1-like responses. These immunoregulatory elements, generated in response to the original infection, as a consequence, can lead to secondary immune deficiency and the development of severe or fatal infection with other microbes. Some of the microbes that cause temporary or permanent changes in immune responses to other organisms are shown in <xref rid="t0010" ref-type="table">Table&#x000a0;49.1</xref>
(see below). In addition, <xref rid="f0010" ref-type="fig">Fig.&#x000a0;49.1</xref>
shows the functional diversity of CD4<sup>+</sup> T&#x000a0;cells that has evolved to control the microbiome present on mucosal surfaces. In concert with the repertoire of these T&#x000a0;cells, and the cytokines and chemokines that they express, the continuum of macrophages (<xref rid="f0015" ref-type="fig">Fig.&#x000a0;49.2</xref>
)<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> and their respective cytokine/chemokine repertoires expressed in response to microbial infection, form the critical immune response elements that are required to mount and maintain an effective immune response against these microbes.<table-wrap position="float" id="t0010"><label>Table&#x000a0;49.1</label><caption><p>Microbes that cause secondary immune deficiency states.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Microbe</th><th>Affected immunocyte</th><th>Immune dysregulation phenotype</th><th>Pathogens causing secondary infection</th><th>Abnormal lab tests associated with microbe infection</th></tr></thead><tbody><tr><td colspan="5">Viruses:</td></tr><tr><td>Measles</td><td>T Cells<break/>Dendritic cells</td><td><list list-type="simple" id="olist0010"><list-item id="o0010"><label>(1)</label><p id="p0010">Diminished lymphocyte proliferation</p></list-item><list-item id="o0015"><label>(2)</label><p id="p0015">Decreased antibody production</p></list-item><list-item id="o0020"><label>(3)</label><p id="p0020">Increased susceptibility to co-infection or super-infection with viral, bacterial or fungal pathogens</p></list-item></list></td><td><list list-type="simple" id="olist0015"><list-item id="o0025"><label>(1)</label><p id="p0025">Viral: Herpes simplex, cytomegalovirus, parainfluenza, adenovirus, coxsackie, respiratory syncytial virus</p></list-item><list-item id="o0030"><label>(2)</label><p id="p0030">Bacteria: <italic>S.&#x000a0;aureus</italic>, S. pneumonia, Klebsiella, Pseudomonas, mycobacteria, Acinetobacter</p></list-item><list-item id="o0035"><label>(3)</label><p id="p0035">fungal: Candida</p></list-item></list></td><td><list list-type="simple" id="olist0020"><list-item id="o0040"><label>(1)</label><p id="p0040">Anti-measles IgM</p></list-item><list-item id="o0045"><label>(2)</label><p id="p0045">Mitogen/Lymphocyte Proliferation Assay</p></list-item><list-item id="o0050"><label>(3)</label><p id="p0055">Lymphocyte profile (T/B/NK cell immunocyte counts)</p></list-item></list></td></tr><tr><td>Influenza A Virus</td><td>Neutrophils</td><td><list list-type="simple" id="olist0025"><list-item id="o0055"><label>(1)</label><p id="p0060">Deactivation of chemotaxis, respiratory burst, degranulation, and bacterial killing</p></list-item><list-item id="o0060"><label>(2)</label><p id="p0065">IFNs-&#x003b3;, -&#x003b1;, -&#x003b2; triggered by IAV depresses macrophage function and macrophage scavenger receptor (MARCO)</p></list-item><list-item id="o0065"><label>(3)</label><p id="p0070">Impaired murine chemokine recruitment of neutrophils to the lung</p></list-item></list></td><td><list list-type="simple" id="olist0030"><list-item id="o0070"><label>(1)</label><p id="p0075">Bacteria: Streptococcal pneumoniae, Staphylococcal (MRSA), Haemophilus influenzae pneumonia post Influenza A Virus infection</p></list-item></list></td><td><list list-type="simple" id="olist0035"><list-item id="o0075"><label>(1)</label><p id="p0080">PCR-based influenza assay</p></list-item><list-item id="o0080"><label>(2)</label><p id="p0085">complete blood count with manual differential</p></list-item></list></td></tr><tr><td>Human Immune deficiency Virus (HIV)</td><td>CD4<sup>+</sup> cells (T cells, macrophages)</td><td>Depletion of CD4<sup>+</sup> T&#x000a0;cells over time</td><td>Opportunistic infections: Bacteria, fungi, parasites</td><td><list list-type="simple" id="olist0040"><list-item id="o0085"><label>(1)</label><p id="p0090">4<sup>th</sup> generation HIV-1/2 Ag/Ab Assay</p></list-item><list-item id="o0090"><label>(2)</label><p id="p0095">Lymphocyte count (T/B/NK immunophenotype)</p></list-item></list></td></tr><tr><td>Human T&#x000a0;cell Lymphotropic Virus (HTLV)</td><td>T cells, NK cells</td><td><list list-type="simple" id="olist0045"><list-item id="o0095"><label>(1)</label><p id="p0100">induces cytotoxic T cells to kill virus-infected cells,</p></list-item><list-item id="o0100"><label>(2)</label><p id="p0105">alter CD4<sup>+</sup> T&#x000a0;cell function and cytokine production</p></list-item><list-item id="o0105"><label>(3)</label><p id="p0110">decreases NK cell activation</p></list-item></list></td><td>Strongyloides schistosomiasis</td><td><list list-type="simple" id="olist0050"><list-item id="o0110"><label>(1)</label><p id="p0115">HTLV-1 and HTLV-2 IgG/IgM</p></list-item><list-item id="o0115"><label>(2)</label><p id="p0120">Lymphocyte count (T/B/NK immunophenotype)</p></list-item></list></td></tr><tr><td>Cytomegalovirus</td><td>T Cells</td><td><list list-type="simple" id="olist0055"><list-item id="o0120"><label>(1)</label><p id="p0125">lower frequency of na&#x000ef;ve T&#x000a0;cells and accumulation of memory T&#x000a0;cells</p></list-item><list-item id="o0125"><label>(2)</label><p id="p0130">immune senescence</p></list-item></list></td><td>Rare secondary bacterial/viral super infection</td><td><list list-type="simple" id="olist0060"><list-item id="o0130"><label>(1)</label><p id="p0135">CMV PCR</p></list-item><list-item id="o0135"><label>(2)</label><p id="p0140">CMV IgG</p></list-item><list-item id="o0140"><label>(3)</label><p id="p0145">Lymphocyte count (T/B/NK immunophenotype)</p></list-item></list></td></tr><tr><td>Epstein-Barr Virus</td><td>B Cells</td><td><list list-type="simple" id="olist0065"><list-item id="o0145"><label>(1)</label><p id="p0150">Depletion of B cells (X-linked lymphoproliferative syndrome (XLP))</p></list-item><list-item id="o0150"><label>(2)</label><p id="p0155">Monoclonal/polyclonal gammopathy</p></list-item><list-item id="o0155"><label>(3)</label><p id="p0160">Autoimmunity</p></list-item><list-item id="o0160"><label>(4)</label><p id="p0165">Cancer</p></list-item></list></td><td>Parvoviridae, Streptococcus group A.</td><td><list list-type="simple" id="olist0070"><list-item id="o0165"><label>(1)</label><p id="p0170">EBV DNA by PCR</p></list-item><list-item id="o0170"><label>(2)</label><p id="p0175">Heterphile Ab</p></list-item><list-item id="o0175"><label>(3)</label><p id="p0180">EBV Serology (EBV Viral capsid IgG/IgM, EBV early Antigen, EBV Nuclear Antigen)</p></list-item><list-item id="o0180"><label>4)</label><p id="p0185">Lymphocyte count (T/B/NK immunophenotype)</p></list-item></list></td></tr><tr><td colspan="5">Parasites:</td></tr><tr><td>Leishmania</td><td>Macrophages</td><td><list list-type="simple" id="olist0075"><list-item id="o0185"><label>(1)</label><p id="p0190">Decreased MHC class II expression</p></list-item><list-item id="o0190"><label>(2)</label><p id="p0195">Decreased IL-1 production</p></list-item></list></td><td>Bacteria that cause infection in patients with chronic granulomatous disease.</td><td><list list-type="simple" id="olist0080"><list-item id="o0195"><label>(1)</label><p id="p0200">Visualization of amastigote in smears or tissue (histopathology)</p></list-item><list-item id="o0200"><label>(2)</label><p id="p0201">parasite isolation by <italic>in&#x000a0;vitro</italic> culture</p></list-item><list-item id="o0205"><label>(3)</label><p id="p0210">molecular detection of parasite DNA</p></list-item><list-item id="o0210"><label>(4)</label><p id="p0215">serologic testing</p></list-item></list></td></tr><tr><td>Malaria</td><td>T Cells<break/>Dendritic cells</td><td><list list-type="simple" id="olist0085"><list-item id="o0215"><label>(1)</label><p id="p0220">Impaired dendritic cell maturation and activation</p></list-item><list-item id="o0220"><label>(2)</label><p id="p0225">Increased susceptibility to co-infection with viral and bacterial pathogens</p></list-item><list-item id="o0225"><label>(3)</label><p id="p0230">Decreased efficacy of heterologous vaccines</p></list-item><list-item id="o0230"><label>(4)</label><p id="p0235">Reactivation of existing Epstein-Barr infection, with increased susceptibility to develop lymphoma</p></list-item></list></td><td><list list-type="simple" id="olist0090"><list-item id="o0235"><label>(1)</label><p id="p0240">viral: Herpes zoster, hepatitis B, Moloney leukemia virus, Epstein-Barr virus</p></list-item><list-item id="o0240"><label>(2)</label><p id="p0245">bacterial: Salmonella</p></list-item></list></td><td><list list-type="simple" id="olist0095"><list-item id="o0245"><label>(1)</label><p id="p0250">Light microscopy - Giemsa stained blood smears</p></list-item><list-item id="o0250"><label>(2)</label><p id="p0255">Rapid diagnostic test &#x02013; antigen based assay (HRP2, pLDH, aldolase)</p></list-item><list-item id="o0255"><label>(3)</label><p id="p0260">PCR based confirmation for research and epidemiological uses</p></list-item><list-item id="o0260"><label>(4)</label><p id="p0265">Lymphocyte count (T/B/NK immunophenotype)</p></list-item></list></td></tr><tr><td colspan="5">Bacteria:</td></tr><tr><td><italic>Bordetella Pertussis</italic></td><td>Airway macrophages, neutrophils</td><td><list list-type="simple" id="olist0100"><list-item id="o0265"><label>(1)</label><p id="p0270">Delay of neutrophil recruitment and influx into airways</p></list-item><list-item id="o0270"><label>(2)</label><p id="p0275">Depletion of airway neutrophils</p></list-item></list></td><td>Pyogenic bacterial and mycoplasma pneumonia</td><td><list list-type="simple" id="olist0105"><list-item id="o0271"><label>(1)</label><p id="p0280">culture - ciliated respiratory epithelium posterior nasopharynx</p></list-item><list-item id="o0280"><label>(2)</label><p id="p0285">polymerase chain reaction (PCR) &#x02013; polyester/ rayon swab - ciliated respiratory epithelium of posterior nasopharynx</p></list-item><list-item id="o0285"><label>(3)</label><p id="p0290">Serology of pertussis antibodies (IgA or IgG to pertussis toxin, filamentous hemagglutinin, pertactin, fimbriae, or sonicated whole organism) acutely versus 4&#x000a0;weeks later</p></list-item></list></td></tr></tbody></table></table-wrap><fig id="f0010"><label>Fig.&#x000a0;49.1</label><caption><p>Adaptive T&#x000a0;cell responses to microbes.</p><p>T helper (T<sub>H</sub>) cell responses to microbial antigens presented by antigen-presenting cells (APCs), their&#x000a0;cytokine milieu and role in driving the subsequent T-cell responses that are involved in protection against bacteria, fungi and parasites.</p></caption><graphic xlink:href="f49-01-9780128167687"/><attrib>Figure from D'Elios MM, Benagiano M, Della Bella C, Amedei A. T-cell response to bacterial agents. J Infect Dev Ctries 2011;5(9):640&#x02013;5. Reprinted under <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/" id="interref1">https://creativecommons.org/licenses/by/4.0/</ext-link>.</attrib></fig><fig id="f0015"><label>Fig.&#x000a0;49.2</label><caption><p>General concepts and properties of polarized macrophages.</p><p>Classically activated macrophages (M1) are induced through LPS and/or microbial product stimulation. Their inflammatory repertoire is characterized by the secretion of pro-inflammatory mediators and the release of reactive oxygen and nitrogen intermediates. In contrast, alternative activation of macrophages (M2) covers a continuum of functional states classified as M2a, induced by IL-4/IL-13; M2b, induced by immune complexes and TLR agonists; and M2c, induced by IL-10 and glucocorticoid hormones.</p></caption><graphic xlink:href="f49-02-9780128167687"/><attrib>From Labonte AC, Tosello-Trampont AC, Hahn YS. The role of macrophage polarization in infectious and inflammatory diseases. Mol Cells. 2014 Apr 30; 37(4): 275&#x02013;285.</attrib></fig></p><p id="p0305">The amount of immunomodulatory cytokines, such as IL-10, expressed during infection contributes to the development of secondary infections during and after recovery from the primary infection. Alteration in the balance between immunity and immune suppression is in part, based on how much IL-10 is expressed during a given infection. IL-10 promoter polymorphisms that control high, intermediate, or low expression of IL-10<xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref> during and after microbial infection may influence the development of resistance or susceptibility to secondary microbial infection. Excessive IL-10 levels defined by a given host's IL-10 genotype could predispose an individual to develop secondary infections by blocking appropriate pro-inflammatory responses. In contrast, low IL-10 levels, also defined by a given host's genotype, could protect against&#x000a0;secondary infection, at the expense of limiting collateral tissue damage and T&#x000a0;cell memory that higher IL-10 expression would support.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> Taken together, the successful balance of cellular innate and adaptive immune responses, and the cytokine/chemokine repertoires that they express during a primary infection to an infectious microbe, can temporarily or permanently &#x0201c;hijack&#x0201d; effective immune responses that are necessary to prevent other infections by microbes that are commonly found in the environment. Thus, an imbalance in the immune responses made during a primary infection can have devastating consequences on the ability of an individual to generate effective immune responses to prevent or survive secondary infections caused by different microbes. Failure to establish an appropriate innate/adaptive immune balance can lead to persistent, severe, or fatal infections cause by secondary infections.</p></sec><sec id="s0015"><title>Distinguishing secondary immune deficiency from primary immune deficiency</title><p id="p0310">It is often difficult to distinguish secondary immune deficiency in a normal individual with a significant initial primary infection, where the offending microbe temporarily subverts or paralyzes the adaptive immune response to other microbes, from a patient with primary immune deficiency disease (PIDD) who presents with a serious initial infection (<xref rid="b0010" ref-type="boxed-text">Box&#x000a0;49.1</xref>
). Several clues help distinguish between an initial infection in these different patient populations.<xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref> Among these clues that patients with PIDD are more likely to have are:<list list-type="simple" id="ulist0050"><list-item id="u0395"><label>&#x02022;</label><p id="p0315">a family history of recurrent infections that persist despite optimal medical management</p></list-item><list-item id="u0400"><label>&#x02022;</label><p id="p0320">evidence of neonatal/early childhood demise secondary to infection</p></list-item><list-item id="u0405"><label>&#x02022;</label><p id="p0325">bloodline relatives who have had frequent miscarriages</p></list-item><list-item id="u0410"><label>&#x02022;</label><p id="p0330">unusual infections, such as meningitis or deep seeded organ abscesses</p></list-item><list-item id="u0415"><label>&#x02022;</label><p id="p0335">relatives with repetitive infections with unusual organisms especially in male relatives</p></list-item><list-item id="u0420"><label>&#x02022;</label><p id="p0340">multiple microbes causing an infection at the same time.</p></list-item></list>
<boxed-text id="b0010"><label>Box&#x000a0;49.1</label><caption><title>Causes of lymphopenia</title></caption><sec id="boxsec0005"><title>Primary immune deficiencies</title><sec id="boxsec0010"><title>Infections</title><p id="bpar0010">
<list list-type="simple" id="ulist0010"><list-item id="u0015"><label>&#x02022;</label><p id="bpar0015">Brucellosis</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="bpar0020">Cytomegalovirus (CMV)</p></list-item><list-item id="u0025"><label>&#x02022;</label><p id="bpar0025">Epstein Barr Virus (EBV)</p></list-item><list-item id="u0030"><label>&#x02022;</label><p id="bpar0030">Human immunodeficiency virus (HIV)</p></list-item><list-item id="u0035"><label>&#x02022;</label><p id="bpar0035">Histoplasmosis</p></list-item><list-item id="u0040"><label>&#x02022;</label><p id="bpar0040">Human lymphotropic virus (HTLV)</p></list-item><list-item id="u0045"><label>&#x02022;</label><p id="bpar0045">Influenza</p></list-item><list-item id="u0050"><label>&#x02022;</label><p id="bpar0050">Leishmania</p></list-item><list-item id="u0055"><label>&#x02022;</label><p id="bpar0055">Malaria</p></list-item><list-item id="u0060"><label>&#x02022;</label><p id="bpar0060">Measles</p></list-item><list-item id="u0065"><label>&#x02022;</label><p id="bpar0065">Pertussis</p></list-item><list-item id="u0070"><label>&#x02022;</label><p id="bpar0070">Parvovirus B19</p></list-item><list-item id="u0075"><label>&#x02022;</label><p id="bpar0075">Viral hepatitis</p></list-item><list-item id="u0080"><label>&#x02022;</label><p id="bpar0080">Tuberculosis</p></list-item><list-item id="u0085"><label>&#x02022;</label><p id="bpar0085">Typhoid fever</p></list-item><list-item id="u0090"><label>&#x02022;</label><p id="bpar0090">Rickettsia</p></list-item><list-item id="u0095"><label>&#x02022;</label><p id="bpar0095">Varicella zoster virus</p></list-item></list>
</p></sec><sec id="boxsec0015"><title>Autoimmunity</title><p id="bpar0100">
<list list-type="simple" id="ulist0015"><list-item id="u0100"><label>&#x02022;</label><p id="bpar0105">Sarcoidosis</p></list-item><list-item id="u0105"><label>&#x02022;</label><p id="bpar0110">Sj&#x000f6;gren's syndrome</p></list-item><list-item id="u0110"><label>&#x02022;</label><p id="bpar0115">Systemic lupus erythematosus</p></list-item><list-item id="u0115"><label>&#x02022;</label><p id="bpar0120">Rheumatoid arthritis</p></list-item><list-item id="u0120"><label>&#x02022;</label><p id="bpar0125">Myasthenia gravis</p></list-item></list>
</p></sec><sec id="boxsec0020"><title>Medications</title><p id="bpar0130">
<list list-type="simple" id="ulist0020"><list-item id="u0125"><label>&#x02022;</label><p id="bpar0135">Chemotherapy (most)</p></list-item><list-item id="u0130"><label>&#x02022;</label><p id="bpar0140">Anti-lymphocyte globulin</p></list-item><list-item id="u0135"><label>&#x02022;</label><p id="bpar0145">Alemtuzumab</p></list-item><list-item id="u0140"><label>&#x02022;</label><p id="bpar0150">Azathioprine</p></list-item><list-item id="u0145"><label>&#x02022;</label><p id="bpar0155">Bisphosphonates (some)</p></list-item><list-item id="u0150"><label>&#x02022;</label><p id="bpar0160">Carbamazepine</p></list-item><list-item id="u0155"><label>&#x02022;</label><p id="bpar0165">Cimetidine</p></list-item><list-item id="u0160"><label>&#x02022;</label><p id="bpar0170">Corticosteroids</p></list-item><list-item id="u0165"><label>&#x02022;</label><p id="bpar0175">Dimethyl fumarate</p></list-item><list-item id="u0170"><label>&#x02022;</label><p id="bpar0180">Imidazoles</p></list-item><list-item id="u0175"><label>&#x02022;</label><p id="bpar0185">Interferons</p></list-item><list-item id="u0180"><label>&#x02022;</label><p id="bpar0190">Methotrexate</p></list-item><list-item id="u0185"><label>&#x02022;</label><p id="bpar0195">Opioids</p></list-item><list-item id="u0190"><label>&#x02022;</label><p id="bpar0200">Psoralen</p></list-item><list-item id="u0195"><label>&#x02022;</label><p id="bpar0205">Rituximab</p></list-item></list>
</p></sec><sec id="boxsec0025"><title>Gastrointestinal/nutritional conditions</title><p id="bpar0210">
<list list-type="simple" id="ulist0025"><list-item id="u0200"><label>&#x02022;</label><p id="bpar0215">Celiac disease</p></list-item><list-item id="u0205"><label>&#x02022;</label><p id="bpar0220">Ethanol Abuse</p></list-item><list-item id="u0210"><label>&#x02022;</label><p id="bpar0225">Inflammatory bowel disease</p></list-item><list-item id="u0215"><label>&#x02022;</label><p id="bpar0230">Lymphangiectasia</p></list-item><list-item id="u0220"><label>&#x02022;</label><p id="bpar0235">Malnutrition</p></list-item><list-item id="u0225"><label>&#x02022;</label><p id="bpar0240">Protein loosing enteropathy</p></list-item><list-item id="u0230"><label>&#x02022;</label><p id="bpar0245">Zinc deficiency</p></list-item></list>
</p></sec><sec id="boxsec0030"><title>Hematology/Oncology conditions</title><p id="bpar0250">
<list list-type="simple" id="ulist0030"><list-item id="u0235"><label>&#x02022;</label><p id="bpar0255">Bone marrow failure</p></list-item><list-item id="u0240"><label>&#x02022;</label><p id="bpar0260">Hodgkin's disease</p></list-item><list-item id="u0245"><label>&#x02022;</label><p id="bpar0265">Aplastic anemia</p></list-item></list>
</p></sec><sec id="boxsec0035"><title>Radiation</title><p id="bpar0270">
<list list-type="simple" id="ulist0035"><list-item id="u0250"><label>&#x02022;</label><p id="bpar0275">Radiation therapy</p></list-item><list-item id="u0255"><label>&#x02022;</label><p id="bpar0280">Radiation injury</p></list-item><list-item id="u0260"><label>&#x02022;</label><p id="bpar0285">Thermal energy (burn)</p></list-item><list-item id="u0265"><label>&#x02022;</label><p id="bpar0290">Ultraviolet A irradiation</p></list-item></list>
</p></sec><sec id="boxsec0040"><title>Other conditions</title><p id="bpar0295">
<list list-type="simple" id="ulist0040"><list-item id="u0270"><label>&#x02022;</label><p id="bpar0300">Cushing Syndrome</p></list-item><list-item id="u0275"><label>&#x02022;</label><p id="bpar0305">Exercise</p></list-item><list-item id="u0280"><label>&#x02022;</label><p id="bpar0310">Idiopathic CD4<sup>+</sup> lymphocytopenia</p></list-item><list-item id="u0285"><label>&#x02022;</label><p id="bpar0315">Lymphocyte loss conditions</p></list-item><list-item id="u0290"><label>&#x02022;</label><p id="bpar0320">Renal failure</p></list-item><list-item id="u0295"><label>&#x02022;</label><p id="bpar0325">Sepsis/Severe Acute Respiratory Syndrome (SARS)</p></list-item><list-item id="u0300"><label>&#x02022;</label><p id="bpar0330">Stress</p></list-item><list-item id="u0305"><label>&#x02022;</label><p id="bpar0335">Thoracic duct drainage, leak, rupture, diversion</p></list-item><list-item id="u0310"><label>&#x02022;</label><p id="bpar0340">Trauma</p></list-item></list>
</p></sec></sec></boxed-text></p><p id="p0345">Patients with normal immune systems who become infected with viruses, bacteria, or parasites known to temporarily subvert or paralyze adaptive immunity without the above history are more likely to have secondary immune defects caused by microbes that prevent appropriate immunity to other organisms. Thus, the challenge for clinicians is to distinguish between patients with PID versus those with microbe-induced, secondary immune deficiency at the time of first presentation of a serious infection. In this review, we address the patient population with secondary, infection driven immune compromise, in contrast to patients with PIDD who are the focus of the remainder of this textbook.
</p></sec><sec id="s0020"><title>Sepsis</title><p id="p0350">Sepsis with a wide variety of organisms causes a profound secondary immune deficiency. It is not an uncommon scenario to have to rule out a PIDD in the intensive care setting where both the underlying disease and medications may alter the immunologic findings. Sepsis is one of the more common causes of secondary lymphopenia (<xref rid="b0010" ref-type="boxed-text">Box&#x000a0;49.1</xref>). Furthermore, there are both acute disruptions of immunologic function and longer term findings that are poorly characterized that are seen after trauma and burn injuries as well. In fact, increased mortality persists for years after an episode of sepsis. Immunologic findings occurring with acute sepsis include:<list list-type="simple" id="ulist0055"><list-item id="u0425"><label>&#x02022;</label><p id="p0355">Decreased CD4<sup>+</sup> T&#x000a0;cells (apoptosis)</p></list-item><list-item id="u0430"><label>&#x02022;</label><p id="p0360">Decreased &#x003b3;&#x003b4; T&#x000a0;cells</p></list-item><list-item id="u0435"><label>&#x02022;</label><p id="p0365">Decreased NK cells</p></list-item><list-item id="u0440"><label>&#x02022;</label><p id="p0370">Decreased B cells</p></list-item><list-item id="u0445"><label>&#x02022;</label><p id="p0375">Diminished neutrophil oxidative burst</p></list-item><list-item id="u0450"><label>&#x02022;</label><p id="p0380">Diminished TLR responses from monocytes</p></list-item><list-item id="u0455"><label>&#x02022;</label><p id="p0385">Diminished monocyte HLA-DR expression</p></list-item><list-item id="u0460"><label>&#x02022;</label><p id="p0390">Diminished NK cytotoxicity</p></list-item></list>
</p><p id="p0395">Thus, findings of altered immune function during sepsis require confirmation after clinical recovery. When immediate action is required, interpretation of results requires placing the laboratory results in the context of recognized secondary immunologic effects.
</p></sec><sec id="s0025"><title>Examples of microbes that cause temporary or long-term secondary immune deficiency</title><p id="p0400">
<xref rid="t0010" ref-type="table">Table&#x000a0;49.1</xref>
<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> shows some of the microbes that are known to induce secondary immune deficiency, the cells that they affect, and the pathogens causing secondary infection. In some cases, secondary immune deficiency occurs as a result of a cytokine storm. Some infections known to cause a cytokine storm are shown in <xref rid="b0015" ref-type="boxed-text">Box&#x000a0;49.2</xref>
. Below, we describe examples of how some of these microbes suppress immunity and thereby cause secondary immune deficiency, predisposing patients to secondary microbial infections.<boxed-text id="b0015"><label>Box&#x000a0;49.2</label><caption><title>Select Infections causing cytokine storm<xref rid="bib224" ref-type="bibr">224</xref>, <xref rid="bib225" ref-type="bibr">225</xref>, <xref rid="bib226" ref-type="bibr">226</xref>, <xref rid="bib227" ref-type="bibr">227</xref>, <xref rid="bib228" ref-type="bibr">228</xref>, <xref rid="bib229" ref-type="bibr">229</xref>, <xref rid="bib230" ref-type="bibr">230</xref>, <xref rid="bib231" ref-type="bibr">231</xref>, <xref rid="bib232" ref-type="bibr">232</xref>, <xref rid="bib233" ref-type="bibr">233</xref></title></caption><p id="bpar0345">
<list list-type="simple" id="ulist0045"><list-item id="u0315"><label>&#x02022;</label><p id="bpar0350">
<italic>Anaplasma phagocytophilum</italic>
</p></list-item><list-item id="u0320"><label>&#x02022;</label><p id="bpar0355">
<italic>Burkholderia pseudomallei</italic>
</p></list-item><list-item id="u0325"><label>&#x02022;</label><p id="bpar0360">Crimean-Congo hemorrhagic fever virus</p></list-item><list-item id="u0330"><label>&#x02022;</label><p id="bpar0365">Dengue virus</p></list-item><list-item id="u0335"><label>&#x02022;</label><p id="bpar0370">Ebola virus</p></list-item><list-item id="u0340"><label>&#x02022;</label><p id="bpar0375">
<italic>Ehrlichia chaffeensis</italic>
</p></list-item><list-item id="u0345"><label>&#x02022;</label><p id="bpar0380">
<italic>Francisella tularensis</italic>
</p></list-item><list-item id="u0350"><label>&#x02022;</label><p id="bpar0385">Influenza (H5N1, H7N9 more than H1N1, H3N2)</p></list-item><list-item id="u0355"><label>&#x02022;</label><p id="bpar0390">Junin virus</p></list-item><list-item id="u0360"><label>&#x02022;</label><p id="bpar0395">Lassa virus</p></list-item><list-item id="u0365"><label>&#x02022;</label><p id="bpar0400">Marburgvirus</p></list-item><list-item id="u0370"><label>&#x02022;</label><p id="bpar0405">
<italic>Puumala orthohantavirus</italic>
</p></list-item><list-item id="u0375"><label>&#x02022;</label><p id="bpar0410">Middle East respiratory syndrome CoV (MERS-CoV)</p></list-item><list-item id="u0380"><label>&#x02022;</label><p id="bpar0415">Severe acute respiratory syndrome CoV (SARS-CoV)</p></list-item><list-item id="u0385"><label>&#x02022;</label><p id="bpar0420">Visceral Leishmaniasis</p></list-item><list-item id="u0390"><label>&#x02022;</label><p id="bpar0425">Yellow fever virus</p></list-item></list>
</p></boxed-text></p><sec id="s0030"><title>Viruses that hijack immune responses to other microbes</title><sec id="s0035"><title>Measles virus: temporary immunosuppression</title><p id="p0405">Measles virus (MV) continues to cause child morbidity and mortality worldwide, despite the availability and use of an effective live attenuated measles vaccine.<xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref> Part of the reason why control of MV continues to be elusive is that it is highly contagious for susceptible individuals and there are difficulties with vaccine delivery. MV infection begins in the respiratory tract, spreads systemically in lymphoid, epithelial and endothelial cells, and ultimately infects multiple organs,<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> causing a characteristic fever, rash, and conjunctivitis 10&#x02013;14&#x000a0;days after respiratory infection (<xref rid="f0020" ref-type="fig">Fig.&#x000a0;49.3A and B</xref>
). High fever, rhinorrhea and conjunctivitis typically precede the rash and the rash migrates from the head and neck to the hands and feet over 3&#x02013;4&#x000a0;days. Many of these manifestations are caused by the immune response made to MV, and commonly this response clears MV in infected tissues and prevents re-infection for life (<xref rid="f0020" ref-type="fig">Fig.&#x000a0;49.3C and D</xref>). However, MV infection can cause several weeks of immune suppression after resolution in select individuals. This is the primary cause of measles-associated deaths: MV-induced secondary infection.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> Although vaccination against measles is very high in the United States, 92.7% of children aged 19&#x02013;35&#x000a0;months were vaccinated in 2017,<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> there are pockets of unvaccinated people who are susceptible to local outbreaks of measles. Since &#x0201c;herd immunity&#x0201d; is primarily effective when the vaccination rate is around 96%,<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> vaccination levels below this level leave children and adults at risk for primary MV infection and secondary microbial infections.
<fig id="f0020"><label>Fig.&#x000a0;49.3</label><caption><p>Outline of the pathogenesis of measles virus (MV) from the time of infection through recovery.</p><p>(A) MV infection is initiated in the respiratory tract and spreads systemically to infect multiple organs, including lymphoid tissue, liver, lungs, and skin. Epithelial cells, endothelial cells, B and T&#x000a0;cells, monocytes/macrophages, and dendritic cells can be infected. MV clearance begins with the onset of the rash. Clearance of MV is complete 20&#x000a0;days after infection; however, viral RNA (dashed line) persists at multiple sites. (B) Clinical signs and symptoms begin approximately 10&#x000a0;days after infection, with prodromal symptoms of fever, conjunctivitis, and oral Koplik's spots, followed by a maculopapular rash for 3&#x02013;5&#x000a0;days. (C) The rash represents adaptive immune responses with infiltration of CD4<sup><italic>+</italic></sup> and CD8<sup><italic>+</italic></sup> T&#x000a0;cells into sites of MV replication and clearance. There is a rapid activation, expansion, and then contraction of MV-specific CD8<sup>+</sup> T&#x000a0;cells. CD4<sup>+</sup> T&#x000a0;cell responses appear at the same time, but activation is prolonged. MV-specific IgM appears with the rash, and this is commonly used for diagnostic purposes. This is followed by the sustained MV-specific IgG synthesis. Immune suppression is evident during acute disease and for many weeks after recovery. (D) Cytokines and chemokines produced during infection are found in plasma in elevated amounts. Early, IL-8 is increased. During the rash, IFN-&#x003b3; and IL-2 are &#x003b3; and IL-2 are produced by activated T<sub>H</sub>1-like, CD4<sup>+</sup> and CD8<sup>+</sup> T&#x000a0;cells. After rash resolution, T<sub>H</sub>2-like T&#x000a0;cells and regulatory CD4<sup>+</sup> T&#x000a0;cells produce IL-4, IL-10, and IL-13.</p></caption><graphic xlink:href="f49-03-9780128167687"/><attrib>Figure reproduced from Griffin DE. Measles virus-induced suppression of immune responses. Immunol Rev 2010;236:176&#x02013;89 &#x000a9;2010 John Wiley &#x00026; Sons A/S.</attrib></fig></p><p id="p0410">Measles was the first virus clearly identified to cause increased susceptibility to other microbial secondary infections. Most often, measles-associated deaths are caused by severe, overwhelming pneumonia and diarrhea.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> Suppression of delayed hypersensitivity has been identified in tuberculin-sensitized individuals many weeks after complete resolution of MV infection (<xref rid="f0020" ref-type="fig">Fig.&#x000a0;49.3C</xref>).<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> Furthermore, several weeks after successful MV recovery, increased susceptibility to other infections has been reported, and T&#x000a0;cell function and <italic>in&#x000a0;vitro</italic> proliferation of T&#x000a0;cells in response to mitogens has been shown to be markedly decreased (<xref rid="f0025" ref-type="fig">Fig.&#x000a0;49.4A and B</xref>
).<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref>
<sup>,</sup>
<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref>
<sup>,</sup>
<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> Immunosuppression occurs during a period of intense immune activation that occurs during the onset of the MV rash and anti-MV immune responses (<xref rid="f0020" ref-type="fig">Fig.&#x000a0;49.3C and D</xref>). Lymphopenia, skewing of Th2-like chemokine polarized responses, and suppression of lymphocyte proliferation have also been documented (<xref rid="f0020" ref-type="fig">Fig.&#x000a0;49.3D</xref>). MV infection causes decreases in T and B cells in the blood during the MV rash period.<xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref> Altered trafficking and increased apoptosis of MV-infected and uninfected lymphocytes contribute to the development of lymphopenia.<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref>
<sup>,</sup>
<xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib30" ref-type="bibr">30</xref> While lymphocyte numbers rapidly return to normal in the blood after the rash resolves, immunologic abnormalities persist.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref>
<sup>,</sup>
<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref>
<sup>,</sup>
<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref>
<sup>,</sup>
<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> Immune suppression, Th2 cytokine polarization of CD4<sup>+</sup> T&#x000a0;cells, and Treg induction have been associated with indirect immunosuppression caused by MV infection.<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref>
<sup>,</sup>
<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> MV infection is also associated with suppression of IL-12 expression, lymphocyte CD30 expression, and IL-4, IL-10, and IL-13 expression after rash resolution.<xref rid="bib35" ref-type="bibr">35</xref>, <xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib37" ref-type="bibr">37</xref> Reduction of IL-12 production reduces T&#x000a0;cell expression of type I cytokines, particularly IFN-&#x003b3;<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref>
<sup>,</sup>
<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> (<xref rid="f0020" ref-type="fig">Fig.&#x000a0;49.3D</xref>). It is possible that MV interacts with the complement regulatory molecule CD46 in polarizing Th2-like cytokine production, causing activation of signaling cascades that modify cell function, although this interaction is not firmly established.<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref>
<sup>,</sup>
<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> The MV-CD46 interaction may alter innate immunity by selectively downregulating receptor expression.<xref rid="bib40" ref-type="bibr">40</xref>, <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>, <xref rid="bib45" ref-type="bibr">45</xref>, <xref rid="bib46" ref-type="bibr">46</xref> This would increase susceptibility to complement-mediated lysis of MV-infected cells, and decrease antigen presenting cell production of IL-12<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref>
<sup>,</sup>
<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> and crosslinking of CD46 on T&#x000a0;cells, leading to the induction of regulatory CD4<sup>+</sup> T&#x000a0;cells and enhanced IL-10 levels.<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref> These interactions would induce Th2-like polarization that would favor B cell maturation, provide lifelong MV antibody memory, and protect against MV re-infection. This polarization, however, would also depress APC activation and Th1-like responses to new pathogens.<fig id="f0025"><label>Fig.&#x000a0;49.4</label><caption><p>Immune suppression during measles.</p><p>(A) Delayed-type hypersensitivity skin test responses to tuberculin in Peruvian children before (control) and after the onset of measles. (B) Peripheral blood mononuclear cell proliferation in response to phytohemagglutinin from rhesus macaques during a primate center outbreak of MV.</p></caption><graphic xlink:href="f49-04-9780128167687"/><attrib>Figure reproduced from Griffin DE. Measles virus-induced suppression of immune responses. Immunol Rev 2010;236:176&#x02013;89 &#x000a9;2010 John Wiley &#x00026; Sons A/S.</attrib></fig></p><p id="p0415">MV suppresses PBMC proliferation to mitogens after MV resolution, and this continues for several weeks (<xref rid="f0025" ref-type="fig">Fig.&#x000a0;49.4B</xref>).<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref>
<sup>,</sup>
<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> IL-2 supplementation can improve, but not fully restore, this responsiveness. This suggests that defective IL-2 expression is in part responsible for this proliferative defect.<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> Cell cycle arrest in G1 after <italic>in&#x000a0;vitro</italic> infection with MV is a recognized cause of hyporesponsiveness to mitogens.<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref>
<sup>,</sup>
<xref rid="bib51" ref-type="bibr">51</xref>, <xref rid="bib52" ref-type="bibr">52</xref>, <xref rid="bib53" ref-type="bibr">53</xref> MV RNA can persist in PBMCs for months after MV resolution<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref>
<sup>,</sup>
<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> and may reduce mitogen proliferation, although this has not been established. The receptor used by wild-type MV to infect cells, CD150, is a dual function co-receptor for lymphocyte activation, and enhances IFN-&#x003b3; expression.<xref rid="bib56" ref-type="bibr">56</xref>, <xref rid="bib57" ref-type="bibr">57</xref>, <xref rid="bib58" ref-type="bibr">58</xref> However, MV binding to CD150 can also downregulate receptor expression.<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref>
<sup>,</sup>
<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref> T&#x000a0;cell signaling through the MV glycoprotein complex of H and F1-F2 in the membranes of virions or MV-infected cells<xref rid="bib61" ref-type="bibr">61</xref>, <xref rid="bib62" ref-type="bibr">62</xref>, <xref rid="bib63" ref-type="bibr">63</xref>, <xref rid="bib64" ref-type="bibr">64</xref>, <xref rid="bib65" ref-type="bibr">65</xref> may also contribute to immunosuppression. This inhibitory signal prevents T&#x000a0;cell S-phase entry for several days, and is independent of cell death, membrane fusion, soluble inhibitor production, or T&#x000a0;cell infection.<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref>
<sup>,</sup>
<xref rid="bib61" ref-type="bibr"><sup>61</sup></xref>
<sup>,</sup>
<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref>
<sup>,</sup>
<xref rid="bib65" ref-type="bibr">65</xref>, <xref rid="bib66" ref-type="bibr">66</xref>, <xref rid="bib67" ref-type="bibr">67</xref> Thus, there is a delay in cell cycle progression and an accumulation of T&#x000a0;cells in the G0/G1 phase.<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref>
<sup>,</sup>
<xref rid="bib66" ref-type="bibr"><sup>66</sup></xref>
<sup>,</sup>
<xref rid="bib67" ref-type="bibr"><sup>67</sup></xref> The mechanism by which H/F1-F2 suppresses mitogen-induced proliferation is unknown, but it is associated with MV-induced interference of T&#x000a0;cell activation of phosphoinositide 3-kinase (PI3K) in T&#x000a0;cells, or IL-2 receptor ligation.<xref rid="bib68" ref-type="bibr"><sup>68</sup></xref> IL-2 added to MV-treated cells activates signal transducer and activator of transcription 3 (STAT3) but fails to activate Akt kinase, which is required for cell cycle progression.<xref rid="bib69" ref-type="bibr"><sup>69</sup></xref> The modulatory effects of MV with glycoprotein complexes, and the downstream consequences of this interaction, have recently been summarized.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref>
<sup>,</sup>
<xref rid="bib68" ref-type="bibr">68</xref>, <xref rid="bib69" ref-type="bibr">69</xref>, <xref rid="bib70" ref-type="bibr">70</xref> While the relevance of these processes to the <italic>in&#x000a0;vivo</italic> suppression of T&#x000a0;cell lymphoproliferation remains to be identified. The combination of the established mechanisms leading to post-MV infection immunosuppression, and those that remain to be elucidated, cause, in select individuals, severe and on occasion, fatal secondary infection with other microbes.</p><p id="p0420">A key epidemiologic factor in measles-related deaths is vitamin A deficiency. In the developing world, the World Health Organization recommends vitamin A supplementation. Studies have demonstrated improved outcomes and suggest an effect on the mucosal barrier and also on improved T&#x000a0;cell function though by an undefined mechanism.</p></sec><sec id="s0040"><title>Influenza virus: temporary immunosuppression</title><p id="p0425">Three world-wide (pandemic) outbreaks of influenza virus (IV) occurred in the 20th century, in 1918, 1957, and 1968. They are now known to represent three different antigenic subtypes of influenza A virus: H1N1, H2N2, and H3N2, respectively.<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref> The 1918 &#x0201c;Spanish Flu&#x0201d; epidemic claimed an estimated 50 million lives and 20%&#x02013;40% of the worldwide population became ill; approximately 675,000 Americans died during this epidemic.<xref rid="bib72" ref-type="bibr"><sup>72</sup></xref> Since then, IV infections have caused more than 20,000 deaths yearly in each of the 20 epidemics from 1957 to 1991,<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref> and greater than 40,000 deaths occurred in each of the more recent epidemics, Thus, IV is a formidable pathogen.<xref rid="bib74" ref-type="bibr"><sup>74</sup></xref> While influenza-related mortality can in part be attributed to direct effects on the respiratory system, many of the deaths associated with IV infection are caused by increases in susceptibility to secondary bacterial pneumonia.<xref rid="bib75" ref-type="bibr"><sup>75</sup></xref> In fact, it has been suggested that the major mortality and morbidity resulting from IV infection may be caused by secondary bacterial infection that is associated with the inhibition of neutrophil function.<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref> The bacteria commonly causing pneumonia in the most severely ill influenza patients are <italic>Streptococcus(S.) pneumoniae</italic>, <italic>Staphylococcus aureus</italic>, and <italic>Haemophilus influenzae</italic>. Together, IV infection itself, and secondary bacterial pneumonia, were the most common causes of infectious death in the United States in 2002.<xref rid="bib76" ref-type="bibr"><sup>76</sup></xref> Research, clinical, and epidemiological studies show that there is a positive correlation between the increase in morbidity and mortality during influenza epidemics and pandemics, and an increase in secondary <italic>S.&#x000a0;pneumoniae</italic> infection.<xref rid="bib75" ref-type="bibr"><sup>75</sup></xref>
<sup>,</sup>
<xref rid="bib77" ref-type="bibr"><sup>77</sup></xref>
<sup>,</sup>
<xref rid="bib78" ref-type="bibr"><sup>78</sup></xref> It has been hypothesized that influenza infection alters neutrophil function, thereby reducing the effectiveness of phagocyte-mediated killing of bacteria. An alternative hypothesis is that the tissue damage caused by IV alters the epithelial surface of the respiratory tract, thereby exposing different surface receptors to which <italic>S.&#x000a0;pneumoniae</italic> adhere, and/or increasing the affinity of <italic>S.&#x000a0;pneumoniae</italic> for its receptors, which may result in increased growth and decreased neutrophil killing of <italic>S.&#x000a0;pneumoniae</italic> in the respiratory tract. Support for the former hypothesis comes from reports using both <italic>in&#x000a0;vitro</italic> and <italic>in&#x000a0;vivo</italic> models of influenza infection.<xref rid="bib79" ref-type="bibr">79</xref>, <xref rid="bib80" ref-type="bibr">80</xref>, <xref rid="bib81" ref-type="bibr">81</xref>, <xref rid="bib82" ref-type="bibr">82</xref>, <xref rid="bib83" ref-type="bibr">83</xref>, <xref rid="bib84" ref-type="bibr">84</xref>, <xref rid="bib85" ref-type="bibr">85</xref>, <xref rid="bib86" ref-type="bibr">86</xref>, <xref rid="bib87" ref-type="bibr">87</xref>, <xref rid="bib88" ref-type="bibr">88</xref>, <xref rid="bib89" ref-type="bibr">89</xref>, <xref rid="bib90" ref-type="bibr">90</xref> Neutrophils are important in resistance to <italic>S.&#x000a0;pneumoniae</italic> infection independent of an influenza infection.<xref rid="bib91" ref-type="bibr"><sup>91</sup></xref> Influenza A virus alters the three major properties of the neutrophil that are crucial for bacterial clearance, namely chemotactic responsiveness, phagocytosis, and intracellular killing. This alteration of neutrophil function likely increases the susceptibility of an influenza-infected patient to <italic>S.&#x000a0;pneumoniae</italic> infection because of decreased phagocytosis and killing of these bacteria by neutrophils.<xref rid="bib80" ref-type="bibr"><sup>80</sup></xref>
<sup>,</sup>
<xref rid="bib84" ref-type="bibr"><sup>84</sup></xref>
<sup>,</sup>
<xref rid="bib89" ref-type="bibr"><sup>89</sup></xref>
<sup>,</sup>
<xref rid="bib92" ref-type="bibr"><sup>92</sup></xref>
</p><p id="p0430">In humans, IV was reported to alter cell function by interacting with G proteins.<xref rid="bib81" ref-type="bibr"><sup>81</sup></xref>
<sup>,</sup>
<xref rid="bib90" ref-type="bibr"><sup>90</sup></xref>
<sup>,</sup>
<xref rid="bib93" ref-type="bibr"><sup>93</sup></xref> Human neutrophils express monomeric and trimeric G proteins that have critical roles in activation and regulation of various signal pathways, leading to chemotaxis and metabolic function.<xref rid="bib94" ref-type="bibr"><sup>94</sup></xref>
<sup>,</sup>
<xref rid="bib95" ref-type="bibr"><sup>95</sup></xref> Susceptibility to <italic>S.&#x000a0;pneumoniae</italic> in mice is greatest at six days after influenza infection, consistent with the clinical findings.<xref rid="bib96" ref-type="bibr">96</xref>, <xref rid="bib97" ref-type="bibr">97</xref>, <xref rid="bib98" ref-type="bibr">98</xref>, <xref rid="bib99" ref-type="bibr">99</xref> Influenza-induced tissue damage is also greatest six days after influenza infection, as is adherence of <italic>S.&#x000a0;pneumoniae</italic> to murine influenza-infected tracheas.<xref rid="bib100" ref-type="bibr"><sup>100</sup></xref> Influenza-induced neutrophil dysfunction is also greatest six days after influenza infection,<xref rid="bib101" ref-type="bibr"><sup>101</sup></xref> and murine mortality secondary to <italic>S.&#x000a0;pneumoniae</italic> infection is greatest seven days after infection. Although neutrophils accumulate in the lungs of mice infected with influenza by day six, they do not function in resistance to <italic>S.&#x000a0;pneumoniae</italic>. Thus, it is likely that bactericidal function of lung neutrophils is suppressed, making these influenza-infected mice susceptible to <italic>S.&#x000a0;pneumoniae</italic>. Effective neutrophil phagocytosis and killing of <italic>S.&#x000a0;pneumoniae</italic> is necessary to eliminate <italic>S.&#x000a0;pneumoniae</italic> from the lungs.<xref rid="bib102" ref-type="bibr"><sup>102</sup></xref> Neutrophils are affected within 30&#x000a0;min of <italic>in&#x000a0;vitro</italic> influenza infection,<xref rid="bib83" ref-type="bibr"><sup>83</sup></xref>
<sup>,</sup>
<xref rid="bib84" ref-type="bibr"><sup>84</sup></xref>
<sup>,</sup>
<xref rid="bib87" ref-type="bibr"><sup>87</sup></xref>
<sup>,</sup>
<xref rid="bib89" ref-type="bibr"><sup>89</sup></xref>
<sup>,</sup>
<xref rid="bib103" ref-type="bibr"><sup>103</sup></xref> with some effects seen as rapidly as 5&#x000a0;min after incubation with IV. Changes in infected neutrophils include decreased protein phosphorylation, accelerated apoptosis, decreased respiratory burst activity, an altered cytoskeleton, depressed bactericidal capacity identified by release of reactive oxygen species, decreased chemotactic ability, decreased adherence, decreased release of lactoferrin into phagosomes, and inhibition of lysosome&#x02013;phagosome fusion.<xref rid="bib81" ref-type="bibr"><sup>81</sup></xref>
<sup>,</sup>
<xref rid="bib82" ref-type="bibr"><sup>82</sup></xref>
<sup>,</sup>
<xref rid="bib84" ref-type="bibr"><sup>84</sup></xref>
<sup>,</sup>
<xref rid="bib87" ref-type="bibr"><sup>87</sup></xref>
<sup>,</sup>
<xref rid="bib89" ref-type="bibr"><sup>89</sup></xref>
<sup>,</sup>
<xref rid="bib92" ref-type="bibr"><sup>92</sup></xref>
<sup>,</sup>
<xref rid="bib103" ref-type="bibr"><sup>103</sup></xref> In addition, the effects of influenza virus infection on neutrophil function are not limited to the lungs, indicating that these effects are systemic in nature.<xref rid="bib89" ref-type="bibr"><sup>89</sup></xref>
<sup>,</sup>
<xref rid="bib90" ref-type="bibr"><sup>90</sup></xref> Influenza infection also increases susceptibility to <italic>S.&#x000a0;pneumoniae</italic> by increasing cytokine production (TNF, IFN-&#x003b3;, MCP-1, IL-10, IL-6) in the lung.<xref rid="bib75" ref-type="bibr"><sup>75</sup></xref>
</p><p id="p0435">IL-10 is also elevated in post-influenza pneumococcal pneumonia, leading to increased susceptibility to <italic>S.&#x000a0;pneumoniae</italic> long after an influenza infection has been resolved.<xref rid="bib104" ref-type="bibr"><sup>104</sup></xref> Susceptibility remains at least 14&#x000a0;days after a primary influenza infection, and is thought to be mediated by IL-10 inhibition of neutrophil function, resulting in increased bacterial growth in the lungs leading to mortality.<xref rid="bib104" ref-type="bibr"><sup>104</sup></xref> Of note, viral influenza neuraminidase increases <italic>S.&#x000a0;pneumoniae</italic> adherence in the lungs by cleaving sialic acid residues, and exposing receptors to which <italic>S.&#x000a0;pneumoniae</italic> can adhere.<xref rid="bib78" ref-type="bibr"><sup>78</sup></xref> Thus, both neutrophil-dependent and -independent mechanisms cause increased susceptibility to secondary <italic>S.&#x000a0;pneumoniae</italic> infection after a primary influenza infection. Novel therapies that can restore neutrophil function caused by IV infection may be helpful.<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref>
<sup>,</sup>
<xref rid="bib75" ref-type="bibr"><sup>75</sup></xref>
</p></sec><sec id="s0045"><title>Human immune deficiency virus: long-term immunosuppression</title><p id="p0440">HIV is a double-stranded, enveloped RNA retrovirus from the genus Lentivirus within the subfamily Retroviridae, with a tropism for human CD4<sup>+</sup> cells, including T&#x000a0;cells and macrophages.<xref rid="bib105" ref-type="bibr"><sup>105</sup></xref> Two HIV types have been identified, HIV-1 and HIV-2, and both cause similar but not identical human disease. The HIV genome contains three structural genes (<italic>gag</italic>, <italic>pol</italic>, and <italic>env</italic>) and six regulatory genes (<italic>tat</italic>, <italic>rev</italic>, <italic>nef</italic>, <italic>vif</italic>, <italic>vpr</italic>, and <italic>vpu</italic>). These proteins, their function, and their role in forming the viral particle have recently been summarized.<xref rid="bib105" ref-type="bibr"><sup>105</sup></xref> The Env protein is cleaved to produce two envelope proteins, gp120 and gp41, which are involved in HIV binding to CD4 and the chemokine receptors CXCR4 and CCR5 on cell surfaces.<xref rid="bib105" ref-type="bibr"><sup>105</sup></xref> Tat, Nef, and Rev proteins play a role in downregulating classical MHC class I molecules on the surface of HIV-infected T&#x000a0;cells.<xref rid="bib106" ref-type="bibr">106</xref>, <xref rid="bib107" ref-type="bibr">107</xref>, <xref rid="bib108" ref-type="bibr">108</xref> In the case of Tat, HLA-C and HLA-E are spared.<xref rid="bib109" ref-type="bibr"><sup>109</sup></xref> The classical HLA presenting molecule HLA-C on antigen presenting cells is not as potent in presenting viral peptides to T&#x000a0;cells similar to the non-classical MHC class I molecule HLA-E. However, the non-classical MHC class I molecule HLA-E, similar to HLA-A, HLA-B, and HLA-C, suppress NK function. This viral strategy to evade immune surveillance serves two functions: (1) prevent CD8<sup>+</sup> T&#x000a0;cells from recognizing HIV peptides presented by class I MHC molecules, and (2) prevent NK cell recognition and activation because HLA-C and HLA-E remain on HIV-infected cells leading to inhibition of NK killing of class I MHC expressing target cells. The Nef protein also downregulates CD4 expression on the surface of HIV-infected cells, which is a co-receptor of the T&#x000a0;cell receptor participating in T&#x000a0;cell activation.<xref rid="bib110" ref-type="bibr"><sup>110</sup></xref> This facilitates HIV-infected cell escape from immune surveillance.</p><p id="p0445">Following HIV gp120 protein binding to CD4 and CCR5 molecules on target cells, HIV-infected cells migrate to the&#x000a0;lymph nodes, where initial replication and infection of nearby CD4<sup>+</sup> T&#x000a0;cells occurs.<xref rid="bib111" ref-type="bibr"><sup>111</sup></xref> During acute HIV infection, gut-associated lymphoid tissues, predominantly memory CD4<sup>+</sup> T&#x000a0;cells, are severely depleted. There is high HIV viremia and immune activation.<xref rid="bib112" ref-type="bibr"><sup>112</sup></xref>
<sup>,</sup>
<xref rid="bib113" ref-type="bibr"><sup>113</sup></xref> HIV induces T&#x000a0;cell lymphopenia through several mechanisms: HIV-induced apoptosis; a viral cytopathic effect; non-specific immune activation-induced apoptosis; and cytotoxicity of HIV-infected cells.<xref rid="bib105" ref-type="bibr"><sup>105</sup></xref> Autophagy is also induced by HIV Env protein in uninfected T&#x000a0;cells.<xref rid="bib114" ref-type="bibr"><sup>114</sup></xref> In addition, shedding of gp120 molecules by HIV triggers a series of events that cause the adaptive immune system to become less effective by altering the normal balance of immunoregulatory Th1 and Th2 T&#x000a0;cells. Impaired function of HIV-infected macrophages and dendritic cells contributes to the failure of effective innate and adaptive immune responses to secondary infection.</p><p id="p0450">The acute and latency phase of HIV infection is shown in <xref rid="f0030" ref-type="fig">Fig.&#x000a0;49.5</xref>
.<xref rid="bib115" ref-type="bibr"><sup>115</sup></xref>
<sup>,</sup>
<xref rid="bib116" ref-type="bibr"><sup>116</sup></xref> Without combined antiretroviral therapy (cARV), CD4<sup>+</sup> T&#x000a0;cell counts progressively decrease, and the host usually succumbs to infections with opportunistic organisms that occur because of HIV-induced secondary immune deficiency. Specific anti-HIV, CD4<sup>+</sup>, and CD8<sup>+</sup> T&#x000a0;cells, and neutralizing anti-HIV antibodies develop, however, these responses are eventually overcome by viral escape strategies.<xref rid="bib105" ref-type="bibr"><sup>105</sup></xref> Patients can present with constitutional symptoms, such as fever, weight loss, diarrhea, lymphadenopathy, secondary opportunistic infections, and viral skin infections, heralding the presence of an immunocompromised immune system. Peripheral CD4<sup>+</sup> T&#x000a0;cell counts of&#x000a0;&#x0003c;200&#x000a0;cells/mL herald the development of AIDS. This T&#x000a0;cell depletion predisposes patients to develop opportunistic infections including, but not limited to, cytomegalovirus, <italic>Herpes simplex</italic>, varicella zoster virus, <italic>Pneumocystis jirovecii</italic> pneumonia, histoplasmosis, toxoplasmosis, coccidioidomycosis, <italic>Cryptosporidium</italic>, <italic>Nocardia</italic>, <italic>Mycobacterium avium</italic> complex, salmonella, and <italic>Toxoplasma gondii</italic>. If HIV-infected patients do not receive antiretroviral treatment, repeated infections with these opportunistic secondary infections ultimately lead to death. Thus, HIV infection exhausts the adaptive immune system, leading to chronic depletion of CD4<sup>+</sup> T&#x000a0;cells and immune dysfunction of the multiple effector immune responses that are required to prevent secondary bacterial, viral, fungal, and protozoan infections.<fig id="f0030"><label>Fig.&#x000a0;49.5</label><caption><p>Typical course of HIV Infection.</p><p>During the early period after primary infection, there is widespread dissemination of virus and a sharp decrease in the number of CD4<sup>+</sup> T&#x000a0;cells in peripheral blood. An immune response to HIV ensues, with a decrease in detectable viremia followed by a prolonged period of clinical latency. The CD4<sup>+</sup> T&#x000a0;cell count continues to decrease during subsequent years, until it reaches a critical level below which there is a substantial risk of opportunistic diseases.</p></caption><graphic xlink:href="f49-05-9780128167687"/><attrib>Figure reproduced from Reid S, McGrath L. HIV/AIDS. Sleep Medicine Clinics 2019;2(1):51&#x02013;8 with permission from Elsevier.</attrib></fig></p></sec><sec id="s0050"><title>Human T-lymphotropic virus: long-term immunosuppression</title><p id="p0455">Human T-Lymphotropic viruses (HTLV) are complex type C retroviruses with a capsid that contains two simple RNA strands with associated reverse transcriptase and integrase enzymes which are essential for insertion of the virus into the host genome.<xref rid="bib117" ref-type="bibr"><sup>117</sup></xref> Several types of HTLV have been identified (HTLV-1, HTLV-2, HTLV-3, HTLV-4). While HIV-1 was previously called HTLV-3, HTLV-3 is a different virus.<xref rid="bib117" ref-type="bibr"><sup>117</sup></xref> Similar to other retroviruses, HTLV-1 contains <italic>gag</italic>, <italic>pro/pol</italic> and <italic>env</italic> genes that have structural and functional roles. In addition, the pX region codes for regulatory proteins (such as transactivator protein, Tax, and the helix basic zipper protein, HBZ) essential for viral transcription, and inhibition of signal transduction pathways, such as NF&#x003ba;B (leading to decreased SOCS1), and AP-1. This leads to HTLV-1 inducing cytotoxic T&#x000a0;cells that can kill virus-infected cells.<xref rid="bib118" ref-type="bibr"><sup>118</sup></xref>
</p><p id="p0460">The HTLV-1 <italic>Tax</italic> gene can decrease Th1-like antiviral signaling pathways both by modulating the suppressor of cytokine signaling 1 (SOCS1)<xref rid="bib119" ref-type="bibr"><sup>119</sup></xref> and also through the aryl hydrocarbon receptor protein (AIP) that binds to interferon regulatory factor 7 (IRF7), thus decreasing Type I interferon (IFN-&#x003b1;/&#x003b2;) expression.<xref rid="bib120" ref-type="bibr"><sup>120</sup></xref> HTLV-1 modifies the behavior of CD4<sup>+</sup> T&#x000a0;cells and alters their cytokine production. HTLV-1 is clinically associated with adult T&#x000a0;cell leukemia/lymphoma (ATL), and tropical spastic paraparesis/HTLV-1-associated myelopathy (PET/HAM)<xref rid="bib121" ref-type="bibr"><sup>121</sup></xref> and can cause autoimmune disease, such as rheumatoid arthritis, systemic lupus erythematosis, and Sj&#x000f6;gren's syndrome.<xref rid="bib117" ref-type="bibr">117</xref>, <xref rid="bib118" ref-type="bibr">118</xref>, <xref rid="bib119" ref-type="bibr">119</xref>, <xref rid="bib120" ref-type="bibr">120</xref>
</p><p id="p0465">The development of the HTLV-1 induced autoimmunity is thought to rely on molecular mimicry, and HTLV-1 induced T&#x000a0;cell immunosuppression is caused by direct infection of CD4<sup>+</sup> T&#x000a0;cells. CD4<sup>+</sup> T&#x000a0;cells that have altered function and cytokine production. Tax is the primary inducer of clonal infected T&#x000a0;cell expansion, and genetic instability.<xref rid="bib117" ref-type="bibr"><sup>117</sup></xref> Tax expression promotes T&#x000a0;cell activation, proliferation, and resistance to apoptosis.<xref rid="bib122" ref-type="bibr"><sup>122</sup></xref> Clinically, patients infected with HTLV1 have increased infections and increased autoimmunity, particularly rheumatoid arthritis and Sjogren syndrome. The autoimmunity correlates somewhat with viral load, however, there are immunologic mechanisms that probably facilitate breaks in tolerance leading to autoimmunity.</p><p id="p0470">In addition, natural killer (NK) cells from individuals with PET/HAM have decreased expression of the activating receptor NKp30.<xref rid="bib123" ref-type="bibr"><sup>123</sup></xref> This likely results in decreased NK cell activation, leading to decreased ability of NK cells to kill virus-infected cells. HTLV infection is clinically associated with an increased risk of disseminated strongyloidiasis,<xref rid="bib124" ref-type="bibr"><sup>124</sup></xref> schistosomiasis,<xref rid="bib125" ref-type="bibr"><sup>125</sup></xref> likely due to high levels of IFN-&#x003b3;, decreasing the production of Th2-like cytokines (IL-4, IL-5, IL-13) and IgE essential to contain these parasitic infections. Taken together, HTLV induces cytotoxic T&#x000a0;cells to kill virus-infected cells, alters CD4<sup>+</sup> T&#x000a0;cell function and cytokine production and it decreases NK cell activation leading to susceptibility to subsequent disseminated parasitic infections.
</p></sec></sec></sec><sec id="s0055"><title>Bone marrow (BM) suppression related to viral infection</title><p id="p0475">Many viral infections have been associated with BM failure or hyperproliferative syndromes. <xref rid="t0015" ref-type="table">Table&#x000a0;49.2</xref>
summarizes some of the human viral infections that cause self-resolving or persistent BM suppression.<xref rid="bib126" ref-type="bibr"><sup>126</sup></xref> However, the specific pathogenic mechanisms that underlie the reported virally induced BM manifestations have not been fully characterized. Nonetheless, many different viruses generate the same pathological condition. This suggests that a common underlying mechanism(s), specifically virologic or immunologic are responsible for the clinical pathologic outcome. Certain virus can also lead to different pathological manifestations in different patients heralding a genetic basis for aberrant immune activation in BM failure.<table-wrap position="float" id="t0015"><label>Table&#x000a0;49.2</label><caption><p>Bone marrow pathologies associated with human viral infections.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Pathology</th><th>Virus</th><th>Comments</th></tr></thead><tbody><tr><td rowspan="2">Pancytopenia</td><td>EBV</td><td>Self-resolving</td></tr><tr><td>HCV</td><td>Affected by medication</td></tr><tr><td rowspan="3">Aplastic anemia</td><td>Parvovirus B19</td><td>Driven by infection of erythroid progenitors</td></tr><tr><td>EBV, CMV, VZV, HHV, HIV, HAV, and HCV</td><td>Driven by a strong antiviral T&#x000a0;cell response and ensuing cytokine production</td></tr><tr><td>Dengue</td><td>Mechanism unknown</td></tr><tr><td rowspan="5">HLH</td><td>CMV</td><td rowspan="5">Driven by the ensuing antiviral immune response rather than the virus itself</td></tr><tr><td>Parvovirus B19</td></tr><tr><td>Dengue</td></tr><tr><td>HAV</td></tr><tr><td>HIV (acute)</td></tr><tr><td rowspan="2">Lymphoproliferative disorders and malignancies</td><td>EBV</td><td>Infectious mononucleosis and chronic active EBV disease</td></tr><tr><td>HCV</td><td>Acute myeloid leukemia, primary myelodysplastic syndrome</td></tr></tbody></table><table-wrap-foot><fn><p>Table&#x000a0;reproduced from Pascutti MF, Erkelens MN, Nolte MA. Impact of viral infections on hematopoiesis: from beneficial to detrimental effects on Bone marrow output. Front Immunol 2016;7:364. Reprinted under <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/" id="interref7">https://creativecommons.org/licenses/by/4.0/</ext-link>.</p></fn></table-wrap-foot></table-wrap></p><p id="p0480">There are 4 different mechanisms by which viruses can affect hematopoietic stem and progenitor cells (HSPC). These mechanisms include: (1) direct viral infection, (2) viral recognition by HSPCs and indirect effects, (3) inflammatory mediators, and (4) changes in the BM microenvironment. Taken together, many types of viruses can affect hematopoiesis acutely (Parvovirus B19, dengue), transiently, permanently, chronically (CMV, HIV), systemically (HIV), locally (Influenza), directly, or indirectly, causing disruption of the hematopoietic process.<xref rid="bib126" ref-type="bibr"><sup>126</sup></xref>
</p></sec><sec id="s0060"><title>Parasites that hijack immune responses to other microbes</title><sec id="s0065"><title>Leishmaniasis: temporary immune suppression</title><p id="p0485">Leishmaniasis is caused by protozoan parasites of the genus <italic>Leishmania</italic> of the family Trypanosomatidae, and is transmitted by a sand fly vector. It infects over 12 million individuals globally in tropical and subtropical regions, with approximatel<italic>y</italic> 2 million new clinical cases (0.5 million visceral leishmaniasis [VL] and 1.5 million cutaneous leishmaniasis [CL]) each year. The estimated death toll caused by these infections is approximately 50,000 persons per year.<xref rid="bib127" ref-type="bibr"><sup>127</sup></xref>
<sup>,</sup>
<xref rid="bib128" ref-type="bibr"><sup>128</sup></xref> Three major clinical forms of leishmaniasis are known (VL, CL, and mucocutaneous leishmaniasis [MCL]); all are the result of infection by different species of this parasite and the various host immune responses made to these microbes (<xref rid="b0020" ref-type="boxed-text">Box&#x000a0;49.3</xref>
). Leishmaniasis is transmitted by sand flies with dogs, rodents (East Africa, Ethiopia, the Sudan and Kenya) and foxes (Mediterranean and Asia) as reservoirs.<boxed-text id="b0020"><label>Box&#x000a0;49.3</label><caption><title>Leishmaniasis (L)</title></caption><p id="bpar0430">Visceral Leishmania.</p><p id="bpar0435">Fever, weakness, weight loss, splenomegaly.</p><p id="bpar0440">L. donovani.</p><p id="bpar0445">Cutaneous Leishmania (simple or diffuse).</p><p id="bpar0450">Single or multiple ulcers.</p><p id="bpar0455">L. tropica.</p><p id="bpar0460">L. major.</p><p id="bpar0465">L. aethiopica.</p><p id="bpar0470">L. Mexicana.</p><p id="bpar0475">L. braziliensis.</p><p id="bpar0480">Mucocutaneous Leishmania.</p><p id="bpar0485">Mucous membrane ulceration.</p><p id="bpar0490">L. braziliensis.</p></boxed-text></p><p id="p0490">VL is fatal if not treated, and is caused by <italic>Leishmania donovani</italic>, <italic>Leishmania infantum</italic>, and <italic>Leishmania chagasi</italic>.<xref rid="bib129" ref-type="bibr"><sup>129</sup></xref>
<sup>,</sup>
<xref rid="bib130" ref-type="bibr"><sup>130</sup></xref> Immunity to leishmaniasis is mediated by the cellular and humoral arms of the mammalian immune system: the innate system (by neutrophils, macrophages, and dendritic cells) and by adaptive (T cells) responses.<xref rid="bib131" ref-type="bibr"><sup>131</sup></xref> Sand-fly bites cause minimal tissue damage, but the bite promotes neutrophil recruitment.<xref rid="bib132" ref-type="bibr"><sup>132</sup></xref>
<sup>,</sup>
<xref rid="bib133" ref-type="bibr"><sup>133</sup></xref> Parasites can survive for a time within neutrophils, and eventually they parasitize neutrophils. Viable parasites are engulfed by macrophages or dendritic cells. Inside the macrophages, promastigotes change into amastigotes and they reproduce by binary fission, ultimately rupturing the macrophage and releasing amastigotes into the blood. Leishmania modulates the normal antimicrobial mechanisms of the macrophages. They increase membrane fluidity and thereby disrupt lipid rafts and APC antigen presentation as well as lysosomal fusion.<xref rid="bib134" ref-type="bibr"><sup>134</sup></xref> Leishmania-infected APCs interact with T&#x000a0;cells, and together they express cytokines and chemokines that begin to &#x0201c;hijack&#x0201d; the immune system, which enables these parasites to survive.<xref rid="bib135" ref-type="bibr"><sup>135</sup></xref> Cell-mediated immunity is the principle host defense against <italic>leishmania</italic> species. T<sub>h</sub>1-like cells primed mainly by APCs and IL-12 expression are major effector responses to this microbe.<xref rid="bib136" ref-type="bibr">136</xref>, <xref rid="bib137" ref-type="bibr">137</xref>, <xref rid="bib138" ref-type="bibr">138</xref>, <xref rid="bib139" ref-type="bibr">139</xref> The dichotomy between T<sub>h</sub>1-like protection (IFN-&#x003b3;, IL-2, and TNF) and Th2-like disease progression (IL-10, IL-4) in mice has been shown to be essential in CL infection,<xref rid="bib140" ref-type="bibr"><sup>140</sup></xref> although this paradigm is less clear in humans infected with VL.<xref rid="bib141" ref-type="bibr"><sup>141</sup></xref>
<sup>,</sup>
<xref rid="bib142" ref-type="bibr"><sup>142</sup></xref> The immunopathology of VL is complex, and involves cellular and genetic factors that confer disease susceptibility, versus resistance to <italic>Leishmania</italic> species.<xref rid="bib143" ref-type="bibr"><sup>143</sup></xref>
</p><p id="p0495">Persistent VL correlates with a chronic Th2-like (IL-10, IL-4, IL-5, and IL-13) response to <italic>L.&#x000a0;donovani</italic>
<xref rid="bib142" ref-type="bibr"><sup>142</sup></xref> and increased serum IL-10 expression.<xref rid="bib144" ref-type="bibr">144</xref>, <xref rid="bib145" ref-type="bibr">145</xref>, <xref rid="bib146" ref-type="bibr">146</xref>, <xref rid="bib147" ref-type="bibr">147</xref> IL-10 is crucial in establishing and maintaining T<sub>h</sub>2-dependent chronic suppression of Th1-like mediated immunity in CL.<xref rid="bib148" ref-type="bibr">148</xref>, <xref rid="bib149" ref-type="bibr">149</xref>, <xref rid="bib150" ref-type="bibr">150</xref> and inhibits amastigote killing.<xref rid="bib150" ref-type="bibr"><sup>150</sup></xref>
<sup>,</sup>
<xref rid="bib151" ref-type="bibr"><sup>151</sup></xref> IL-10 also inhibits the production of IFN-&#x003b3;.<xref rid="bib152" ref-type="bibr"><sup>152</sup></xref> Cellular immunity impairment correlates with active disease progression secondary to IL-10 expression, independent of IFN-&#x003b3; levels.<xref rid="bib153" ref-type="bibr"><sup>153</sup></xref> In murine CL, CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> natural Tregs are a major IL-10 source and are crucial for parasite survival.<xref rid="bib154" ref-type="bibr"><sup>154</sup></xref> However, IL-10 is also derived from non-Tregs.<xref rid="bib146" ref-type="bibr"><sup>146</sup></xref>
<sup>,</sup>
<xref rid="bib155" ref-type="bibr"><sup>155</sup></xref> This suggests that any therapeutic approach to treat leishmania infection will require species-specific manipulation of the immune responses made to these parasites. For example, the potent T<sub>h</sub>2-like cytokine IL-4 is critical in CL, but not in VL.<xref rid="bib141" ref-type="bibr"><sup>141</sup></xref> Thus, modulating IL-4 expression may be helpful in VC, but not in the treatment of CL.<xref rid="bib156" ref-type="bibr"><sup>156</sup></xref>
</p><p id="p0500">Resolution of human and murine VL depends on the production of Th1-like cytokines.<xref rid="bib139" ref-type="bibr"><sup>139</sup></xref>
<sup>,</sup>
<xref rid="bib140" ref-type="bibr"><sup>140</sup></xref>
<sup>,</sup>
<xref rid="bib147" ref-type="bibr"><sup>147</sup></xref>
<sup>,</sup>
<xref rid="bib157" ref-type="bibr">157</xref>, <xref rid="bib158" ref-type="bibr">158</xref>, <xref rid="bib159" ref-type="bibr">159</xref>, <xref rid="bib160" ref-type="bibr">160</xref> IL-12 and IFN-&#x003b3; are crucial in controlling parasite growth and development.<xref rid="bib157" ref-type="bibr"><sup>157</sup></xref>
<sup>,</sup>
<xref rid="bib161" ref-type="bibr"><sup>161</sup></xref> While IL-10 suppresses host immunity and helps parasite survival, it is the antidote to inflammation that reduces tissue damage caused by exaggerated inflammation.<xref rid="bib162" ref-type="bibr"><sup>162</sup></xref> Since IFN-&#x003b3; -producing cells can also produce small amounts of IL-10, this may act as a negative feedback in controlling tissue damage<xref rid="bib142" ref-type="bibr"><sup>142</sup></xref>
<sup>,</sup>
<xref rid="bib146" ref-type="bibr"><sup>146</sup></xref>
<sup>,</sup>
<xref rid="bib163" ref-type="bibr"><sup>163</sup></xref>
<sup>,</sup>
<xref rid="bib164" ref-type="bibr"><sup>164</sup></xref> and supporting immune memory. TNF stimulates IFN-&#x003b3; -induced expression of nitric oxide by APCs that can kill VL parasites.<xref rid="bib165" ref-type="bibr">165</xref>, <xref rid="bib166" ref-type="bibr">166</xref>, <xref rid="bib167" ref-type="bibr">167</xref>, <xref rid="bib168" ref-type="bibr">168</xref>, <xref rid="bib169" ref-type="bibr">169</xref>, <xref rid="bib170" ref-type="bibr">170</xref> Th17-like cells that produce IL-17 are pro-inflammatory, and stimulate IL-6, TNF-&#x003b1;, and chemokine expression. However, <italic>L.&#x000a0;donovani</italic> strongly induces IL-17 and IL-22, and enhances the secretion of these cytokines that protect this parasite.<xref rid="bib171" ref-type="bibr"><sup>171</sup></xref> CD8<sup>+</sup> cytotoxic T&#x000a0;cells are also important in controlling CL and VL.<xref rid="bib172" ref-type="bibr"><sup>172</sup></xref> CD4<sup>+</sup> and CD8<sup>+</sup> T&#x000a0;cells, and their pro-inflammatory cytokines, are required to control VL parasite proliferation and leishmaniacidal activity.<xref rid="bib138" ref-type="bibr"><sup>138</sup></xref>
<sup>,</sup>
<xref rid="bib161" ref-type="bibr"><sup>161</sup></xref>
<sup>,</sup>
<xref rid="bib173" ref-type="bibr">173</xref>, <xref rid="bib174" ref-type="bibr">174</xref>, <xref rid="bib175" ref-type="bibr">175</xref>, <xref rid="bib176" ref-type="bibr">176</xref> However, in canine VL, antibodies are insufficient in providing protection in the absence of -pro-inflammatory T&#x000a0;cell responses.<xref rid="bib132" ref-type="bibr"><sup>132</sup></xref> Thus, in addition to protective T&#x000a0;cell responses, other T&#x000a0;cell subsets, including Tregs and Th17&#x000a0;cells, confer either susceptibility or resistance to animal verses human VC. Other cells may also be important in the resolution of these infections, thus further investigation is required in designing vaccines or treatments for these diseases.</p><p id="p0505">Greater than 20% of CL patients have reported secondary bacterial infections.<xref rid="bib177" ref-type="bibr"><sup>177</sup></xref>
<italic>S.&#x000a0;aureus</italic>, coagulase-negative <italic>Staphylococcus</italic>, <italic>Escherichia coli</italic>, <italic>Proteus</italic>, and <italic>Klebsiella</italic> have been cultured from lesions (listed in decreasing frequency). However, the incidence of these infections is higher in ulcerated compared to non-ulcerated lesions. Thus, both disruption of the skin, and possibly immunosuppression caused by CL, likely play roles in the development of secondary bacterial infection in CL, leading to severe or lethal bacterial infection.<xref rid="bib177" ref-type="bibr"><sup>177</sup></xref> Increased Treg numbers in CL have been linked to activation/reactivation of latent microbial infections (<italic>Mycobacterium tuberculosis</italic>, <italic>Toxoplasma</italic>, herpes viruses) that cause significant morbidity and mortality, possibly as a result of immunosuppression and other factors, although how activation/reactivation of dormant infections occurs remains unknown.<xref rid="bib178" ref-type="bibr"><sup>178</sup></xref> Thus, leishmania infection causes secondary infections, and activation/reactivation of dormant infections that can lead to severe or lethal outcomes through multiple mechanisms.<xref rid="bib178" ref-type="bibr"><sup>178</sup></xref>
<italic>L.&#x000a0;donovani</italic> infection can also clinically resemble and cause hemaphagocytic lymphohistiocytosis (HLH) and successful treatment of leishmaniasis can lead to the complete resolution of HLH symptoms.<xref rid="bib179" ref-type="bibr"><sup>179</sup></xref>
<sup>,</sup>
<xref rid="bib180" ref-type="bibr"><sup>180</sup></xref> These reports open the question as to whether HLH patients should be prescreened and aggressively treated for visceral leishmania infection prior to instituting stem cell transplantation for HLH when from endemic areas.<xref rid="bib179" ref-type="bibr"><sup>179</sup></xref> VL has been associated with significant secondary infections. These may be confounded by HLH where neutropenia is common. Infections ranging from sepsis to urinary tract infections occur in a significant subset of patients with VL. The most common pathogens causing sepsis are <italic>S.&#x000a0;aureus, Klebsialla pneumonia</italic>, and <italic>Pseudomonas aeruginosa</italic>. Common laboratory features include neutropenia, eosinopenia and leukopenia. Co-infection with HIV alters the clinical presentation with more lung and gastrointestinal involvement.</p><p id="p0510">Taken together, the innate response (professional APCs) is altered by leishmaniasis infection, leading to polarized adaptive immune responses that support or block persistent infection by <italic>leishmania</italic> organisms. This subverts or supports effective immunity to these parasites, and in patients with persistent infection, the Th2-like/Treg bias may predispose patients infected with <italic>leishmania</italic> species to develop or reactivate lethal secondary superinfections, and the development of HLH-like clinical symptoms.</p></sec><sec id="s0070"><title>Malaria: temporary immunosuppression</title><p id="p0515">Malarial organisms are parasites with a major public health impact world-wide. There were an estimated 219 million cases of malaria (range 154&#x02013;289 million) and 660,000 deaths (range 610,000&#x02013;971,000) in 2010.<xref rid="bib181" ref-type="bibr"><sup>181</sup></xref>
<italic>Plasmodium</italic> species cause malaria and can induce immunosuppression in infected individuals<xref rid="bib182" ref-type="bibr"><sup>182</sup></xref> resulting in increased susceptibility to secondary infections, such as non-typhoidal salmonella,<xref rid="bib183" ref-type="bibr"><sup>183</sup></xref> herpes zoster virus,<xref rid="bib184" ref-type="bibr"><sup>184</sup></xref> hepatitis B virus,<xref rid="bib185" ref-type="bibr"><sup>185</sup></xref> Moloney leukemia virus,<xref rid="bib186" ref-type="bibr"><sup>186</sup></xref> and Epstein-Barr virus reactivation.<xref rid="bib187" ref-type="bibr"><sup>187</sup></xref> Efficacy of heterologous vaccines can also be suppressed in malaria-infected patients,<xref rid="bib188" ref-type="bibr"><sup>188</sup></xref> further documenting the immunosuppressive effects of malaria infection.</p><p id="p0520">Malaria parasites inhibit DC maturation<xref rid="bib189" ref-type="bibr"><sup>189</sup></xref> via uptake of malaria pigment hemozoin (HZ) from parasitized RBCs.<xref rid="bib190" ref-type="bibr"><sup>190</sup></xref> DC inhibition reduces T&#x000a0;cell expansion, cytokine production, and migration into B cell follicles.<xref rid="bib191" ref-type="bibr"><sup>191</sup></xref> The effect on DC changes occurs during the different phases of this infection. Although DC function is impaired immediately following the initial burst of parasitemia, T and B cell responses to heterologous antigens change dynamically during the course of infection.<xref rid="bib191" ref-type="bibr"><sup>191</sup></xref> T&#x000a0;cell proliferation, and effector function and migration are suppressed, and B cells do not expand or produce antibodies. HZ, prevents the formation of stable, long-lasting cell&#x02013;cell contacts between T&#x000a0;cells and DCs impairing co-stimulatory activity.<xref rid="bib192" ref-type="bibr"><sup>192</sup></xref> Nonetheless, there is also a T&#x000a0;cells functional defect.<xref rid="bib188" ref-type="bibr"><sup>188</sup></xref> Taken together, impairment of both innate and adaptive signaling induced by malarial infection/HZ pigment skews the immune response toward tolerance instead of immunity, and this subversion of effective immunity leads to secondary infection with other organisms as a consequence of this parasitic infection.</p><p id="p0525">Invasive infections in patients with malaria are due to <italic>S.&#x000a0;pneumoniae</italic>, <italic>H.&#x000a0;influenzae</italic> type b, <italic>S.&#x000a0;aureus, E. coli</italic> and other gram-negative bacteria. Risk factors include younger age, recent malaria infection, severe anemia, splenomegaly, HIV-co-infection and severe malnutrition. Some of this susceptibility seems to reflect functional asplenia and impaired barrier function.</p></sec></sec><sec id="s0075"><title>Bacteria that hijack immune responses to other microbes</title><sec id="s0080"><title><italic>Bordetella pertussis:</italic> temporary immunosuppression</title><p id="p0530">
<italic>B.&#x000a0;pertussis,</italic> the causative agent of whooping cough, is an infection that can be fatal in infants, but in older children, adolescents, and adults usually causes a chronic cough of varying severity that generally persists long after clearance of the infection. This bacterial infection of the airways is an important cause of infant death world-wide, and continues to be a public health concern even in countries with high vaccination coverage. While estimates of the incidence of new cases of pertussis vary,<xref rid="bib193" ref-type="bibr"><sup>193</sup></xref>
<sup>,</sup>
<xref rid="bib194" ref-type="bibr"><sup>194</sup></xref> pertussis infection world-wide varies between 16 million and 50 million cases yearly, 95% of which are in developing countries.<xref rid="bib193" ref-type="bibr"><sup>193</sup></xref>
<sup>,</sup>
<xref rid="bib194" ref-type="bibr"><sup>194</sup></xref> In addition, between 195,000 and 300,000 deaths, mostly of young infants who were either unvaccinated or incompletely vaccinated, occur yearly.<xref rid="bib193" ref-type="bibr"><sup>193</sup></xref>
<sup>,</sup>
<xref rid="bib194" ref-type="bibr"><sup>194</sup></xref> For several decades, infant immunization programs using pertussis vaccines of high efficiency have been highly successful in preventing severe pertussis in infants. However, pertussis continues to be a significant health issue world-wide.</p><p id="p0535">Following an incubation period of 9&#x02013;10&#x000a0;days (range 6&#x02013;20&#x000a0;days) patients develop catarrhal symptoms including cough, and over 1&#x02013;2&#x000a0;weeks develop coughing paroxysms that end in the characteristic &#x0201c;whoop&#x0201d; associated with this infection. Although the cause of the characteristic &#x0201c;whoop&#x0201d; associated with <italic>B.&#x000a0;pertussis</italic> infection remains unresolved, a significant body of knowledge has accumulated to explain how <italic>B.&#x000a0;pertussis</italic> induces immune suppression, evasion, and modulation, thereby leading to a poor clinical outcome. <xref rid="f0035" ref-type="fig">Fig.&#x000a0;49.6</xref>
<xref rid="bib195" ref-type="bibr"><sup>195</sup></xref> gives an overview of several <italic>B.&#x000a0;pertussis</italic> virulence factors that have immunomodulatory properties, the cells that they target, and the mechanisms thought to be involved in the induction of immune dysregulation caused by this infection. It has been shown that <italic>B.&#x000a0;pertussis</italic>-derived filamentous hemagglutinin (FHA) is the major surface structure that mediates adherence of <italic>B.&#x000a0;pertussis</italic> to host cells, primarily to cilia of airway ciliated epithelium. However, multiple factors likely contribute to this binding process,<xref rid="bib196" ref-type="bibr"><sup>196</sup></xref> including secreted adenylate cyclase toxin (ACT), which enhances FHA adherence to lung epithelial cells.<xref rid="bib197" ref-type="bibr"><sup>197</sup></xref> FHA also has immunosuppressive and modulatory activities by its ability to induce FHA-specific Tregs that secrete IL-10 and suppress T<sub>h</sub>1-like responses to <italic>B.&#x000a0;pertussis.</italic>
<xref rid="bib198" ref-type="bibr"><sup>198</sup></xref> Anti-FHA antibodies can also reduce phagocytosis of these bacteria by human neutrophils.<xref rid="bib199" ref-type="bibr"><sup>199</sup></xref> ACT, a secreted toxin, targets host phagocytic cells by binding complement receptor 3 (CR3; CD11b/CD18).<xref rid="bib200" ref-type="bibr"><sup>200</sup></xref>
<sup>,</sup>
<xref rid="bib201" ref-type="bibr"><sup>201</sup></xref> ACT-deficient mutants of <italic>B.&#x000a0;pertussis</italic> are more efficiently phagocytosed by human neutrophils,<xref rid="bib202" ref-type="bibr"><sup>202</sup></xref> and in mice, lower bacterial loads are found in the respiratory tract.<xref rid="bib203" ref-type="bibr"><sup>203</sup></xref> Secreted ACT upregulates major histocompatibility complex class II MHC and co-stimulatory molecule expression on dendritic cells (DCs). ACT also prevents maturity, and thereby decreases their pro-inflammatory cytokine production.<xref rid="bib204" ref-type="bibr">204</xref>, <xref rid="bib205" ref-type="bibr">205</xref>, <xref rid="bib206" ref-type="bibr">206</xref> Tracheal cytotoxin (TCT) is also expressed at relatively high levels by <italic>B.&#x000a0;pertussis</italic>, and is a disaccharide-tetrapeptide fragment of peptidoglycan. Purified TCT, in synergy with lipopolysaccharide (LPS), damages ciliated airway epithelial cells through production of IL-1a and nitric oxide,<xref rid="bib207" ref-type="bibr"><sup>207</sup></xref> causing deleterious effects on neutrophils.<xref rid="bib208" ref-type="bibr"><sup>208</sup></xref>
<fig id="f0035"><label>Fig.&#x000a0;49.6</label><caption><p>Bordetella infection.</p><p><italic>Bordetella pertussis</italic> infection begins with infection of the respiratory tract. The toxins elaborated during the infection have multiple effects which modulate the immune response.</p></caption><graphic xlink:href="f49-06-9780128167687"/><attrib>Figure reprinted from Carbonetti NH. Immunomodulation in the pathogenesis of Bordetella pertussis infection and. Curr Opin Pharmacol 2007;7(3):272&#x02013;8 with permission from Elsevier.</attrib></fig></p><p id="p0540">Pertussis toxin (PT), uniquely produced by <italic>B.&#x000a0;pertussis</italic>, is another secreted toxin expressed by this bacterium. PT ADP ribosylates several heterotrimeric G proteins in mammalian cells, has long been known to disrupt signaling pathways with a wide range of downstream effects,<xref rid="bib209" ref-type="bibr"><sup>209</sup></xref> and can cause immunosuppression. PT causes lymphocytosis.<xref rid="bib210" ref-type="bibr"><sup>210</sup></xref> PT-deficient mutant strains show reduce levels of airway infection 24&#x000a0;h after inoculation because PT delays neutrophil recruitment and influx to the airways,<xref rid="bib203" ref-type="bibr"><sup>203</sup></xref>
<sup>,</sup>
<xref rid="bib211" ref-type="bibr"><sup>211</sup></xref>
<sup>,</sup>
<xref rid="bib212" ref-type="bibr"><sup>212</sup></xref> reduces anti-<italic>B.&#x000a0;pertussis</italic> antibody-induced bacterial clearance,<xref rid="bib211" ref-type="bibr"><sup>211</sup></xref> depletes airway macrophages<xref rid="bib213" ref-type="bibr"><sup>213</sup></xref> enhancing infection.<xref rid="bib214" ref-type="bibr"><sup>214</sup></xref> Since ADP ribosylation of airway macrophage G proteins by PT has been shown to be long-lasting, and correlates with active infection-promoting longevity of this microbe.<xref rid="bib212" ref-type="bibr"><sup>212</sup></xref> This evidence supports the concept that the effects of PT on host cells in the airway may be particularly long-lived. PT also exerts multiple suppressive effects on the immune system beyond innate immune cells, including suppression of serum antibody responses to <italic>B.&#x000a0;pertussis</italic> antigens following infection,<xref rid="bib214" ref-type="bibr">214</xref>, <xref rid="bib215" ref-type="bibr">215</xref>, <xref rid="bib216" ref-type="bibr">216</xref> reduction of major histocompatibility complex class II expression on human monocytes,<xref rid="bib217" ref-type="bibr"><sup>217</sup></xref> and modulation of dendritic cell expression of surface markers.<xref rid="bib218" ref-type="bibr"><sup>218</sup></xref>
</p><p id="p0545">
<italic>B.&#x000a0;pertussis</italic> infection causes immunomodulation of Toll-like receptor (TLR4),<xref rid="bib219" ref-type="bibr"><sup>219</sup></xref> which recognizes the lipopolysaccharide found on <italic>B.&#x000a0;pertussis</italic> and Gram-negative bacteria.<xref rid="bib220" ref-type="bibr"><sup>220</sup></xref>
<sup>,</sup>
<xref rid="bib221" ref-type="bibr"><sup>221</sup></xref> TLR4 signaling triggered by <italic>B.&#x000a0;pertussis</italic> induces IL-10, which can inhibit inflammatory responses, and limit airway inflammation,<xref rid="bib220" ref-type="bibr"><sup>220</sup></xref> and can synergize with ACT to induce IL-10.<xref rid="bib206" ref-type="bibr"><sup>206</sup></xref> In addition, TLR4-dependent responses induced by <italic>B.&#x000a0;pertussis</italic> drive lower levels of inflammatory cytokines.<xref rid="bib222" ref-type="bibr"><sup>222</sup></xref>
</p><p id="p0550">Thus, PT promotes <italic>B.&#x000a0;pertussis</italic> infection by multiple mechanisms through its effects on innate immunity in the initial stages of disease in na&#x000ef;ve individuals. This reduces adaptive immune responses during the initial infection, and promotes re-infection in partially immune individuals. The consequences of these suppressive effects on both the innate and adaptive immune responses induced by <italic>B.&#x000a0;pertussis</italic> infection can cause secondary infection, typically pneumonia, which is the major cause of fatal outcome from this infection.<xref rid="bib223" ref-type="bibr"><sup>223</sup></xref> Infants are at highest risk of all complications related to <italic>B.&#x000a0;pertussis</italic> infection but all ages have relatively high rates of secondary complications. Approximately 50% of infants exhibit apnea of greater or lesser duration and a quarter develop pneumonia. Roughly 5% have otitis media and 1% develop seizures. In adults, the most common secondary effect is pneumonia occurring in about 5%.</p></sec></sec><sec id="s0085"><title>Conclusions</title><p id="p0555">Distinguishing patients with secondary immune deficiency disease caused by a primary infection in an individual with an &#x0201c;intact&#x0201d; immune system from patients with an underlying PIDD is often a challenge. Recognizing primary infections that can cause secondary immunodeficiencies is an important factor in discrimination between these two groups of patients. Clinical immunologists need to always consider whether an acute, serious infection is causing a secondary primary infection in an &#x0201c;immunologically intact&#x0201d; individual, or is the herald of an underlying defect in a genetically defined immunocompromised patient with PIDD. The long term treatment and clinical outcomes of these two different patient populations is linked to understanding how severe primary infections cause disease in these two different settings.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="ref0010"><person-group person-group-type="author"><name><surname>Benoit</surname><given-names>M.</given-names></name><name><surname>Desnues</surname><given-names>B.</given-names></name><name><surname>Mege</surname><given-names>J.L.</given-names></name></person-group><article-title>Macrophage polarization in bacterial infections</article-title><source>J&#x000a0;Immunol</source><volume>181</volume><issue>6</issue><year>2008</year><fpage>3733</fpage><lpage>3739</lpage><pub-id pub-id-type="pmid">18768823</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="ref0015"><person-group person-group-type="author"><name><surname>Suarez</surname><given-names>A.</given-names></name><name><surname>Castro</surname><given-names>P.</given-names></name><name><surname>Alonso</surname><given-names>R.</given-names></name><name><surname>Mozo</surname><given-names>L.</given-names></name><name><surname>Gutierrez</surname><given-names>C.</given-names></name></person-group><article-title>Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms</article-title><source>Transplantation</source><volume>75</volume><issue>5</issue><year>2003</year><fpage>711</fpage><lpage>717</lpage><pub-id pub-id-type="pmid">12640314</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="ref0020"><person-group person-group-type="author"><name><surname>Eskdale</surname><given-names>J.</given-names></name><name><surname>Gallagher</surname><given-names>G.</given-names></name><name><surname>Verweij</surname><given-names>C.L.</given-names></name><name><surname>Keijsers</surname><given-names>V.</given-names></name><name><surname>Westendorp</surname><given-names>R.G.</given-names></name><name><surname>Huizinga</surname><given-names>T.W.</given-names></name></person-group><article-title>Interleukin 10 secretion in relation to human IL-10 locus haplotypes</article-title><source>Proc Natl Acad Sci U S A</source><volume>95</volume><issue>16</issue><year>1998</year><fpage>9465</fpage><lpage>9470</lpage><pub-id pub-id-type="pmid">9689103</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="ref0025"><person-group person-group-type="author"><name><surname>Eskdale</surname><given-names>J.</given-names></name><name><surname>Keijsers</surname><given-names>V.</given-names></name><name><surname>Huizinga</surname><given-names>T.</given-names></name><name><surname>Gallagher</surname><given-names>G.</given-names></name></person-group><article-title>Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus</article-title><source>Genes Immun</source><volume>1</volume><issue>2</issue><year>1999</year><fpage>151</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">11196662</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="ref0030"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>K.W.</given-names></name><name><surname>de Waal Malefyt</surname><given-names>R.</given-names></name><name><surname>Coffman</surname><given-names>R.L.</given-names></name><name><surname>O'Garra</surname><given-names>A.</given-names></name></person-group><article-title>Interleukin-10 and the interleukin-10 receptor</article-title><source>Annu Rev Immunol</source><volume>19</volume><year>2001</year><fpage>683</fpage><lpage>765</lpage><pub-id pub-id-type="pmid">11244051</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="ref0035"><person-group person-group-type="author"><name><surname>Costa-Carvalho</surname><given-names>B.T.</given-names></name><name><surname>Grumach</surname><given-names>A.S.</given-names></name><name><surname>Franco</surname><given-names>J.L.</given-names></name></person-group><article-title>Attending to warning signs of primary immunodeficiency diseases across the range of clinical practice</article-title><source>J&#x000a0;Clin Immunol</source><volume>34</volume><issue>1</issue><year>2014</year><fpage>10</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">24241582</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="ref0040"><person-group person-group-type="author"><name><surname>Arkwright</surname><given-names>P.D.</given-names></name><name><surname>Gennery</surname><given-names>A.R.</given-names></name></person-group><article-title>Ten warning signs of primary immunodeficiency: a new paradigm is needed for the 21st century</article-title><source>Ann N Y Acad Sci</source><volume>1238</volume><year>2011</year><fpage>7</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">22129048</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="ref0045"><person-group person-group-type="author"><name><surname>Arslan</surname><given-names>S.</given-names></name><name><surname>Ucar</surname><given-names>R.</given-names></name><name><surname>Caliskaner</surname><given-names>A.Z.</given-names></name></person-group><article-title>How effective are the 6 European Society of Immunodeficiency warning signs for primary immunodeficiency disease?</article-title><source>Ann Allergy Asthma Immunol</source><volume>116</volume><issue>2</issue><year>2016</year><comment>151&#x02013;155.e1</comment></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="ref0050"><person-group person-group-type="author"><name><surname>D'Elios</surname><given-names>M.M.</given-names></name><name><surname>Benagiano</surname><given-names>M.</given-names></name><name><surname>Della Bella</surname><given-names>C.</given-names></name><name><surname>Amedei</surname><given-names>A.</given-names></name></person-group><article-title>T-cell response to bacterial agents</article-title><source>J&#x000a0;Infect Dev Ctries</source><volume>5</volume><issue>9</issue><year>2011</year><fpage>640</fpage><lpage>645</lpage><pub-id pub-id-type="pmid">21918304</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="ref0055"><person-group person-group-type="author"><name><surname>Griffin</surname><given-names>D.E.</given-names></name></person-group><article-title>Measles virus-induced suppression of immune responses</article-title><source>Immunol Rev</source><volume>236</volume><year>2010</year><fpage>176</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">20636817</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="ref0060"><person-group person-group-type="author"><name><surname>Muscat</surname><given-names>M.</given-names></name><name><surname>Bang</surname><given-names>H.</given-names></name><name><surname>Wohlfahrt</surname><given-names>J.</given-names></name><name><surname>Glismann</surname><given-names>S.</given-names></name><name><surname>M&#x000f8;lbak</surname><given-names>K.</given-names></name><name><surname>Group</surname><given-names>E.N.</given-names></name></person-group><article-title>Measles in Europe: an epidemiological assessment</article-title><source>Lancet</source><volume>373</volume><issue>9661</issue><year>2009</year><fpage>383</fpage><lpage>389</lpage><pub-id pub-id-type="pmid">19131097</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="ref0065"><person-group person-group-type="author"><name><surname>Grais</surname><given-names>R.F.</given-names></name><name><surname>Dubray</surname><given-names>C.</given-names></name><name><surname>Gerstl</surname><given-names>S.</given-names></name></person-group><article-title>Unacceptably high mortality related to measles epidemics in Niger, Nigeria, and Chad</article-title><source>PLoS Med</source><volume>4</volume><issue>1</issue><year>2007</year><fpage>e16</fpage><pub-id pub-id-type="pmid">17199407</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="ref0070"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>M.J.</given-names></name><name><surname>Grais</surname><given-names>R.F.</given-names></name><name><surname>Bharti</surname><given-names>N.</given-names></name></person-group><article-title>The dynamics of measles in sub-Saharan Africa</article-title><source>Nature</source><volume>451</volume><issue>7179</issue><year>2008</year><fpage>679</fpage><lpage>684</lpage><pub-id pub-id-type="pmid">18256664</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="ref0075"><person-group person-group-type="author"><name><surname>Richard</surname><given-names>J.L.</given-names></name><name><surname>Masserey Spicher</surname><given-names>V.</given-names></name></person-group><article-title>Large measles epidemic in Switzerland from 2006 to 2009: consequences for the elimination of measles in Europe</article-title><source>Euro Surveill</source><volume>14</volume><issue>50</issue><year>2009</year></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="ref0080"><person-group person-group-type="author"><name><surname>Moench</surname><given-names>T.R.</given-names></name><name><surname>Griffin</surname><given-names>D.E.</given-names></name><name><surname>Obriecht</surname><given-names>C.R.</given-names></name><name><surname>Vaisberg</surname><given-names>A.J.</given-names></name><name><surname>Johnson</surname><given-names>R.T.</given-names></name></person-group><article-title>Acute measles in patients with and without neurological involvement: distribution of measles virus antigen and RNA</article-title><source>J&#x000a0;Infect Dis</source><volume>158</volume><issue>2</issue><year>1988</year><fpage>433</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">3042879</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="ref0085"><person-group person-group-type="author"><name><surname>Beckford</surname><given-names>A.P.</given-names></name><name><surname>Kaschula</surname><given-names>R.O.</given-names></name><name><surname>Stephen</surname><given-names>C.</given-names></name></person-group><article-title>Factors associated with fatal cases of measles. A retrospective autopsy study</article-title><source>S&#x000a0;Afr Med J</source><volume>68</volume><issue>12</issue><year>1985</year><fpage>858</fpage><lpage>863</lpage><pub-id pub-id-type="pmid">3877996</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="ref0090"><article-title>Measles | frequently asked questions about measles in U.S | CDC</article-title><source>Center for Disease Control</source><year>2019</year><ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/measles/about/faqs.html" id="interref6">https://www.cdc.gov/measles/about/faqs.html</ext-link></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="ref0095"><person-group person-group-type="author"><name><surname>Majumder</surname><given-names>M.S.</given-names></name><name><surname>Cohn</surname><given-names>E.L.</given-names></name><name><surname>Mekaru</surname><given-names>S.R.</given-names></name><name><surname>Huston</surname><given-names>J.E.</given-names></name><name><surname>Brownstein</surname><given-names>J.S.</given-names></name></person-group><article-title>Substandard vaccination compliance and the 2015 measles outbreak</article-title><source>JAMA Pediatrics</source><volume>169</volume><issue>5</issue><year>2019</year><fpage>494</fpage><lpage>495</lpage></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="ref0100"><person-group person-group-type="author"><name><surname>Tamashiro</surname><given-names>V.G.</given-names></name><name><surname>Perez</surname><given-names>H.H.</given-names></name><name><surname>Griffin</surname><given-names>D.E.</given-names></name></person-group><article-title>Prospective study of the magnitude and duration of changes in tuberculin reactivity during uncomplicated and complicated measles</article-title><source>Pediatr Infect Dis J</source><volume>6</volume><issue>5</issue><year>1987</year><fpage>451</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">3601492</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="ref0105"><person-group person-group-type="author"><name><surname>Hirsch</surname><given-names>R.L.</given-names></name><name><surname>Griffin</surname><given-names>D.E.</given-names></name><name><surname>Johnson</surname><given-names>R.T.</given-names></name></person-group><article-title>Cellular immune responses during complicated and uncomplicated measles virus infections of man</article-title><source>Clin Immunol Immunopathol</source><volume>31</volume><issue>1</issue><year>1984</year><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">6230187</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="ref0110"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>B.J.</given-names></name><name><surname>Johnson</surname><given-names>R.T.</given-names></name><name><surname>Vaisberg</surname><given-names>A.</given-names></name><name><surname>Jauregui</surname><given-names>E.</given-names></name><name><surname>Griffin</surname><given-names>D.E.</given-names></name></person-group><article-title>Cytokine production in&#x000a0;vitro and the lymphoproliferative defect of natural measles virus infection</article-title><source>Clin Immunol Immunopathol</source><volume>61</volume><issue>2 Pt 1</issue><year>1991</year><fpage>236</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">1914259</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="ref0115"><person-group person-group-type="author"><name><surname>Ryon</surname><given-names>J.J.</given-names></name><name><surname>Moss</surname><given-names>W.J.</given-names></name><name><surname>Monze</surname><given-names>M.</given-names></name><name><surname>Griffin</surname><given-names>D.E.</given-names></name></person-group><article-title>Functional and phenotypic changes in circulating lymphocytes from hospitalized zambian children with measles</article-title><source>Clin Diagn Lab Immunol</source><volume>9</volume><issue>5</issue><year>2002</year><fpage>994</fpage><lpage>1003</lpage><pub-id pub-id-type="pmid">12204949</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="ref0120"><person-group person-group-type="author"><name><surname>Bachmann</surname><given-names>M.F.</given-names></name><name><surname>Lutz</surname><given-names>M.B.</given-names></name><name><surname>Layton</surname><given-names>G.T.</given-names></name></person-group><article-title>Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes</article-title><source>Eur J Immunol</source><volume>26</volume><issue>11</issue><year>1996</year><fpage>2595</fpage><lpage>2600</lpage><pub-id pub-id-type="pmid">8921944</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="ref0125"><person-group person-group-type="author"><name><surname>Arneborn</surname><given-names>P.</given-names></name><name><surname>Biberfeld</surname><given-names>G.</given-names></name></person-group><article-title>T-lymphocyte subpopulations in relation to immunosuppression in measles and varicella</article-title><source>Infect Immun</source><volume>39</volume><issue>1</issue><year>1983</year><fpage>29</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">6600445</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="ref0130"><person-group person-group-type="author"><name><surname>Kobune</surname><given-names>F.</given-names></name><name><surname>Takahashi</surname><given-names>H.</given-names></name><name><surname>Terao</surname><given-names>K.</given-names></name></person-group><article-title>Nonhuman primate models of measles</article-title><source>Lab Anim Sci</source><volume>46</volume><issue>3</issue><year>1996</year><fpage>315</fpage><lpage>320</lpage><pub-id pub-id-type="pmid">8799939</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="ref0135"><person-group person-group-type="author"><name><surname>Esolen</surname><given-names>L.M.</given-names></name><name><surname>Park</surname><given-names>S.W.</given-names></name><name><surname>Hardwick</surname><given-names>J.M.</given-names></name><name><surname>Griffin</surname><given-names>D.E.</given-names></name></person-group><article-title>Apoptosis as a cause of death in measles virus-infected cells</article-title><source>J&#x000a0;Virol</source><volume>69</volume><issue>6</issue><year>1995</year><fpage>3955</fpage><lpage>3958</lpage><pub-id pub-id-type="pmid">7745753</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="ref0140"><person-group person-group-type="author"><name><surname>Sidorenko</surname><given-names>S.P.</given-names></name><name><surname>Clark</surname><given-names>E.A.</given-names></name></person-group><article-title>The dual-function CD150 receptor subfamily: the viral attraction</article-title><source>Nat Immunol</source><volume>4</volume><issue>1</issue><year>2003</year><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">12496974</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="ref0145"><person-group person-group-type="author"><name><surname>Engel</surname><given-names>P.</given-names></name><name><surname>Eck</surname><given-names>M.J.</given-names></name><name><surname>Terhorst</surname><given-names>C.</given-names></name></person-group><article-title>The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease</article-title><source>Nat Rev Immunol</source><volume>3</volume><issue>10</issue><year>2003</year><fpage>813</fpage><lpage>821</lpage><pub-id pub-id-type="pmid">14523387</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="ref0150"><person-group person-group-type="author"><name><surname>Fugier-Vivier</surname><given-names>I.</given-names></name><name><surname>Servet-Delprat</surname><given-names>C.</given-names></name><name><surname>Rivailler</surname><given-names>P.</given-names></name><name><surname>Rissoan</surname><given-names>M.C.</given-names></name><name><surname>Liu</surname><given-names>Y.J.</given-names></name><name><surname>Rabourdin-Combe</surname><given-names>C.</given-names></name></person-group><article-title>Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of dendritic and T&#x000a0;cells</article-title><source>J&#x000a0;Exp Med</source><volume>186</volume><issue>6</issue><year>1997</year><fpage>813</fpage><lpage>823</lpage><pub-id pub-id-type="pmid">9294136</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="ref0155"><person-group person-group-type="author"><name><surname>Laine</surname><given-names>D.</given-names></name><name><surname>Bourhis</surname><given-names>J.M.</given-names></name><name><surname>Longhi</surname><given-names>S.</given-names></name></person-group><article-title>Measles virus nucleoprotein induces cell-proliferation arrest and apoptosis through NTAIL-NR and NCORE-FcgammaRIIB1 interactions, respectively</article-title><source>J&#x000a0;Gen Virol</source><volume>86</volume><issue>Pt 6</issue><year>2005</year><fpage>1771</fpage><lpage>1784</lpage><pub-id pub-id-type="pmid">15914856</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="ref0160"><person-group person-group-type="author"><name><surname>Auwaerter</surname><given-names>P.G.</given-names></name><name><surname>Rota</surname><given-names>P.A.</given-names></name><name><surname>Elkins</surname><given-names>W.R.</given-names></name></person-group><article-title>Measles virus infection in rhesus macaques: altered immune responses and comparison of the virulence of six different virus strains</article-title><source>J&#x000a0;Infect Dis</source><volume>180</volume><issue>4</issue><year>1999</year><fpage>950</fpage><lpage>958</lpage><pub-id pub-id-type="pmid">10479117</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="ref0165"><person-group person-group-type="author"><name><surname>Griffin</surname><given-names>D.E.</given-names></name></person-group><article-title>Immunologic abnormalities accompanying acute and chronic viral infections</article-title><source>Rev Infect Dis</source><volume>13</volume><issue>Suppl. 1</issue><year>1991</year><fpage>S129</fpage><lpage>S133</lpage><pub-id pub-id-type="pmid">1850539</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="ref0170"><person-group person-group-type="author"><name><surname>Griffin</surname><given-names>D.E.</given-names></name><name><surname>Ward</surname><given-names>B.J.</given-names></name></person-group><article-title>Differential CD4 T&#x000a0;cell activation in measles</article-title><source>J&#x000a0;Infect Dis</source><volume>168</volume><issue>2</issue><year>1993</year><fpage>275</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">8101549</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="ref0175"><person-group person-group-type="author"><name><surname>Griffin</surname><given-names>D.E.</given-names></name><name><surname>Ward</surname><given-names>B.J.</given-names></name><name><surname>Esolen</surname><given-names>L.M.</given-names></name></person-group><article-title>Pathogenesis of measles virus infection: an hypothesis for altered immune responses</article-title><source>J&#x000a0;Infect Dis</source><volume>170</volume><issue>Suppl. 1</issue><year>1994</year><fpage>S24</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">7930750</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="ref0180"><person-group person-group-type="author"><name><surname>Carsillo</surname><given-names>M.</given-names></name><name><surname>Klapproth</surname><given-names>K.</given-names></name><name><surname>Niewiesk</surname><given-names>S.</given-names></name></person-group><article-title>Cytokine imbalance after measles virus infection has no correlation with immune suppression</article-title><source>J&#x000a0;Virol</source><volume>83</volume><issue>14</issue><year>2009</year><fpage>7244</fpage><lpage>7251</lpage><pub-id pub-id-type="pmid">19420081</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="ref0185"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>R.S.</given-names></name><name><surname>Enwonwu</surname><given-names>C.O.</given-names></name><name><surname>Okolo</surname><given-names>S.</given-names></name><name><surname>Hassan</surname><given-names>A.</given-names></name></person-group><article-title>Metabolic effects of acute measles in chronically malnourished Nigerian children</article-title><source>J&#x000a0;Nutr Biochem</source><volume>15</volume><issue>5</issue><year>2004</year><fpage>281</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">15135152</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="ref0190"><person-group person-group-type="author"><name><surname>Vinante</surname><given-names>F.</given-names></name><name><surname>Krampera</surname><given-names>M.</given-names></name><name><surname>Morosato</surname><given-names>L.</given-names></name><name><surname>Rigo</surname><given-names>A.</given-names></name><name><surname>Romagnani</surname><given-names>S.</given-names></name><name><surname>Pizzolo</surname><given-names>G.</given-names></name></person-group><article-title>Peripheral T lymphocyte cytokine profile (IFNgamma, IL-2, IL-4) and CD30 expression/release during measles infection</article-title><source>Haematologica</source><volume>84</volume><issue>8</issue><year>1999</year><fpage>683</fpage><lpage>689</lpage><pub-id pub-id-type="pmid">10457402</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="ref0195"><person-group person-group-type="author"><name><surname>Ono</surname><given-names>N.</given-names></name><name><surname>Tatsuo</surname><given-names>H.</given-names></name><name><surname>Hidaka</surname><given-names>Y.</given-names></name><name><surname>Aoki</surname><given-names>T.</given-names></name><name><surname>Minagawa</surname><given-names>H.</given-names></name><name><surname>Yanagi</surname><given-names>Y.</given-names></name></person-group><article-title>Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor</article-title><source>J&#x000a0;Virol</source><volume>75</volume><issue>9</issue><year>2001</year><fpage>4399</fpage><lpage>4401</lpage><pub-id pub-id-type="pmid">11287589</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="ref0200"><person-group person-group-type="author"><name><surname>Bartz</surname><given-names>R.</given-names></name><name><surname>Firsching</surname><given-names>R.</given-names></name><name><surname>Rima</surname><given-names>B.</given-names></name><name><surname>ter Meulen</surname><given-names>V.</given-names></name><name><surname>Schneider-Schaulies</surname><given-names>J.</given-names></name></person-group><article-title>Differential receptor usage by measles virus strains</article-title><source>J&#x000a0;Gen Virol</source><volume>79</volume><issue>Pt 5</issue><year>1998</year><fpage>1015</fpage><lpage>1025</lpage><pub-id pub-id-type="pmid">9603316</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="ref0205"><person-group person-group-type="author"><name><surname>Kurita-Taniguchi</surname><given-names>M.</given-names></name><name><surname>Fukui</surname><given-names>A.</given-names></name><name><surname>Hazeki</surname><given-names>K.</given-names></name></person-group><article-title>Functional modulation of human macrophages through CD46 (measles virus receptor): production of IL-12 p40 and nitric oxide in association with recruitment of protein-tyrosine phosphatase SHP-1 to CD46</article-title><source>J&#x000a0;Immunol</source><volume>165</volume><issue>9</issue><year>2000</year><fpage>5143</fpage><lpage>5152</lpage><pub-id pub-id-type="pmid">11046046</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="ref0210"><person-group person-group-type="author"><name><surname>Yant</surname><given-names>S.</given-names></name><name><surname>Hirano</surname><given-names>A.</given-names></name><name><surname>Wong</surname><given-names>T.C.</given-names></name></person-group><article-title>Identification of a cytoplasmic Tyr-X-X-Leu motif essential for down regulation of the human cell receptor CD46 in persistent measles virus infection</article-title><source>J&#x000a0;Virol</source><volume>71</volume><issue>1</issue><year>1997</year><fpage>766</fpage><lpage>770</lpage><pub-id pub-id-type="pmid">8985414</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="ref0215"><person-group person-group-type="author"><name><surname>Naniche</surname><given-names>D.</given-names></name><name><surname>Wild</surname><given-names>T.F.</given-names></name><name><surname>Rabourdin-Combe</surname><given-names>C.</given-names></name><name><surname>Gerlier</surname><given-names>D.</given-names></name></person-group><article-title>Measles virus haemagglutinin induces down-regulation of gp57/67, a molecule involved in virus binding</article-title><source>J&#x000a0;Gen Virol</source><volume>74</volume><issue>Pt 6</issue><year>1993</year><fpage>1073</fpage><lpage>1079</lpage><pub-id pub-id-type="pmid">8509760</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="ref0220"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>T.C.</given-names></name><name><surname>Yant</surname><given-names>S.</given-names></name><name><surname>Harder</surname><given-names>B.J.</given-names></name><name><surname>Korte-Sarfaty</surname><given-names>J.</given-names></name><name><surname>Hirano</surname><given-names>A.</given-names></name></person-group><article-title>The cytoplasmic domains of complement regulatory protein CD46 interact with multiple kinases in macrophages</article-title><source>J&#x000a0;Leukoc Biol</source><volume>62</volume><issue>6</issue><year>1997</year><fpage>892</fpage><lpage>900</lpage><pub-id pub-id-type="pmid">9400832</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="ref0225"><person-group person-group-type="author"><name><surname>Johnstone</surname><given-names>R.W.</given-names></name><name><surname>Russell</surname><given-names>S.M.</given-names></name><name><surname>Loveland</surname><given-names>B.E.</given-names></name><name><surname>McKenzie</surname><given-names>I.F.</given-names></name></person-group><article-title>Polymorphic expression of CD46 protein isoforms due to tissue-specific RNA splicing</article-title><source>Mol Immunol</source><volume>30</volume><issue>14</issue><year>1993</year><fpage>1231</fpage><lpage>1241</lpage><pub-id pub-id-type="pmid">7692239</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="ref0230"><person-group person-group-type="author"><name><surname>Krantic</surname><given-names>S.</given-names></name><name><surname>Gimenez</surname><given-names>C.</given-names></name><name><surname>Rabourdin-Combe</surname><given-names>C.</given-names></name></person-group><article-title>Cell-to-cell contact via measles virus haemagglutinin-CD46 interaction triggers CD46 downregulation</article-title><source>J&#x000a0;Gen Virol</source><volume>76</volume><issue>Pt 11</issue><year>1995</year><fpage>2793</fpage><lpage>2800</lpage><pub-id pub-id-type="pmid">7595386</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="ref0235"><person-group person-group-type="author"><name><surname>Schneider-Schaulies</surname><given-names>J.</given-names></name><name><surname>Schnorr</surname><given-names>J.J.</given-names></name><name><surname>Brinckmann</surname><given-names>U.</given-names></name></person-group><article-title>Receptor usage and differential downregulation of CD46 by measles virus wild-type and vaccine strains</article-title><source>Proc Natl Acad Sci U S A</source><volume>92</volume><issue>9</issue><year>1995</year><fpage>3943</fpage><lpage>3947</lpage><pub-id pub-id-type="pmid">7732009</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="ref0240"><person-group person-group-type="author"><name><surname>Karp</surname><given-names>C.L.</given-names></name><name><surname>Wysocka</surname><given-names>M.</given-names></name><name><surname>Wahl</surname><given-names>L.M.</given-names></name></person-group><article-title>Mechanism of suppression of cell-mediated immunity by measles virus</article-title><source>Science</source><volume>273</volume><issue>5272</issue><year>1996</year><fpage>228</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">8662504</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="ref0245"><person-group person-group-type="author"><name><surname>Grosjean</surname><given-names>I.</given-names></name><name><surname>Caux</surname><given-names>C.</given-names></name><name><surname>Bella</surname><given-names>C.</given-names></name></person-group><article-title>Measles virus infects human dendritic cells and blocks their allostimulatory properties for CD4+ T&#x000a0;cells</article-title><source>J&#x000a0;Exp Med</source><volume>186</volume><issue>6</issue><year>1997</year><fpage>801</fpage><lpage>812</lpage><pub-id pub-id-type="pmid">9294135</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="ref0250"><person-group person-group-type="author"><name><surname>Kemper</surname><given-names>C.</given-names></name><name><surname>Chan</surname><given-names>A.C.</given-names></name><name><surname>Green</surname><given-names>J.M.</given-names></name><name><surname>Brett</surname><given-names>K.A.</given-names></name><name><surname>Murphy</surname><given-names>K.M.</given-names></name><name><surname>Atkinson</surname><given-names>J.P.</given-names></name></person-group><article-title>Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype</article-title><source>Nature</source><volume>421</volume><issue>6921</issue><year>2003</year><fpage>388</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">12540904</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="ref0255"><person-group person-group-type="author"><name><surname>Griffin</surname><given-names>D.E.</given-names></name><name><surname>Johnson</surname><given-names>R.T.</given-names></name><name><surname>Tamashiro</surname><given-names>V.G.</given-names></name></person-group><article-title>In&#x000a0;vitro studies of the role of monocytes in the immunosuppression associated with natural measles virus infections</article-title><source>Clin Immunol Immunopathol</source><volume>45</volume><issue>3</issue><year>1987</year><fpage>375</fpage><lpage>383</lpage><pub-id pub-id-type="pmid">3500003</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="ref0260"><person-group person-group-type="author"><name><surname>McChesney</surname><given-names>M.B.</given-names></name><name><surname>Altman</surname><given-names>A.</given-names></name><name><surname>Oldstone</surname><given-names>M.B.</given-names></name></person-group><article-title>Suppression of T lymphocyte function by measles virus is due to cell cycle arrest in G1</article-title><source>J&#x000a0;Immunol</source><volume>140</volume><issue>4</issue><year>1988</year><fpage>1269</fpage><lpage>1273</lpage><pub-id pub-id-type="pmid">2449499</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="ref0265"><person-group person-group-type="author"><name><surname>Schnorr</surname><given-names>J.J.</given-names></name><name><surname>Seufert</surname><given-names>M.</given-names></name><name><surname>Schlender</surname><given-names>J.</given-names></name></person-group><article-title>Cell cycle arrest rather than apoptosis is associated with measles virus contact-mediated immunosuppression in&#x000a0;vitro</article-title><source>J&#x000a0;Gen Virol</source><volume>78</volume><issue>Pt 12</issue><year>1997</year><fpage>3217</fpage><lpage>3226</lpage><pub-id pub-id-type="pmid">9400972</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="ref0270"><person-group person-group-type="author"><name><surname>Yanagi</surname><given-names>Y.</given-names></name><name><surname>Cubitt</surname><given-names>B.A.</given-names></name><name><surname>Oldstone</surname><given-names>M.B.</given-names></name></person-group><article-title>Measles virus inhibits mitogen-induced T&#x000a0;cell proliferation but does not directly perturb the T&#x000a0;cell activation process inside the cell</article-title><source>Virology</source><volume>187</volume><issue>1</issue><year>1992</year><fpage>280</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">1736530</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="ref0275"><person-group person-group-type="author"><name><surname>Permar</surname><given-names>S.R.</given-names></name><name><surname>Moss</surname><given-names>W.J.</given-names></name><name><surname>Ryon</surname><given-names>J.J.</given-names></name></person-group><article-title>Prolonged measles virus shedding in human immunodeficiency virus-infected children, detected by reverse transcriptase-polymerase chain reaction</article-title><source>J&#x000a0;Infect Dis</source><volume>183</volume><issue>4</issue><year>2001</year><fpage>532</fpage><lpage>538</lpage><pub-id pub-id-type="pmid">11170977</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="ref0280"><person-group person-group-type="author"><name><surname>Riddell</surname><given-names>M.A.</given-names></name><name><surname>Moss</surname><given-names>W.J.</given-names></name><name><surname>Hauer</surname><given-names>D.</given-names></name><name><surname>Monze</surname><given-names>M.</given-names></name><name><surname>Griffin</surname><given-names>D.E.</given-names></name></person-group><article-title>Slow clearance of measles virus RNA after acute infection</article-title><source>J&#x000a0;Clin Virol</source><volume>39</volume><issue>4</issue><year>2007</year><fpage>312</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">17625962</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="ref0285"><person-group person-group-type="author"><name><surname>Cocks</surname><given-names>B.G.</given-names></name><name><surname>Chang</surname><given-names>C.C.</given-names></name><name><surname>Carballido</surname><given-names>J.M.</given-names></name><name><surname>Yssel</surname><given-names>H.</given-names></name><name><surname>de Vries</surname><given-names>J.E.</given-names></name><name><surname>Aversa</surname><given-names>G.</given-names></name></person-group><article-title>A&#x000a0;novel receptor involved in T-cell activation</article-title><source>Nature</source><volume>376</volume><issue>6537</issue><year>1995</year><fpage>260</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">7617038</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="ref0290"><person-group person-group-type="author"><name><surname>Aversa</surname><given-names>G.</given-names></name><name><surname>Chang</surname><given-names>C.C.</given-names></name><name><surname>Carballido</surname><given-names>J.M.</given-names></name><name><surname>Cocks</surname><given-names>B.G.</given-names></name><name><surname>de Vries</surname><given-names>J.E.</given-names></name></person-group><article-title>Engagement of the signaling lymphocytic activation molecule (SLAM) on activated T&#x000a0;cells results in IL-2-independent, cyclosporin A-sensitive T&#x000a0;cell proliferation and IFN-gamma production</article-title><source>J&#x000a0;Immunol</source><volume>158</volume><issue>9</issue><year>1997</year><fpage>4036</fpage><lpage>4044</lpage><pub-id pub-id-type="pmid">9126961</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="ref0295"><person-group person-group-type="author"><name><surname>Garc&#x000ed;a</surname><given-names>V.E.</given-names></name><name><surname>Quiroga</surname><given-names>M.F.</given-names></name><name><surname>Ochoa</surname><given-names>M.T.</given-names></name></person-group><article-title>Signaling lymphocytic activation molecule expression and regulation in human intracellular infection correlate with Th1 cytokine patterns</article-title><source>J&#x000a0;Immunol</source><volume>167</volume><issue>10</issue><year>2001</year><fpage>5719</fpage><lpage>5724</lpage><pub-id pub-id-type="pmid">11698444</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="ref0300"><person-group person-group-type="author"><name><surname>Erlenhoefer</surname><given-names>C.</given-names></name><name><surname>Wurzer</surname><given-names>W.J.</given-names></name><name><surname>L&#x000f6;ffler</surname><given-names>S.</given-names></name><name><surname>Schneider-Schaulies</surname><given-names>S.</given-names></name><name><surname>ter Meulen</surname><given-names>V.</given-names></name><name><surname>Schneider-Schaulies</surname><given-names>J.</given-names></name></person-group><article-title>CD150 (SLAM) is a receptor for measles virus but is not involved in viral contact-mediated proliferation inhibition</article-title><source>J&#x000a0;Virol</source><volume>75</volume><issue>10</issue><year>2001</year><fpage>4499</fpage><lpage>4505</lpage><pub-id pub-id-type="pmid">11312320</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="ref0305"><person-group person-group-type="author"><name><surname>Welstead</surname><given-names>G.G.</given-names></name><name><surname>Hsu</surname><given-names>E.C.</given-names></name><name><surname>Iorio</surname><given-names>C.</given-names></name><name><surname>Bolotin</surname><given-names>S.</given-names></name><name><surname>Richardson</surname><given-names>C.D.</given-names></name></person-group><article-title>Mechanism of CD150 (SLAM) down regulation from the host cell surface by measles virus hemagglutinin protein</article-title><source>J&#x000a0;Virol</source><volume>78</volume><issue>18</issue><year>2004</year><fpage>9666</fpage><lpage>9674</lpage><pub-id pub-id-type="pmid">15331699</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="ref0310"><person-group person-group-type="author"><name><surname>Schlender</surname><given-names>J.</given-names></name><name><surname>Schnorr</surname><given-names>J.J.</given-names></name><name><surname>Spielhoffer</surname><given-names>P.</given-names></name></person-group><article-title>Interaction of measles virus glycoproteins with the surface of uninfected peripheral blood lymphocytes induces immunosuppression in&#x000a0;vitro</article-title><source>Proc Natl Acad Sci U S A</source><volume>93</volume><issue>23</issue><year>1996</year><fpage>13194</fpage><lpage>13199</lpage><pub-id pub-id-type="pmid">8917567</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="ref0315"><person-group person-group-type="author"><name><surname>Dubois</surname><given-names>B.</given-names></name><name><surname>Lamy</surname><given-names>P.J.</given-names></name><name><surname>Chemin</surname><given-names>K.</given-names></name><name><surname>Lachaux</surname><given-names>A.</given-names></name><name><surname>Kaiserlian</surname><given-names>D.</given-names></name></person-group><article-title>Measles virus exploits dendritic cells to suppress CD4+ T-cell proliferation via expression of surface viral glycoproteins independently of T-cell trans-infection</article-title><source>Cell Immunol</source><volume>214</volume><issue>2</issue><year>2001</year><fpage>173</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">12088416</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="ref0320"><person-group person-group-type="author"><name><surname>Klagge</surname><given-names>I.M.</given-names></name><name><surname>ter Meulen</surname><given-names>V.</given-names></name><name><surname>Schneider-Schaulies</surname><given-names>S.</given-names></name></person-group><article-title>Measles virus-induced promotion of dendritic cell maturation by soluble mediators does not overcome the immunosuppressive activity of viral glycoproteins on the cell surface</article-title><source>Eur J Immunol</source><volume>30</volume><issue>10</issue><year>2000</year><fpage>2741</fpage><lpage>2750</lpage><pub-id pub-id-type="pmid">11069053</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="ref0325"><person-group person-group-type="author"><name><surname>Schnorr</surname><given-names>J.J.</given-names></name><name><surname>Xanthakos</surname><given-names>S.</given-names></name><name><surname>Keikavoussi</surname><given-names>P.</given-names></name><name><surname>K&#x000e4;mpgen</surname><given-names>E.</given-names></name><name><surname>ter Meulen</surname><given-names>V.</given-names></name><name><surname>Schneider-Schaulies</surname><given-names>S.</given-names></name></person-group><article-title>Induction of maturation of human blood dendritic cell precursors by measles virus is associated with immunosuppression</article-title><source>Proc Natl Acad Sci U S A</source><volume>94</volume><issue>10</issue><year>1997</year><fpage>5326</fpage><lpage>5331</lpage><pub-id pub-id-type="pmid">9144236</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="ref0330"><person-group person-group-type="author"><name><surname>Weidmann</surname><given-names>A.</given-names></name><name><surname>Maisner</surname><given-names>A.</given-names></name><name><surname>Garten</surname><given-names>W.</given-names></name><name><surname>Seufert</surname><given-names>M.</given-names></name><name><surname>ter Meulen</surname><given-names>V.</given-names></name><name><surname>Schneider-Schaulies</surname><given-names>S.</given-names></name></person-group><article-title>Proteolytic cleavage of the fusion protein but not membrane fusion is required for measles virus-induced immunosuppression in&#x000a0;vitro</article-title><source>J&#x000a0;Virol</source><volume>74</volume><issue>4</issue><year>2000</year><comment>1985-93</comment></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="ref0335"><person-group person-group-type="author"><name><surname>Niewiesk</surname><given-names>S.</given-names></name><name><surname>Ohnimus</surname><given-names>H.</given-names></name><name><surname>Schnorr</surname><given-names>J.J.</given-names></name></person-group><article-title>Measles virus-induced immunosuppression in cotton rats is associated with cell cycle retardation in uninfected lymphocytes</article-title><source>J&#x000a0;Gen Virol</source><volume>80</volume><issue>Pt 8</issue><year>1999</year><fpage>2023</fpage><lpage>2029</lpage><pub-id pub-id-type="pmid">10466800</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="ref0340"><person-group person-group-type="author"><name><surname>Engelking</surname><given-names>O.</given-names></name><name><surname>Fedorov</surname><given-names>L.M.</given-names></name><name><surname>Lilischkis</surname><given-names>R.</given-names></name><name><surname>ter Meulen</surname><given-names>V.</given-names></name><name><surname>Schneider-Schaulies</surname><given-names>S.</given-names></name></person-group><article-title>Measles virus-induced immunosuppression in&#x000a0;vitro is associated with deregulation of G1 cell cycle control proteins</article-title><source>J&#x000a0;Gen Virol</source><volume>80</volume><issue>Pt 7</issue><year>1999</year><fpage>1599</fpage><lpage>1608</lpage><pub-id pub-id-type="pmid">10423127</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="ref0345"><person-group person-group-type="author"><name><surname>Avota</surname><given-names>E.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>N.</given-names></name><name><surname>Klett</surname><given-names>M.</given-names></name><name><surname>Schneider-Schaulies</surname><given-names>S.</given-names></name></person-group><article-title>Measles virus interacts with and alters signal transduction in T-cell lipid rafts</article-title><source>J&#x000a0;Virol</source><volume>78</volume><issue>17</issue><year>2004</year><fpage>9552</fpage><lpage>9559</lpage><pub-id pub-id-type="pmid">15308747</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="ref0350"><person-group person-group-type="author"><name><surname>Avota</surname><given-names>E.</given-names></name><name><surname>Avots</surname><given-names>A.</given-names></name><name><surname>Niewiesk</surname><given-names>S.</given-names></name></person-group><article-title>Disruption of Akt kinase activation is important for immunosuppression induced by measles virus</article-title><source>Nat Med</source><volume>7</volume><issue>6</issue><year>2001</year><fpage>725</fpage><lpage>731</lpage><pub-id pub-id-type="pmid">11385511</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="ref0355"><person-group person-group-type="author"><name><surname>Avota</surname><given-names>E.</given-names></name><name><surname>Harms</surname><given-names>H.</given-names></name><name><surname>Schneider-Schaulies</surname><given-names>S.</given-names></name></person-group><article-title>Measles virus induces expression of SIP110, a constitutively membrane clustered lipid phosphatase, which inhibits T&#x000a0;cell proliferation</article-title><source>Cell Microbiol</source><volume>8</volume><issue>11</issue><year>2006</year><fpage>1826</fpage><lpage>1839</lpage><pub-id pub-id-type="pmid">16824039</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="ref0360"><person-group person-group-type="author"><name><surname>Kilbourne</surname><given-names>E.D.</given-names></name></person-group><article-title>Influenza pandemics of the 20th century</article-title><source>Emerg Infect Dis</source><volume>12</volume><issue>1</issue><year>2006</year><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">16494710</pub-id></element-citation></ref><ref id="bib72"><label>72</label><mixed-citation publication-type="other" id="ceotherref0010">Services USDoHH. Pandemic Flu History. <ext-link ext-link-type="uri" xlink:href="http://www.flu.gov/pandemic/history2013" id="interref3">http://www.flu.gov/pandemic/history2013</ext-link>).</mixed-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="ref0365"><person-group person-group-type="author"><name><surname>Abramson</surname><given-names>J.S.</given-names></name><name><surname>Wagner</surname><given-names>M.P.</given-names></name><name><surname>Ralston</surname><given-names>E.P.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Wheeler</surname><given-names>J.G.</given-names></name></person-group><article-title>The ability of polymorphonuclear leukocyte priming agents to overcome influenza A virus-induced cell dysfunction</article-title><source>J&#x000a0;Leukoc Biol</source><volume>50</volume><issue>2</issue><year>1991</year><fpage>160</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">2072033</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="ref0370"><article-title>Influenza vaccination levels in selected states - behavior risk factor surveillance system 1987</article-title><source>MMWR (Morb Mortal Wkly Rep)</source><volume>38</volume><year>1989</year><fpage>124</fpage><pub-id pub-id-type="pmid">2493127</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="ref0375"><person-group person-group-type="author"><name><surname>McNamee</surname><given-names>L.A.</given-names></name><name><surname>Harmsen</surname><given-names>A.G.</given-names></name></person-group><article-title>Both influenza-induced neutrophil dysfunction and neutrophil-independent mechanisms contribute to increased susceptibility to a secondary Streptococcus pneumoniae infection</article-title><source>Infect Immun</source><volume>74</volume><issue>12</issue><year>2006</year><fpage>6707</fpage><lpage>6721</lpage><pub-id pub-id-type="pmid">16982840</pub-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="ref0380"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>R.N.</given-names></name><name><surname>Smith</surname><given-names>B.L.</given-names></name></person-group><article-title>Deaths: leading causes for 2002</article-title><source>Natl Vital Stat Rep</source><volume>53</volume><issue>17</issue><year>2005</year><fpage>1</fpage><lpage>89</lpage></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="ref0385"><person-group person-group-type="author"><name><surname>Klimov</surname><given-names>A.</given-names></name><name><surname>Simonsen</surname><given-names>L.</given-names></name><name><surname>Fukuda</surname><given-names>K.</given-names></name><name><surname>Cox</surname><given-names>N.</given-names></name></person-group><article-title>Surveillance and impact of influenza in the United States</article-title><source>Vaccine</source><volume>17</volume><issue>Suppl. 1</issue><year>1999</year><fpage>S42</fpage><lpage>S46</lpage><pub-id pub-id-type="pmid">10471179</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="ref0390"><person-group person-group-type="author"><name><surname>McCullers</surname><given-names>J.A.</given-names></name><name><surname>Bartmess</surname><given-names>K.C.</given-names></name></person-group><article-title>Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae</article-title><source>J&#x000a0;Infect Dis</source><volume>187</volume><issue>6</issue><year>2003</year><fpage>1000</fpage><lpage>1009</lpage><pub-id pub-id-type="pmid">12660947</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="ref0395"><person-group person-group-type="author"><name><surname>Wheeler</surname><given-names>J.G.</given-names></name><name><surname>Winkler</surname><given-names>L.S.</given-names></name><name><surname>Seeds</surname><given-names>M.</given-names></name><name><surname>Bass</surname><given-names>D.</given-names></name><name><surname>Abramson</surname><given-names>J.S.</given-names></name></person-group><article-title>Influenza A virus alters structural and biochemical functions of the neutrophil cytoskeleton</article-title><source>J&#x000a0;Leukoc Biol</source><volume>47</volume><issue>4</issue><year>1990</year><fpage>332</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">2319207</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="ref0400"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>R.R.</given-names></name><name><surname>Couch</surname><given-names>R.B.</given-names></name><name><surname>Greenberg</surname><given-names>S.B.</given-names></name><name><surname>Cate</surname><given-names>T.R.</given-names></name><name><surname>Warr</surname><given-names>G.A.</given-names></name></person-group><article-title>Effects of infection with influenza virus on the function of polymorphonuclear leukocytes</article-title><source>J&#x000a0;Infect Dis</source><volume>144</volume><issue>3</issue><year>1981</year><fpage>279</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">7276637</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="ref0405"><person-group person-group-type="author"><name><surname>Caldwell</surname><given-names>S.E.</given-names></name><name><surname>Cassidy</surname><given-names>L.F.</given-names></name><name><surname>Abramson</surname><given-names>J.S.</given-names></name></person-group><article-title>Alterations in cell protein phosphorylation in human neutrophils exposed to influenza A virus. A possible mechanism for depressed cellular end-stage functions</article-title><source>J&#x000a0;Immunol</source><volume>140</volume><issue>10</issue><year>1988</year><fpage>3560</fpage><lpage>3567</lpage><pub-id pub-id-type="pmid">2834442</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="ref0410"><person-group person-group-type="author"><name><surname>Abramson</surname><given-names>J.S.</given-names></name><name><surname>Wheeler</surname><given-names>J.G.</given-names></name></person-group><article-title>Virus-induced neutrophil dysfunction: role in the pathogenesis of bacterial infections</article-title><source>Pediatr Infect Dis J</source><volume>13</volume><issue>7</issue><year>1994</year><fpage>643</fpage><lpage>652</lpage><pub-id pub-id-type="pmid">7970955</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="ref0415"><person-group person-group-type="author"><name><surname>Abramson</surname><given-names>J.S.</given-names></name><name><surname>Parce</surname><given-names>J.W.</given-names></name><name><surname>Lewis</surname><given-names>J.C.</given-names></name></person-group><article-title>Characterization of the effect of influenza virus on polymorphonuclear leukocyte membrane responses</article-title><source>Blood</source><volume>64</volume><issue>1</issue><year>1984</year><fpage>131</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">6733266</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="ref0420"><person-group person-group-type="author"><name><surname>Abramson</surname><given-names>J.S.</given-names></name><name><surname>Mills</surname><given-names>E.L.</given-names></name><name><surname>Giebink</surname><given-names>G.S.</given-names></name><name><surname>Quie</surname><given-names>P.G.</given-names></name></person-group><article-title>Depression of monocyte and polymorphonuclear leukocyte oxidative metabolism and bactericidal capacity by influenza A virus</article-title><source>Infect Immun</source><volume>35</volume><issue>1</issue><year>1982</year><fpage>350</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">7054126</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="ref0425"><person-group person-group-type="author"><name><surname>Abramson</surname><given-names>J.S.</given-names></name><name><surname>Mills</surname><given-names>E.L.</given-names></name></person-group><article-title>Depression of neutrophil function induced by viruses and its role in secondary microbial infections</article-title><source>Rev Infect Dis</source><volume>10</volume><issue>2</issue><year>1988</year><fpage>326</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">3131864</pub-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="ref0430"><person-group person-group-type="author"><name><surname>Abramson</surname><given-names>J.S.</given-names></name><name><surname>Giebink</surname><given-names>G.S.</given-names></name><name><surname>Quie</surname><given-names>P.G.</given-names></name></person-group><article-title>Influenza A virus-induced polymorphonuclear leukocyte dysfunction in the pathogenesis of experimental pneumococcal otitis media</article-title><source>Infect Immun</source><volume>36</volume><issue>1</issue><year>1982</year><fpage>289</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">7076299</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="ref0435"><person-group person-group-type="author"><name><surname>Abramson</surname><given-names>J.S.</given-names></name><name><surname>Lewis</surname><given-names>J.C.</given-names></name><name><surname>Lyles</surname><given-names>D.S.</given-names></name><name><surname>Heller</surname><given-names>K.A.</given-names></name><name><surname>Mills</surname><given-names>E.L.</given-names></name><name><surname>Bass</surname><given-names>D.A.</given-names></name></person-group><article-title>Inhibition of neutrophil lysosome-phagosome fusion associated with influenza virus infection in&#x000a0;vitro. Role in depressed bactericidal activity</article-title><source>J&#x000a0;Clin Investig</source><volume>69</volume><issue>6</issue><year>1982</year><fpage>1393</fpage><lpage>1397</lpage><pub-id pub-id-type="pmid">7085879</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="ref0440"><person-group person-group-type="author"><name><surname>Abramson</surname><given-names>J.S.</given-names></name><name><surname>Hudnor</surname><given-names>H.R.</given-names></name></person-group><article-title>Effect of priming polymorphonuclear leukocytes with cytokines (granulocyte-macrophage colony-stimulating factor [GM-CSF] and G-CSF) on the host resistance to Streptococcus pneumoniae in chinchillas infected with influenza A virus</article-title><source>Blood</source><volume>83</volume><issue>7</issue><year>1994</year><comment>1929-34</comment></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="ref0445"><person-group person-group-type="author"><name><surname>Abramson</surname><given-names>J.S.</given-names></name><name><surname>Lyles</surname><given-names>D.S.</given-names></name><name><surname>Heller</surname><given-names>K.A.</given-names></name><name><surname>Bass</surname><given-names>D.A.</given-names></name></person-group><article-title>Influenza A virus-induced polymorphonuclear leukocyte dysfunction</article-title><source>Infect Immun</source><volume>37</volume><issue>2</issue><year>1982</year><fpage>794</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">7118256</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="ref0450"><person-group person-group-type="author"><name><surname>Abramson</surname><given-names>J.S.</given-names></name><name><surname>Giebink</surname><given-names>G.S.</given-names></name><name><surname>Mills</surname><given-names>E.L.</given-names></name><name><surname>Quie</surname><given-names>P.G.</given-names></name></person-group><article-title>Polymorphonuclear leukocyte dysfunction during influenza virus infection in chinchillas</article-title><source>J&#x000a0;Infect Dis</source><volume>143</volume><issue>6</issue><year>1981</year><fpage>836</fpage><lpage>845</lpage><pub-id pub-id-type="pmid">7252265</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="ref0455"><person-group person-group-type="author"><name><surname>Garvy</surname><given-names>B.A.</given-names></name><name><surname>Harmsen</surname><given-names>A.G.</given-names></name></person-group><article-title>The importance of neutrophils in resistance to pneumococcal pneumonia in adult and neonatal mice</article-title><source>Inflammation</source><volume>20</volume><issue>5</issue><year>1996</year><fpage>499</fpage><lpage>512</lpage><pub-id pub-id-type="pmid">8894714</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="ref0460"><person-group person-group-type="author"><name><surname>Colamussi</surname><given-names>M.L.</given-names></name><name><surname>White</surname><given-names>M.R.</given-names></name><name><surname>Crouch</surname><given-names>E.</given-names></name><name><surname>Hartshorn</surname><given-names>K.L.</given-names></name></person-group><article-title>Influenza A virus accelerates neutrophil apoptosis and markedly potentiates apoptotic effects of bacteria</article-title><source>Blood</source><volume>93</volume><issue>7</issue><year>1999</year><fpage>2395</fpage><lpage>2403</lpage><pub-id pub-id-type="pmid">10090951</pub-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="book" id="ref0465"><person-group person-group-type="author"><name><surname>Abramson</surname><given-names>J.S.</given-names></name><name><surname>Mills</surname><given-names>E.L.</given-names></name></person-group><chapter-title>G-protein alteractions in polymorphonuclear leukocytes (PMNL) induced by influenza A virus (IAV)</chapter-title><source>29th Interscience conference on antimirobial agents abstract 332</source><year>1989</year></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="ref0470"><person-group person-group-type="author"><name><surname>Bokoch</surname><given-names>G.M.</given-names></name><name><surname>Quilliam</surname><given-names>L.A.</given-names></name></person-group><article-title>Guanine nucleotide binding properties of rap1 purified from human neutrophils</article-title><source>Biochem J</source><volume>267</volume><issue>2</issue><year>1990</year><fpage>407</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">2110451</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="ref0475"><person-group person-group-type="author"><name><surname>Coffey</surname><given-names>R.G.</given-names></name></person-group><article-title>Mechanism of GM-CSF stimulation of neutrophils</article-title><source>Immunol Res</source><volume>8</volume><issue>3</issue><year>1989</year><fpage>236</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">2664037</pub-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="ref0480"><person-group person-group-type="author"><name><surname>Takase</surname><given-names>H.</given-names></name><name><surname>Nitanai</surname><given-names>H.</given-names></name><name><surname>Yamamura</surname><given-names>E.</given-names></name><name><surname>Otani</surname><given-names>T.</given-names></name></person-group><article-title>Facilitated expansion of pneumococcal colonization from the nose to the lower respiratory tract in mice preinfected with influenza virus</article-title><source>Microbiol Immunol</source><volume>43</volume><issue>9</issue><year>1999</year><fpage>905</fpage><lpage>907</lpage><pub-id pub-id-type="pmid">10553684</pub-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="ref0485"><person-group person-group-type="author"><name><surname>McCullers</surname><given-names>J.A.</given-names></name><name><surname>Rehg</surname><given-names>J.E.</given-names></name></person-group><article-title>Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor</article-title><source>J&#x000a0;Infect Dis</source><volume>186</volume><issue>3</issue><year>2002</year><fpage>341</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">12134230</pub-id></element-citation></ref><ref id="bib98"><label>98</label><element-citation publication-type="journal" id="ref0490"><person-group person-group-type="author"><name><surname>Cate</surname><given-names>T.R.</given-names></name></person-group><article-title>Impact of influenza and other community-acquired viruses</article-title><source>Semin Respir Infect</source><volume>13</volume><issue>1</issue><year>1998</year><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">9543472</pub-id></element-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal" id="ref0495"><person-group person-group-type="author"><name><surname>Gerone</surname><given-names>P.J.</given-names></name><name><surname>Ward</surname><given-names>T.G.</given-names></name><name><surname>Chappell</surname><given-names>W.A.</given-names></name></person-group><article-title>Combined infections in mice with influenza virus and Diplococcus pneumoniae</article-title><source>Am J Hyg</source><volume>66</volume><issue>3</issue><year>1957</year><fpage>331</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">13478583</pub-id></element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="journal" id="ref0500"><person-group person-group-type="author"><name><surname>Plotkowski</surname><given-names>M.C.</given-names></name><name><surname>Puchelle</surname><given-names>E.</given-names></name><name><surname>Beck</surname><given-names>G.</given-names></name><name><surname>Jacquot</surname><given-names>J.</given-names></name><name><surname>Hannoun</surname><given-names>C.</given-names></name></person-group><article-title>Adherence of type I Streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 virus</article-title><source>Am Rev Respir Dis</source><volume>134</volume><issue>5</issue><year>1986</year><fpage>1040</fpage><lpage>1044</lpage><pub-id pub-id-type="pmid">3777666</pub-id></element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="journal" id="ref0505"><person-group person-group-type="author"><name><surname>Nugent</surname><given-names>K.M.</given-names></name><name><surname>Pesanti</surname><given-names>E.L.</given-names></name></person-group><article-title>Tracheal function during influenza infections</article-title><source>Infect Immun</source><volume>42</volume><issue>3</issue><year>1983</year><fpage>1102</fpage><lpage>1108</lpage><pub-id pub-id-type="pmid">6642660</pub-id></element-citation></ref><ref id="bib102"><label>102</label><element-citation publication-type="journal" id="ref0510"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>R.B.</given-names></name></person-group><article-title>The host response to invasion by Streptococcus pneumoniae: protection and the pathogenesis to tissue damage</article-title><source>Rev Infect Dis</source><volume>3</volume><issue>2</issue><year>1981</year><fpage>282</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">7020045</pub-id></element-citation></ref><ref id="bib103"><label>103</label><element-citation publication-type="journal" id="ref0515"><person-group person-group-type="author"><name><surname>Hinshaw</surname><given-names>V.S.</given-names></name><name><surname>Olsen</surname><given-names>C.W.</given-names></name><name><surname>Dybdahl-Sissoko</surname><given-names>N.</given-names></name><name><surname>Evans</surname><given-names>D.</given-names></name></person-group><article-title>Apoptosis: a mechanism of cell killing by influenza A and B viruses</article-title><source>J&#x000a0;Virol</source><volume>68</volume><issue>6</issue><year>1994</year><fpage>3667</fpage><lpage>3673</lpage><pub-id pub-id-type="pmid">8189504</pub-id></element-citation></ref><ref id="bib104"><label>104</label><element-citation publication-type="journal" id="ref0520"><person-group person-group-type="author"><name><surname>van der Sluijs</surname><given-names>K.F.</given-names></name><name><surname>van Elden</surname><given-names>L.J.</given-names></name><name><surname>Nijhuis</surname><given-names>M.</given-names></name></person-group><article-title>IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection</article-title><source>J&#x000a0;Immunol</source><volume>172</volume><issue>12</issue><year>2004</year><fpage>7603</fpage><lpage>7609</lpage><pub-id pub-id-type="pmid">15187140</pub-id></element-citation></ref><ref id="bib105"><label>105</label><element-citation publication-type="journal" id="ref0525"><person-group person-group-type="author"><name><surname>Chinen</surname><given-names>J.</given-names></name><name><surname>Shearer</surname><given-names>W.T.</given-names></name></person-group><article-title>Secondary immunodeficiencies, including HIV infection</article-title><source>J&#x000a0;Allergy Clin Immunol</source><volume>125</volume><issue>2 Suppl. 2</issue><year>2010</year><fpage>S195</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">20042227</pub-id></element-citation></ref><ref id="bib106"><label>106</label><element-citation publication-type="journal" id="ref0530"><person-group person-group-type="author"><name><surname>Lubben</surname><given-names>N.B.</given-names></name><name><surname>Sahlender</surname><given-names>D.A.</given-names></name><name><surname>Motley</surname><given-names>A.M.</given-names></name><name><surname>Lehner</surname><given-names>P.J.</given-names></name><name><surname>Benaroch</surname><given-names>P.</given-names></name><name><surname>Robinson</surname><given-names>M.S.</given-names></name></person-group><article-title>HIV-1 Nef-induced down-regulation of MHC class I requires AP-1 and clathrin but not PACS-1 and is impeded by AP-2</article-title><source>Mol Biol Cell</source><volume>18</volume><issue>9</issue><year>2007</year><fpage>3351</fpage><lpage>3365</lpage><pub-id pub-id-type="pmid">17581864</pub-id></element-citation></ref><ref id="bib107"><label>107</label><element-citation publication-type="journal" id="ref0535"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>J.L.</given-names></name><name><surname>Morris</surname><given-names>C.R.</given-names></name><name><surname>Solheim</surname><given-names>J.C.</given-names></name></person-group><article-title>Virus evasion of MHC class I molecule presentation</article-title><source>J&#x000a0;Immunol</source><volume>171</volume><issue>9</issue><year>2003</year><fpage>4473</fpage><lpage>4478</lpage><pub-id pub-id-type="pmid">14568919</pub-id></element-citation></ref><ref id="bib108"><label>108</label><element-citation publication-type="journal" id="ref0540"><person-group person-group-type="author"><name><surname>Bobbitt</surname><given-names>K.R.</given-names></name><name><surname>Addo</surname><given-names>M.M.</given-names></name><name><surname>Altfeld</surname><given-names>M.</given-names></name></person-group><article-title>Rev activity determines sensitivity of HIV-1-infected primary T&#x000a0;cells to CTL killing</article-title><source>Immunity</source><volume>18</volume><issue>2</issue><year>2003</year><fpage>289</fpage><lpage>299</lpage><pub-id pub-id-type="pmid">12594955</pub-id></element-citation></ref><ref id="bib109"><label>109</label><element-citation publication-type="journal" id="ref0545"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>G.B.</given-names></name><name><surname>Gandhi</surname><given-names>R.T.</given-names></name><name><surname>Davis</surname><given-names>D.M.</given-names></name></person-group><article-title>The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells</article-title><source>Immunity</source><volume>10</volume><issue>6</issue><year>1999</year><fpage>661</fpage><lpage>671</lpage><pub-id pub-id-type="pmid">10403641</pub-id></element-citation></ref><ref id="bib110"><label>110</label><element-citation publication-type="journal" id="ref0550"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Y.J.</given-names></name><name><surname>Cai</surname><given-names>C.Y.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>H.T.</given-names></name><name><surname>Hirst</surname><given-names>J.A.</given-names></name><name><surname>Burakoff</surname><given-names>S.J.</given-names></name></person-group><article-title>HIV Nef-mediated CD4 down-regulation is adaptor protein complex 2 dependent</article-title><source>J&#x000a0;Immunol</source><volume>175</volume><issue>5</issue><year>2005</year><fpage>3157</fpage><lpage>3164</lpage><pub-id pub-id-type="pmid">16116206</pub-id></element-citation></ref><ref id="bib111"><label>111</label><element-citation publication-type="journal" id="ref0555"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>L.</given-names></name><name><surname>Siliciano</surname><given-names>R.F.</given-names></name></person-group><article-title>Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection</article-title><source>J&#x000a0;Allergy Clin Immunol</source><volume>122</volume><issue>1</issue><year>2008</year><fpage>22</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">18602567</pub-id></element-citation></ref><ref id="bib112"><label>112</label><element-citation publication-type="journal" id="ref0560"><person-group person-group-type="author"><name><surname>Brenchley</surname><given-names>J.M.</given-names></name><name><surname>Schacker</surname><given-names>T.W.</given-names></name><name><surname>Ruff</surname><given-names>L.E.</given-names></name></person-group><article-title>CD4+ T&#x000a0;cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract</article-title><source>J&#x000a0;Exp Med</source><volume>200</volume><issue>6</issue><year>2004</year><fpage>749</fpage><lpage>759</lpage><pub-id pub-id-type="pmid">15365096</pub-id></element-citation></ref><ref id="bib113"><label>113</label><element-citation publication-type="journal" id="ref0565"><person-group person-group-type="author"><name><surname>Norris</surname><given-names>P.J.</given-names></name><name><surname>Pappalardo</surname><given-names>B.L.</given-names></name><name><surname>Custer</surname><given-names>B.</given-names></name><name><surname>Spotts</surname><given-names>G.</given-names></name><name><surname>Hecht</surname><given-names>F.M.</given-names></name><name><surname>Busch</surname><given-names>M.P.</given-names></name></person-group><article-title>Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection</article-title><source>AIDS Res Hum Retrovir</source><volume>22</volume><issue>8</issue><year>2006</year><fpage>757</fpage><lpage>762</lpage><pub-id pub-id-type="pmid">16910831</pub-id></element-citation></ref><ref id="bib114"><label>114</label><element-citation publication-type="journal" id="ref0570"><person-group person-group-type="author"><name><surname>Espert</surname><given-names>L.</given-names></name><name><surname>Denizot</surname><given-names>M.</given-names></name><name><surname>Grimaldi</surname><given-names>M.</given-names></name></person-group><article-title>Autophagy is involved in T&#x000a0;cell death after binding of HIV-1 envelope proteins to CXCR4</article-title><source>J&#x000a0;Clin Investig</source><volume>116</volume><issue>8</issue><year>2006</year><fpage>2161</fpage><lpage>2172</lpage><pub-id pub-id-type="pmid">16886061</pub-id></element-citation></ref><ref id="bib115"><label>115</label><element-citation publication-type="journal" id="ref0575"><person-group person-group-type="author"><name><surname>Pantaleo</surname><given-names>G.</given-names></name><name><surname>Graziosi</surname><given-names>C.</given-names></name><name><surname>Fauci</surname><given-names>A.S.</given-names></name></person-group><article-title>The immunopathogenesis of human immunodeficiency virus infection</article-title><source>N&#x000a0;Engl J Med</source><volume>328</volume><issue>5</issue><year>1993</year><fpage>327</fpage><lpage>335</lpage><pub-id pub-id-type="pmid">8093551</pub-id></element-citation></ref><ref id="bib116"><label>116</label><element-citation publication-type="journal" id="ref0580"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>S.</given-names></name><name><surname>McGrath</surname><given-names>L.</given-names></name></person-group><article-title>HIV/AIDS</article-title><source>Sleep Medicine Clinics</source><volume>2</volume><issue>1</issue><year>2019</year><fpage>51</fpage><lpage>58</lpage></element-citation></ref><ref id="bib117"><label>117</label><element-citation publication-type="journal" id="ref0585"><person-group person-group-type="author"><name><surname>Quaresma</surname><given-names>J.A.</given-names></name><name><surname>Yoshikawa</surname><given-names>G.T.</given-names></name><name><surname>Koyama</surname><given-names>R.V.</given-names></name><name><surname>Dias</surname><given-names>G.A.</given-names></name><name><surname>Fujihara</surname><given-names>S.</given-names></name><name><surname>Fuzii</surname><given-names>H.T.</given-names></name></person-group><article-title>HTLV-1, immune response and autoimmunity</article-title><source>Viruses</source><volume>8</volume><issue>1</issue><year>2015</year></element-citation></ref><ref id="bib118"><label>118</label><element-citation publication-type="journal" id="ref0590"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>G.P.</given-names></name><name><surname>Matsuoka</surname><given-names>M.</given-names></name></person-group><article-title>Natural history of adult T-cell leukemia/lymphoma and approaches to therapy</article-title><source>Oncogene</source><volume>24</volume><issue>39</issue><year>2005</year><fpage>6047</fpage><lpage>6057</lpage><pub-id pub-id-type="pmid">16155611</pub-id></element-citation></ref><ref id="bib119"><label>119</label><element-citation publication-type="journal" id="ref0595"><person-group person-group-type="author"><name><surname>Charoenthongtrakul</surname><given-names>S.</given-names></name><name><surname>Zhou</surname><given-names>Q.</given-names></name><name><surname>Shembade</surname><given-names>N.</given-names></name><name><surname>Harhaj</surname><given-names>N.S.</given-names></name><name><surname>Harhaj</surname><given-names>E.W.</given-names></name></person-group><article-title>Human T&#x000a0;cell leukemia virus type 1 Tax inhibits innate antiviral signaling via NF-&#x003ba;B-Dependent induction of SOCS1&#x025bf;</article-title><source>J&#x000a0;Virol</source><year>2011</year><fpage>6955</fpage><lpage>6962</lpage><pub-id pub-id-type="pmid">21593151</pub-id></element-citation></ref><ref id="bib120"><label>120</label><element-citation publication-type="journal" id="ref0600"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Q.</given-names></name><name><surname>Lavorgna</surname><given-names>A.</given-names></name><name><surname>Bowman</surname><given-names>M.</given-names></name><name><surname>Hiscott</surname><given-names>J.</given-names></name><name><surname>Harhaj</surname><given-names>E.W.</given-names></name></person-group><article-title>Aryl hydrocarbon receptor interacting protein targets IRF7 to suppress antiviral signaling and the induction of type I interferon&#x02217;</article-title><source>J&#x000a0;Biol Chem</source><year>2015</year><fpage>14729</fpage><lpage>14739</lpage><pub-id pub-id-type="pmid">25911105</pub-id></element-citation></ref><ref id="bib121"><label>121</label><element-citation publication-type="journal" id="ref0605"><person-group person-group-type="author"><name><surname>Gessain</surname><given-names>A.</given-names></name><name><surname>Mahieux</surname><given-names>R.</given-names></name></person-group><article-title>Tropical spastic paraparesis and HTLV-1 associated myelopathy: clinical, epidemiological, virological and therapeutic aspects</article-title><source>Rev Neurol (Paris)</source><volume>168</volume><issue>3</issue><year>2012</year><fpage>257</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">22405461</pub-id></element-citation></ref><ref id="bib122"><label>122</label><element-citation publication-type="journal" id="ref0610"><person-group person-group-type="author"><name><surname>Ratner</surname><given-names>L.</given-names></name></person-group><article-title>Molecular biology of human T&#x000a0;cell leukemia virus</article-title><source>Semin Diagn Pathol</source><year>2019</year><pub-id pub-id-type="doi">10.1053/j.semdp.2019.04.003</pub-id></element-citation></ref><ref id="bib123"><label>123</label><element-citation publication-type="journal" id="ref0615"><person-group person-group-type="author"><name><surname>Queiroz</surname><given-names>G.A.N.</given-names></name><name><surname>Mascarenhas</surname><given-names>R.E.M.</given-names></name><name><surname>Vieillard</surname><given-names>V.</given-names></name><name><surname>Andrade</surname><given-names>R.L.</given-names></name><name><surname>Galvao-Castro</surname><given-names>B.</given-names></name><name><surname>Grassi</surname><given-names>M.F.R.</given-names></name></person-group><article-title>Functional capacity of natural killer cells in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients</article-title><source>BMC Infect Dis</source><volume>19</volume><issue>1</issue><year>2019</year><fpage>433</fpage><pub-id pub-id-type="pmid">31101076</pub-id></element-citation></ref><ref id="bib124"><label>124</label><element-citation publication-type="journal" id="ref0620"><person-group person-group-type="author"><name><surname>Porto</surname><given-names>M.A.</given-names></name><name><surname>Alcantara</surname><given-names>L.M.</given-names></name><name><surname>Leal</surname><given-names>M.</given-names></name><name><surname>Castro</surname><given-names>N.</given-names></name><name><surname>Carvalho</surname><given-names>E.M.</given-names></name></person-group><article-title>Atypical clinical presentation of strongyloidiasis in a patient co-infected with human T&#x000a0;cell lymphotrophic virus type I</article-title><source>Am J Trop Med Hyg</source><volume>72</volume><issue>2</issue><year>2005</year><fpage>124</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">15741545</pub-id></element-citation></ref><ref id="bib125"><label>125</label><element-citation publication-type="journal" id="ref0625"><person-group person-group-type="author"><name><surname>Porto</surname><given-names>A.F.</given-names></name><name><surname>Santos</surname><given-names>S.B.</given-names></name><name><surname>Alcantara</surname><given-names>L.</given-names></name></person-group><article-title>HTLV-1 modifies the clinical and immunological response to schistosomiasis</article-title><source>Clin Exp Immunol</source><volume>137</volume><issue>2</issue><year>2004</year><fpage>424</fpage><lpage>429</lpage><pub-id pub-id-type="pmid">15270862</pub-id></element-citation></ref><ref id="bib126"><label>126</label><element-citation publication-type="journal" id="ref0630"><person-group person-group-type="author"><name><surname>Pascutti</surname><given-names>M.F.</given-names></name><name><surname>Erkelens</surname><given-names>M.N.</given-names></name><name><surname>Nolte</surname><given-names>M.A.</given-names></name></person-group><article-title>Impact of viral infections on hematopoiesis: from beneficial to detrimental effects on Bone marrow output</article-title><source>Front Immunol</source><volume>7</volume><year>2016</year><fpage>364</fpage><pub-id pub-id-type="pmid">27695457</pub-id></element-citation></ref><ref id="bib127"><label>127</label><element-citation publication-type="journal" id="ref0635"><person-group person-group-type="author"><name><surname>Selvapandiyan</surname><given-names>A.</given-names></name><name><surname>Dey</surname><given-names>R.</given-names></name><name><surname>Gannavaram</surname><given-names>S.</given-names></name></person-group><article-title>Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites</article-title><source>J&#x000a0;Trop Med</source><volume>2012</volume><year>2012</year><fpage>631460</fpage><pub-id pub-id-type="pmid">21912560</pub-id></element-citation></ref><ref id="bib128"><label>128</label><element-citation publication-type="journal" id="ref0640"><person-group person-group-type="author"><name><surname>Desjeux</surname><given-names>P.</given-names></name></person-group><article-title>Leishmaniasis: current situation and new perspectives</article-title><source>Comp Immunol Microbiol Infect Dis</source><volume>27</volume><issue>5</issue><year>2004</year><fpage>305</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">15225981</pub-id></element-citation></ref><ref id="bib129"><label>129</label><element-citation publication-type="journal" id="ref0645"><person-group person-group-type="author"><name><surname>Chappuis</surname><given-names>F.</given-names></name><name><surname>Sundar</surname><given-names>S.</given-names></name><name><surname>Hailu</surname><given-names>A.</given-names></name></person-group><article-title>Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?</article-title><source>Nat Rev Microbiol</source><volume>5</volume><issue>11</issue><year>2007</year><fpage>873</fpage><lpage>882</lpage><pub-id pub-id-type="pmid">17938629</pub-id></element-citation></ref><ref id="bib130"><label>130</label><element-citation publication-type="journal" id="ref0650"><person-group person-group-type="author"><name><surname>Herwaldt</surname><given-names>B.L.</given-names></name></person-group><source>Leishmaniasis. Lancet</source><volume>354</volume><issue>9185</issue><year>1999</year><fpage>1191</fpage><lpage>1199</lpage><pub-id pub-id-type="pmid">10513726</pub-id></element-citation></ref><ref id="bib131"><label>131</label><element-citation publication-type="journal" id="ref0655"><person-group person-group-type="author"><name><surname>Kedzierski</surname><given-names>L.</given-names></name></person-group><article-title>Leishmaniasis vaccine: where are we today?</article-title><source>J&#x000a0;Glob Infect Dis</source><volume>2</volume><issue>2</issue><year>2010</year><fpage>177</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">20606974</pub-id></element-citation></ref><ref id="bib132"><label>132</label><element-citation publication-type="journal" id="ref0660"><person-group person-group-type="author"><name><surname>van Zandbergen</surname><given-names>G.</given-names></name><name><surname>Klinger</surname><given-names>M.</given-names></name><name><surname>Mueller</surname><given-names>A.</given-names></name></person-group><article-title>Cutting edge: neutrophil granulocyte serves as a vector for Leishmania entry into macrophages</article-title><source>J&#x000a0;Immunol</source><volume>173</volume><issue>11</issue><year>2004</year><fpage>6521</fpage><lpage>6525</lpage><pub-id pub-id-type="pmid">15557140</pub-id></element-citation></ref><ref id="bib133"><label>133</label><element-citation publication-type="journal" id="ref0665"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>N.C.</given-names></name><name><surname>Egen</surname><given-names>J.G.</given-names></name><name><surname>Secundino</surname><given-names>N.</given-names></name></person-group><article-title>In&#x000a0;vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies</article-title><source>Science</source><volume>321</volume><issue>5891</issue><year>2008</year><fpage>970</fpage><lpage>974</lpage><pub-id pub-id-type="pmid">18703742</pub-id></element-citation></ref><ref id="bib134"><label>134</label><element-citation publication-type="journal" id="ref0670"><person-group person-group-type="author"><name><surname>Chakraborty</surname><given-names>D.</given-names></name><name><surname>Banerjee</surname><given-names>S.</given-names></name><name><surname>Sen</surname><given-names>A.</given-names></name><name><surname>Banerjee</surname><given-names>K.K.</given-names></name><name><surname>Das</surname><given-names>P.</given-names></name><name><surname>Roy</surname><given-names>S.</given-names></name></person-group><article-title>Leishmania donovani affects antigen presentation of macrophage by disrupting lipid rafts</article-title><source>J&#x000a0;Immunol</source><volume>175</volume><issue>5</issue><year>2005</year><fpage>3214</fpage><lpage>3224</lpage><pub-id pub-id-type="pmid">16116212</pub-id></element-citation></ref><ref id="bib135"><label>135</label><element-citation publication-type="journal" id="ref0675"><person-group person-group-type="author"><name><surname>Bogdan</surname><given-names>C.</given-names></name><name><surname>R&#x000f6;llinghoff</surname><given-names>M.</given-names></name></person-group><article-title>The immune response to Leishmania: mechanisms of parasite control and evasion</article-title><source>Int J Parasitol</source><volume>28</volume><issue>1</issue><year>1998</year><fpage>121</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">9504340</pub-id></element-citation></ref><ref id="bib136"><label>136</label><element-citation publication-type="journal" id="ref0680"><person-group person-group-type="author"><name><surname>Bacellar</surname><given-names>O.</given-names></name><name><surname>Brodskyn</surname><given-names>C.</given-names></name><name><surname>Guerreiro</surname><given-names>J.</given-names></name></person-group><article-title>Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis</article-title><source>J&#x000a0;Infect Dis</source><volume>173</volume><issue>6</issue><year>1996</year><fpage>1515</fpage><lpage>1518</lpage><pub-id pub-id-type="pmid">8648233</pub-id></element-citation></ref><ref id="bib137"><label>137</label><element-citation publication-type="journal" id="ref0685"><person-group person-group-type="author"><name><surname>Bacellar</surname><given-names>O.</given-names></name><name><surname>D'oliveira</surname><given-names>A.</given-names></name><name><surname>Jer&#x000f4;nimo</surname><given-names>S.</given-names></name><name><surname>Carvalho</surname><given-names>E.M.</given-names></name></person-group><article-title>IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis</article-title><source>Cytokine</source><volume>12</volume><issue>8</issue><year>2000</year><fpage>1228</fpage><lpage>1231</lpage><pub-id pub-id-type="pmid">10930301</pub-id></element-citation></ref><ref id="bib138"><label>138</label><element-citation publication-type="journal" id="ref0690"><person-group person-group-type="author"><name><surname>Engwerda</surname><given-names>C.R.</given-names></name><name><surname>Murphy</surname><given-names>M.L.</given-names></name><name><surname>Cotterell</surname><given-names>S.E.</given-names></name><name><surname>Smelt</surname><given-names>S.C.</given-names></name><name><surname>Kaye</surname><given-names>P.M.</given-names></name></person-group><article-title>Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani</article-title><source>Eur J Immunol</source><volume>28</volume><issue>2</issue><year>1998</year><fpage>669</fpage><lpage>680</lpage><pub-id pub-id-type="pmid">9521077</pub-id></element-citation></ref><ref id="bib139"><label>139</label><element-citation publication-type="journal" id="ref0695"><person-group person-group-type="author"><name><surname>Ghalib</surname><given-names>H.W.</given-names></name><name><surname>Whittle</surname><given-names>J.A.</given-names></name><name><surname>Kubin</surname><given-names>M.</given-names></name></person-group><article-title>IL-12 enhances Th1-type responses in human Leishmania donovani infections</article-title><source>J&#x000a0;Immunol</source><volume>154</volume><issue>9</issue><year>1995</year><fpage>4623</fpage><lpage>4629</lpage><pub-id pub-id-type="pmid">7722314</pub-id></element-citation></ref><ref id="bib140"><label>140</label><element-citation publication-type="journal" id="ref0700"><person-group person-group-type="author"><name><surname>Selvapandiyan</surname><given-names>A.</given-names></name><name><surname>Duncan</surname><given-names>R.</given-names></name><name><surname>Debrabant</surname><given-names>A.</given-names></name></person-group><article-title>Genetically modified live attenuated parasites as vaccines for leishmaniasis</article-title><source>Indian J Med Res</source><volume>123</volume><issue>3</issue><year>2006</year><fpage>455</fpage><lpage>466</lpage><pub-id pub-id-type="pmid">16778323</pub-id></element-citation></ref><ref id="bib141"><label>141</label><element-citation publication-type="journal" id="ref0705"><person-group person-group-type="author"><name><surname>Alexander</surname><given-names>J.</given-names></name><name><surname>Bryson</surname><given-names>K.</given-names></name></person-group><article-title>T&#x000a0;helper (h)1/Th2 and Leishmania: paradox rather than paradigm</article-title><source>Immunol Lett</source><volume>99</volume><issue>1</issue><year>2005</year><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">15894106</pub-id></element-citation></ref><ref id="bib142"><label>142</label><element-citation publication-type="journal" id="ref0710"><person-group person-group-type="author"><name><surname>Nyl&#x000e9;n</surname><given-names>S.</given-names></name><name><surname>Sacks</surname><given-names>D.</given-names></name></person-group><article-title>Interleukin-10 and the pathogenesis of human visceral leishmaniasis</article-title><source>Trends Immunol</source><volume>28</volume><issue>9</issue><year>2007</year><fpage>378</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">17689290</pub-id></element-citation></ref><ref id="bib143"><label>143</label><element-citation publication-type="journal" id="ref0715"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>H.E.</given-names></name><name><surname>Tuladhar</surname><given-names>R.</given-names></name><name><surname>Satoskar</surname><given-names>A.R.</given-names></name></person-group><article-title>Cytokines and their STATs in cutaneous and visceral leishmaniasis</article-title><source>J&#x000a0;Biomed Biotechnol</source><volume>2010</volume><year>2010</year><fpage>294389</fpage><pub-id pub-id-type="pmid">20300429</pub-id></element-citation></ref><ref id="bib144"><label>144</label><element-citation publication-type="journal" id="ref0720"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>M.L.</given-names></name><name><surname>Wille</surname><given-names>U.</given-names></name><name><surname>Villegas</surname><given-names>E.N.</given-names></name><name><surname>Hunter</surname><given-names>C.A.</given-names></name><name><surname>Farrell</surname><given-names>J.P.</given-names></name></person-group><article-title>IL-10 mediates susceptibility to Leishmania donovani infection</article-title><source>Eur J Immunol</source><volume>31</volume><issue>10</issue><year>2001</year><fpage>2848</fpage><lpage>2856</lpage><pub-id pub-id-type="pmid">11592059</pub-id></element-citation></ref><ref id="bib145"><label>145</label><element-citation publication-type="journal" id="ref0725"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>H.W.</given-names></name><name><surname>Moreira</surname><given-names>A.L.</given-names></name><name><surname>Lu</surname><given-names>C.M.</given-names></name></person-group><article-title>Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis</article-title><source>J&#x000a0;Infect Dis</source><volume>188</volume><issue>3</issue><year>2003</year><fpage>458</fpage><lpage>464</lpage><pub-id pub-id-type="pmid">12870129</pub-id></element-citation></ref><ref id="bib146"><label>146</label><element-citation publication-type="journal" id="ref0730"><person-group person-group-type="author"><name><surname>Nyl&#x000e9;n</surname><given-names>S.</given-names></name><name><surname>Maurya</surname><given-names>R.</given-names></name><name><surname>Eidsmo</surname><given-names>L.</given-names></name><name><surname>Manandhar</surname><given-names>K.D.</given-names></name><name><surname>Sundar</surname><given-names>S.</given-names></name><name><surname>Sacks</surname><given-names>D.</given-names></name></person-group><article-title>Splenic accumulation of IL-10 mRNA in T&#x000a0;cells distinct from CD4+CD25+ (Foxp3) regulatory T&#x000a0;cells in human visceral leishmaniasis</article-title><source>J&#x000a0;Exp Med</source><volume>204</volume><issue>4</issue><year>2007</year><fpage>805</fpage><lpage>817</lpage><pub-id pub-id-type="pmid">17389235</pub-id></element-citation></ref><ref id="bib147"><label>147</label><element-citation publication-type="journal" id="ref0735"><person-group person-group-type="author"><name><surname>Kenney</surname><given-names>R.T.</given-names></name><name><surname>Sacks</surname><given-names>D.L.</given-names></name><name><surname>Gam</surname><given-names>A.A.</given-names></name><name><surname>Murray</surname><given-names>H.W.</given-names></name><name><surname>Sundar</surname><given-names>S.</given-names></name></person-group><article-title>Splenic cytokine responses in Indian kala-azar before and after treatment</article-title><source>J&#x000a0;Infect Dis</source><volume>177</volume><issue>3</issue><year>1998</year><fpage>815</fpage><lpage>818</lpage><pub-id pub-id-type="pmid">9498473</pub-id></element-citation></ref><ref id="bib148"><label>148</label><element-citation publication-type="journal" id="ref0740"><person-group person-group-type="author"><name><surname>Fiorentino</surname><given-names>D.F.</given-names></name><name><surname>Bond</surname><given-names>M.W.</given-names></name><name><surname>Mosmann</surname><given-names>T.R.</given-names></name></person-group><article-title>Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones</article-title><source>J&#x000a0;Exp Med</source><volume>170</volume><issue>6</issue><year>1989</year><comment>2081-95</comment></element-citation></ref><ref id="bib149"><label>149</label><element-citation publication-type="journal" id="ref0745"><person-group person-group-type="author"><name><surname>Mosmann</surname><given-names>T.R.</given-names></name><name><surname>Moore</surname><given-names>K.W.</given-names></name></person-group><article-title>The role of IL-10 in crossregulation of TH1 and TH2 responses</article-title><source>Immunol Today</source><volume>12</volume><issue>3</issue><year>1991</year><fpage>A49</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">1648926</pub-id></element-citation></ref><ref id="bib150"><label>150</label><element-citation publication-type="journal" id="ref0750"><person-group person-group-type="author"><name><surname>Bhattacharyya</surname><given-names>S.</given-names></name><name><surname>Ghosh</surname><given-names>S.</given-names></name><name><surname>Jhonson</surname><given-names>P.L.</given-names></name><name><surname>Bhattacharya</surname><given-names>S.K.</given-names></name><name><surname>Majumdar</surname><given-names>S.</given-names></name></person-group><article-title>Immunomodulatory role of interleukin-10 in visceral leishmaniasis: defective activation of protein kinase C-mediated signal transduction events</article-title><source>Infect Immun</source><volume>69</volume><issue>3</issue><year>2001</year><fpage>1499</fpage><lpage>1507</lpage><pub-id pub-id-type="pmid">11179319</pub-id></element-citation></ref><ref id="bib151"><label>151</label><element-citation publication-type="journal" id="ref0755"><person-group person-group-type="author"><name><surname>Vouldoukis</surname><given-names>I.</given-names></name><name><surname>B&#x000e9;cherel</surname><given-names>P.A.</given-names></name><name><surname>Riveros-Moreno</surname><given-names>V.</given-names></name></person-group><article-title>Interleukin-10 and interleukin-4 inhibit intracellular killing of Leishmania infantum and Leishmania major by human macrophages by decreasing nitric oxide generation</article-title><source>Eur J Immunol</source><volume>27</volume><issue>4</issue><year>1997</year><fpage>860</fpage><lpage>865</lpage><pub-id pub-id-type="pmid">9130636</pub-id></element-citation></ref><ref id="bib152"><label>152</label><element-citation publication-type="journal" id="ref0760"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>K.W.</given-names></name><name><surname>Vieira</surname><given-names>P.</given-names></name><name><surname>Fiorentino</surname><given-names>D.F.</given-names></name><name><surname>Trounstine</surname><given-names>M.L.</given-names></name><name><surname>Khan</surname><given-names>T.A.</given-names></name><name><surname>Mosmann</surname><given-names>T.R.</given-names></name></person-group><article-title>Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI</article-title><source>Science</source><volume>248</volume><issue>4960</issue><year>1990</year><fpage>1230</fpage><lpage>1234</lpage><pub-id pub-id-type="pmid">2161559</pub-id></element-citation></ref><ref id="bib153"><label>153</label><element-citation publication-type="journal" id="ref0765"><person-group person-group-type="author"><name><surname>Holaday</surname><given-names>B.J.</given-names></name><name><surname>Pompeu</surname><given-names>M.M.</given-names></name><name><surname>Jeronimo</surname><given-names>S.</given-names></name></person-group><article-title>Potential role for interleukin-10 in the immunosuppression associated with kala azar</article-title><source>J&#x000a0;Clin Investig</source><volume>92</volume><issue>6</issue><year>1993</year><fpage>2626</fpage><lpage>2632</lpage><pub-id pub-id-type="pmid">8254019</pub-id></element-citation></ref><ref id="bib154"><label>154</label><element-citation publication-type="journal" id="ref0770"><person-group person-group-type="author"><name><surname>Belkaid</surname><given-names>Y.</given-names></name><name><surname>Piccirillo</surname><given-names>C.A.</given-names></name><name><surname>Mendez</surname><given-names>S.</given-names></name><name><surname>Shevach</surname><given-names>E.M.</given-names></name><name><surname>Sacks</surname><given-names>D.L.</given-names></name></person-group><article-title>CD4+CD25+ regulatory T&#x000a0;cells control Leishmania major persistence and immunity</article-title><source>Nature</source><volume>420</volume><issue>6915</issue><year>2002</year><fpage>502</fpage><lpage>507</lpage><pub-id pub-id-type="pmid">12466842</pub-id></element-citation></ref><ref id="bib155"><label>155</label><element-citation publication-type="journal" id="ref0775"><person-group person-group-type="author"><name><surname>St&#x000e4;ger</surname><given-names>S.</given-names></name><name><surname>Maroof</surname><given-names>A.</given-names></name><name><surname>Zubairi</surname><given-names>S.</given-names></name><name><surname>Sanos</surname><given-names>S.L.</given-names></name><name><surname>Kopf</surname><given-names>M.</given-names></name><name><surname>Kaye</surname><given-names>P.M.</given-names></name></person-group><article-title>Distinct roles for IL-6 and IL-12p40 in mediating protection against Leishmania donovani and the expansion of IL-10+ CD4+ T&#x000a0;cells</article-title><source>Eur J Immunol</source><volume>36</volume><issue>7</issue><year>2006</year><fpage>1764</fpage><lpage>1771</lpage><pub-id pub-id-type="pmid">16791879</pub-id></element-citation></ref><ref id="bib156"><label>156</label><element-citation publication-type="journal" id="ref0780"><person-group person-group-type="author"><name><surname>Alexander</surname><given-names>J.</given-names></name><name><surname>Carter</surname><given-names>K.C.</given-names></name><name><surname>Al-Fasi</surname><given-names>N.</given-names></name><name><surname>Satoskar</surname><given-names>A.</given-names></name><name><surname>Brombacher</surname><given-names>F.</given-names></name></person-group><article-title>Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis</article-title><source>Eur J Immunol</source><volume>30</volume><issue>10</issue><year>2000</year><fpage>2935</fpage><lpage>2943</lpage><pub-id pub-id-type="pmid">11069076</pub-id></element-citation></ref><ref id="bib157"><label>157</label><element-citation publication-type="journal" id="ref0785"><person-group person-group-type="author"><name><surname>Dey</surname><given-names>R.</given-names></name><name><surname>Majumder</surname><given-names>N.</given-names></name><name><surname>Bhattacharyya Majumdar</surname><given-names>S.</given-names></name></person-group><article-title>Induction of host protective Th1 immune response by chemokines in Leishmania donovani-infected BALB/c mice</article-title><source>Scand J Immunol</source><volume>66</volume><issue>6</issue><year>2007</year><fpage>671</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">18021365</pub-id></element-citation></ref><ref id="bib158"><label>158</label><element-citation publication-type="journal" id="ref0790"><person-group person-group-type="author"><name><surname>Dey</surname><given-names>R.</given-names></name><name><surname>Khan</surname><given-names>S.</given-names></name><name><surname>Pahari</surname><given-names>S.</given-names></name><name><surname>Srivastava</surname><given-names>N.</given-names></name><name><surname>Jadhav</surname><given-names>M.</given-names></name><name><surname>Saha</surname><given-names>B.</given-names></name></person-group><article-title>Functional paradox in host-pathogen interaction dictates the fate of parasites</article-title><source>Future Microbiol</source><volume>2</volume><issue>4</issue><year>2007</year><fpage>425</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">17683278</pub-id></element-citation></ref><ref id="bib159"><label>159</label><element-citation publication-type="journal" id="ref0795"><person-group person-group-type="author"><name><surname>Selvapandiyan</surname><given-names>A.</given-names></name><name><surname>Dey</surname><given-names>R.</given-names></name><name><surname>Nylen</surname><given-names>S.</given-names></name><name><surname>Duncan</surname><given-names>R.</given-names></name><name><surname>Sacks</surname><given-names>D.</given-names></name><name><surname>Nakhasi</surname><given-names>H.L.</given-names></name></person-group><article-title>Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis</article-title><source>J&#x000a0;Immunol</source><volume>183</volume><issue>3</issue><year>2009</year><fpage>1813</fpage><lpage>1820</lpage><pub-id pub-id-type="pmid">19592661</pub-id></element-citation></ref><ref id="bib160"><label>160</label><element-citation publication-type="journal" id="ref0800"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>A.</given-names></name><name><surname>De</surname><given-names>M.</given-names></name><name><surname>Ali</surname><given-names>N.</given-names></name></person-group><article-title>Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T&#x000a0;cell responses</article-title><source>J&#x000a0;Immunol</source><volume>181</volume><issue>2</issue><year>2008</year><fpage>1386</fpage><lpage>1398</lpage><pub-id pub-id-type="pmid">18606693</pub-id></element-citation></ref><ref id="bib161"><label>161</label><element-citation publication-type="journal" id="ref0805"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>H.W.</given-names></name></person-group><article-title>Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis</article-title><source>J&#x000a0;Infect Dis</source><volume>175</volume><issue>6</issue><year>1997</year><fpage>1477</fpage><lpage>1479</lpage><pub-id pub-id-type="pmid">9180189</pub-id></element-citation></ref><ref id="bib162"><label>162</label><element-citation publication-type="journal" id="ref0810"><person-group person-group-type="author"><name><surname>Mege</surname><given-names>J.L.</given-names></name><name><surname>Meghari</surname><given-names>S.</given-names></name><name><surname>Honstettre</surname><given-names>A.</given-names></name><name><surname>Capo</surname><given-names>C.</given-names></name><name><surname>Raoult</surname><given-names>D.</given-names></name></person-group><article-title>The two faces of interleukin 10 in human infectious diseases</article-title><source>Lancet Infect Dis</source><volume>6</volume><issue>9</issue><year>2006</year><fpage>557</fpage><lpage>569</lpage><pub-id pub-id-type="pmid">16931407</pub-id></element-citation></ref><ref id="bib163"><label>163</label><element-citation publication-type="journal" id="ref0815"><person-group person-group-type="author"><name><surname>Jankovic</surname><given-names>D.</given-names></name><name><surname>Kullberg</surname><given-names>M.C.</given-names></name><name><surname>Feng</surname><given-names>C.G.</given-names></name></person-group><article-title>Conventional T-bet(+)Foxp3(-) Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection</article-title><source>J&#x000a0;Exp Med</source><volume>204</volume><issue>2</issue><year>2007</year><fpage>273</fpage><lpage>283</lpage><pub-id pub-id-type="pmid">17283209</pub-id></element-citation></ref><ref id="bib164"><label>164</label><element-citation publication-type="journal" id="ref0820"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>C.F.</given-names></name><name><surname>Oukka</surname><given-names>M.</given-names></name><name><surname>Kuchroo</surname><given-names>V.J.</given-names></name><name><surname>Sacks</surname><given-names>D.</given-names></name></person-group><article-title>CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis</article-title><source>J&#x000a0;Exp Med</source><volume>204</volume><issue>2</issue><year>2007</year><fpage>285</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">17283207</pub-id></element-citation></ref><ref id="bib165"><label>165</label><element-citation publication-type="journal" id="ref0825"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>H.W.</given-names></name><name><surname>Jungbluth</surname><given-names>A.</given-names></name><name><surname>Ritter</surname><given-names>E.</given-names></name><name><surname>Montelibano</surname><given-names>C.</given-names></name><name><surname>Marino</surname><given-names>M.W.</given-names></name></person-group><article-title>Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment</article-title><source>Infect Immun</source><volume>68</volume><issue>11</issue><year>2000</year><fpage>6289</fpage><lpage>6293</lpage><pub-id pub-id-type="pmid">11035737</pub-id></element-citation></ref><ref id="bib166"><label>166</label><element-citation publication-type="journal" id="ref0830"><person-group person-group-type="author"><name><surname>Tumang</surname><given-names>M.C.</given-names></name><name><surname>Keogh</surname><given-names>C.</given-names></name><name><surname>Moldawer</surname><given-names>L.L.</given-names></name></person-group><article-title>Role and effect of TNF-alpha in experimental visceral leishmaniasis</article-title><source>J&#x000a0;Immunol</source><volume>153</volume><issue>2</issue><year>1994</year><fpage>768</fpage><lpage>775</lpage><pub-id pub-id-type="pmid">8021511</pub-id></element-citation></ref><ref id="bib167"><label>167</label><element-citation publication-type="journal" id="ref0835"><person-group person-group-type="author"><name><surname>Liew</surname><given-names>F.Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Millott</surname><given-names>S.</given-names></name></person-group><article-title>Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide</article-title><source>J&#x000a0;Immunol</source><volume>145</volume><issue>12</issue><year>1990</year><fpage>4306</fpage><lpage>4310</lpage><pub-id pub-id-type="pmid">2175327</pub-id></element-citation></ref><ref id="bib168"><label>168</label><element-citation publication-type="journal" id="ref0840"><person-group person-group-type="author"><name><surname>Oghumu</surname><given-names>S.</given-names></name><name><surname>Lezama-D&#x000e1;vila</surname><given-names>C.M.</given-names></name><name><surname>Isaac-M&#x000e1;rquez</surname><given-names>A.P.</given-names></name><name><surname>Satoskar</surname><given-names>A.R.</given-names></name></person-group><article-title>Role of chemokines in regulation of immunity against leishmaniasis</article-title><source>Exp Parasitol</source><volume>126</volume><issue>3</issue><year>2010</year><fpage>389</fpage><lpage>396</lpage><pub-id pub-id-type="pmid">20206625</pub-id></element-citation></ref><ref id="bib169"><label>169</label><element-citation publication-type="journal" id="ref0845"><person-group person-group-type="author"><name><surname>Stanley</surname><given-names>A.C.</given-names></name><name><surname>Engwerda</surname><given-names>C.R.</given-names></name></person-group><article-title>Balancing immunity and pathology in visceral leishmaniasis</article-title><source>Immunol Cell Biol</source><volume>85</volume><issue>2</issue><year>2007</year><fpage>138</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">17146466</pub-id></element-citation></ref><ref id="bib170"><label>170</label><element-citation publication-type="journal" id="ref0850"><person-group person-group-type="author"><name><surname>Teixeira</surname><given-names>M.J.</given-names></name><name><surname>Teixeira</surname><given-names>C.R.</given-names></name><name><surname>Andrade</surname><given-names>B.B.</given-names></name><name><surname>Barral-Netto</surname><given-names>M.</given-names></name><name><surname>Barral</surname><given-names>A.</given-names></name></person-group><article-title>Chemokines in host-parasite interactions in leishmaniasis</article-title><source>Trends Parasitol</source><volume>22</volume><issue>1</issue><year>2006</year><fpage>32</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">16310413</pub-id></element-citation></ref><ref id="bib171"><label>171</label><element-citation publication-type="journal" id="ref0855"><person-group person-group-type="author"><name><surname>Pitta</surname><given-names>M.G.</given-names></name><name><surname>Romano</surname><given-names>A.</given-names></name><name><surname>Cabantous</surname><given-names>S.</given-names></name></person-group><article-title>IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani</article-title><source>J&#x000a0;Clin Investig</source><volume>119</volume><issue>8</issue><year>2009</year><fpage>2379</fpage><lpage>2387</lpage><pub-id pub-id-type="pmid">19620772</pub-id></element-citation></ref><ref id="bib172"><label>172</label><element-citation publication-type="journal" id="ref0860"><person-group person-group-type="author"><name><surname>Ruiz</surname><given-names>J.H.</given-names></name><name><surname>Becker</surname><given-names>I.</given-names></name></person-group><article-title>CD8 cytotoxic T&#x000a0;cells in cutaneous leishmaniasis</article-title><source>Parasite Immunol</source><volume>29</volume><issue>12</issue><year>2007</year><fpage>671</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">18042173</pub-id></element-citation></ref><ref id="bib173"><label>173</label><element-citation publication-type="journal" id="ref0865"><person-group person-group-type="author"><name><surname>Polley</surname><given-names>R.</given-names></name><name><surname>Stager</surname><given-names>S.</given-names></name><name><surname>Prickett</surname><given-names>S.</given-names></name></person-group><article-title>Adoptive immunotherapy against experimental visceral leishmaniasis with CD8+ T&#x000a0;cells requires the presence of cognate antigen</article-title><source>Infect Immun</source><volume>74</volume><issue>1</issue><year>2006</year><fpage>773</fpage><lpage>776</lpage><pub-id pub-id-type="pmid">16369038</pub-id></element-citation></ref><ref id="bib174"><label>174</label><element-citation publication-type="journal" id="ref0870"><person-group person-group-type="author"><name><surname>Squires</surname><given-names>K.E.</given-names></name><name><surname>Schreiber</surname><given-names>R.D.</given-names></name><name><surname>McElrath</surname><given-names>M.J.</given-names></name><name><surname>Rubin</surname><given-names>B.Y.</given-names></name><name><surname>Anderson</surname><given-names>S.L.</given-names></name><name><surname>Murray</surname><given-names>H.W.</given-names></name></person-group><article-title>Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response</article-title><source>J&#x000a0;Immunol</source><volume>143</volume><issue>12</issue><year>1989</year><fpage>4244</fpage><lpage>4249</lpage><pub-id pub-id-type="pmid">2512353</pub-id></element-citation></ref><ref id="bib175"><label>175</label><element-citation publication-type="journal" id="ref0875"><person-group person-group-type="author"><name><surname>St&#x000e4;ger</surname><given-names>S.</given-names></name><name><surname>Smith</surname><given-names>D.F.</given-names></name><name><surname>Kaye</surname><given-names>P.M.</given-names></name></person-group><article-title>Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis</article-title><source>J&#x000a0;Immunol</source><volume>165</volume><issue>12</issue><year>2000</year><fpage>7064</fpage><lpage>7071</lpage><pub-id pub-id-type="pmid">11120835</pub-id></element-citation></ref><ref id="bib176"><label>176</label><element-citation publication-type="journal" id="ref0880"><person-group person-group-type="author"><name><surname>Stern</surname><given-names>J.J.</given-names></name><name><surname>Oca</surname><given-names>M.J.</given-names></name><name><surname>Rubin</surname><given-names>B.Y.</given-names></name><name><surname>Anderson</surname><given-names>S.L.</given-names></name><name><surname>Murray</surname><given-names>H.W.</given-names></name></person-group><article-title>Role of L3T4+ and LyT-2+ cells in experimental visceral leishmaniasis</article-title><source>J&#x000a0;Immunol</source><volume>140</volume><issue>11</issue><year>1988</year><fpage>3971</fpage><lpage>3977</lpage><pub-id pub-id-type="pmid">3131421</pub-id></element-citation></ref><ref id="bib177"><label>177</label><element-citation publication-type="journal" id="ref0885"><person-group person-group-type="author"><name><surname>Ziaie</surname><given-names>H.</given-names></name><name><surname>Sadeghian</surname><given-names>G.</given-names></name></person-group><article-title>Isolation of bacteria causing secondary bacterial infection in the lesions of Cutaneous Leishmaniasis</article-title><source>Indian J Dermatol</source><volume>53</volume><issue>3</issue><year>2008</year><fpage>129</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">19882011</pub-id></element-citation></ref><ref id="bib178"><label>178</label><element-citation publication-type="journal" id="ref0890"><person-group person-group-type="author"><name><surname>Mendez</surname><given-names>S.</given-names></name><name><surname>Reckling</surname><given-names>S.K.</given-names></name><name><surname>Piccirillo</surname><given-names>C.A.</given-names></name><name><surname>Sacks</surname><given-names>D.</given-names></name><name><surname>Belkaid</surname><given-names>Y.</given-names></name></person-group><article-title>Role for CD4(+) CD25(+) regulatory T&#x000a0;cells in reactivation of persistent leishmaniasis and control of concomitant immunity</article-title><source>J&#x000a0;Exp Med</source><volume>200</volume><issue>2</issue><year>2004</year><fpage>201</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">15263027</pub-id></element-citation></ref><ref id="bib179"><label>179</label><element-citation publication-type="journal" id="ref0895"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>G.</given-names></name><name><surname>Shabani-Rad</surname><given-names>M.T.</given-names></name><name><surname>Vanderkooi</surname><given-names>O.G.</given-names></name></person-group><article-title>Leishmania in HLH: a rare finding with significant treatment implications</article-title><source>J&#x000a0;Pediatr Hematol Oncol</source><volume>35</volume><issue>3</issue><year>2013</year><fpage>e127</fpage><lpage>e129</lpage><pub-id pub-id-type="pmid">23511497</pub-id></element-citation></ref><ref id="bib180"><label>180</label><element-citation publication-type="journal" id="ref0900"><person-group person-group-type="author"><name><surname>Chandra</surname><given-names>H.</given-names></name><name><surname>Chandra</surname><given-names>S.</given-names></name></person-group><article-title>Case of hemophagocytic lymphohistiocytosis with leishmaniasis</article-title><source>Tropenmed Parasitol</source><volume>5</volume><issue>2</issue><year>2015</year><fpage>135</fpage><lpage>136</lpage></element-citation></ref><ref id="bib181"><label>181</label><element-citation publication-type="book" id="ref0905"><person-group person-group-type="author"><name><surname>Organization WH</surname></name></person-group><chapter-title>World malaria report : 2012</chapter-title><year>2012</year><comment>Switzerland</comment></element-citation></ref><ref id="bib182"><label>182</label><element-citation publication-type="journal" id="ref0910"><person-group person-group-type="author"><name><surname>Dessaint</surname><given-names>J.P.</given-names></name><name><surname>Capron</surname><given-names>A.</given-names></name></person-group><article-title>Immunodeficiencies in parasitic diseases</article-title><source>Immunodefic Rev</source><volume>1</volume><issue>4</issue><year>1989</year><fpage>311</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">2534348</pub-id></element-citation></ref><ref id="bib183"><label>183</label><element-citation publication-type="journal" id="ref0915"><person-group person-group-type="author"><name><surname>Mabey</surname><given-names>D.C.</given-names></name><name><surname>Brown</surname><given-names>A.</given-names></name><name><surname>Greenwood</surname><given-names>B.M.</given-names></name></person-group><article-title>Plasmodium falciparum malaria and Salmonella infections in Gambian children</article-title><source>J&#x000a0;Infect Dis</source><volume>155</volume><issue>6</issue><year>1987</year><fpage>1319</fpage><lpage>1321</lpage><pub-id pub-id-type="pmid">3553352</pub-id></element-citation></ref><ref id="bib184"><label>184</label><element-citation publication-type="journal" id="ref0920"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>I.F.</given-names></name></person-group><article-title>Herpes zoster in children following malaria</article-title><source>J&#x000a0;Trop Med Hyg</source><volume>88</volume><issue>4</issue><year>1985</year><fpage>261</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">3910848</pub-id></element-citation></ref><ref id="bib185"><label>185</label><element-citation publication-type="journal" id="ref0925"><person-group person-group-type="author"><name><surname>Thursz</surname><given-names>M.R.</given-names></name><name><surname>Kwiatkowski</surname><given-names>D.</given-names></name><name><surname>Torok</surname><given-names>M.E.</given-names></name></person-group><article-title>Association of hepatitis B surface antigen carriage with severe malaria in Gambian children</article-title><source>Nat Med</source><volume>1</volume><issue>4</issue><year>1995</year><fpage>374</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">7585070</pub-id></element-citation></ref><ref id="bib186"><label>186</label><element-citation publication-type="journal" id="ref0930"><person-group person-group-type="author"><name><surname>Bomford</surname><given-names>R.</given-names></name><name><surname>Wedderburn</surname><given-names>N.</given-names></name></person-group><article-title>Depression of immune response to Moloney leukaemia virus by malarial infection</article-title><source>Nature</source><volume>242</volume><issue>5398</issue><year>1973</year><fpage>471</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">4573475</pub-id></element-citation></ref><ref id="bib187"><label>187</label><element-citation publication-type="journal" id="ref0935"><person-group person-group-type="author"><name><surname>Moormann</surname><given-names>A.M.</given-names></name><name><surname>Chelimo</surname><given-names>K.</given-names></name><name><surname>Sumba</surname><given-names>O.P.</given-names></name></person-group><article-title>Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children</article-title><source>J&#x000a0;Infect Dis</source><volume>191</volume><issue>8</issue><year>2005</year><fpage>1233</fpage><lpage>1238</lpage><pub-id pub-id-type="pmid">15776368</pub-id></element-citation></ref><ref id="bib188"><label>188</label><element-citation publication-type="journal" id="ref0940"><person-group person-group-type="author"><name><surname>Williamson</surname><given-names>W.A.</given-names></name><name><surname>Greenwood</surname><given-names>B.M.</given-names></name></person-group><article-title>Impairment of the immune response to vaccination after acute malaria</article-title><source>Lancet</source><volume>1</volume><issue>8078</issue><year>1978</year><fpage>1328</fpage><lpage>1329</lpage><pub-id pub-id-type="pmid">78096</pub-id></element-citation></ref><ref id="bib189"><label>189</label><element-citation publication-type="journal" id="ref0945"><person-group person-group-type="author"><name><surname>Bru&#x000f1;a-Romero</surname><given-names>O.</given-names></name><name><surname>Rodriguez</surname><given-names>A.</given-names></name></person-group><article-title>Dendritic cells can initiate protective immune responses against malaria</article-title><source>Infect Immun</source><volume>69</volume><issue>8</issue><year>2001</year><fpage>5173</fpage><lpage>5176</lpage><pub-id pub-id-type="pmid">11447201</pub-id></element-citation></ref><ref id="bib190"><label>190</label><element-citation publication-type="journal" id="ref0950"><person-group person-group-type="author"><name><surname>Schwarzer</surname><given-names>E.</given-names></name><name><surname>Alessio</surname><given-names>M.</given-names></name><name><surname>Ulliers</surname><given-names>D.</given-names></name><name><surname>Arese</surname><given-names>P.</given-names></name></person-group><article-title>Phagocytosis of the malarial pigment, hemozoin, impairs expression of major histocompatibility complex class II antigen, CD54, and CD11c in human monocytes</article-title><source>Infect Immun</source><volume>66</volume><issue>4</issue><year>1998</year><fpage>1601</fpage><lpage>1606</lpage><pub-id pub-id-type="pmid">9529087</pub-id></element-citation></ref><ref id="bib191"><label>191</label><element-citation publication-type="journal" id="ref0955"><person-group person-group-type="author"><name><surname>Millington</surname><given-names>O.R.</given-names></name><name><surname>Di Lorenzo</surname><given-names>C.</given-names></name><name><surname>Phillips</surname><given-names>R.S.</given-names></name><name><surname>Garside</surname><given-names>P.</given-names></name><name><surname>Brewer</surname><given-names>J.M.</given-names></name></person-group><article-title>Suppression of adaptive immunity to heterologous antigens during Plasmodium infection through hemozoin-induced failure of dendritic cell function</article-title><source>J&#x000a0;Biol</source><volume>5</volume><issue>2</issue><year>2006</year><fpage>5</fpage><pub-id pub-id-type="pmid">16611373</pub-id></element-citation></ref><ref id="bib192"><label>192</label><element-citation publication-type="journal" id="ref0960"><person-group person-group-type="author"><name><surname>Millington</surname><given-names>O.R.</given-names></name><name><surname>Gibson</surname><given-names>V.B.</given-names></name><name><surname>Rush</surname><given-names>C.M.</given-names></name></person-group><article-title>Malaria impairs T&#x000a0;cell clustering and immune priming despite normal signal 1 from dendritic cells</article-title><source>PLoS Pathog</source><volume>3</volume><issue>10</issue><year>2007</year><fpage>1380</fpage><lpage>1387</lpage><pub-id pub-id-type="pmid">17937497</pub-id></element-citation></ref><ref id="bib193"><label>193</label><mixed-citation publication-type="other" id="ceotherref0015">Organization WH. WHO | Pertussis. 2011-06-21 08:24:01 2011. <ext-link ext-link-type="uri" xlink:href="http://www.who.int/immunization/topics/pertussis/en/index.html" id="interref4">http://www.who.int/immunization/topics/pertussis/en/index.html</ext-link>.</mixed-citation></ref><ref id="bib194"><label>194</label><element-citation publication-type="book" id="ref0965"><person-group person-group-type="author"><name><surname>CDC</surname></name></person-group><chapter-title>Cdc - pertussis: pertussis in other countries</chapter-title><year>2012</year></element-citation></ref><ref id="bib195"><label>195</label><element-citation publication-type="journal" id="ref0970"><person-group person-group-type="author"><name><surname>Carbonetti</surname><given-names>N.H.</given-names></name></person-group><article-title>Immunomodulation in the pathogenesis of Bordetella pertussis infection and</article-title><source>Curr Opin Pharmacol</source><volume>7</volume><issue>3</issue><year>2007</year><fpage>272</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">17418639</pub-id></element-citation></ref><ref id="bib196"><label>196</label><element-citation publication-type="journal" id="ref0975"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>J.A.</given-names></name><name><surname>Groathouse</surname><given-names>N.A.</given-names></name><name><surname>Boitano</surname><given-names>S.</given-names></name></person-group><article-title>Bordetella bronchiseptica adherence to cilia is mediated by multiple adhesin factors and blocked by surfactant protein A</article-title><source>Infect Immun</source><volume>73</volume><issue>6</issue><year>2005</year><fpage>3618</fpage><lpage>3626</lpage><pub-id pub-id-type="pmid">15908391</pub-id></element-citation></ref><ref id="bib197"><label>197</label><element-citation publication-type="journal" id="ref0980"><person-group person-group-type="author"><name><surname>Perez Vidakovics</surname><given-names>M.L.</given-names></name><name><surname>Lamberti</surname><given-names>Y.</given-names></name><name><surname>van der Pol</surname><given-names>W.L.</given-names></name><name><surname>Yantorno</surname><given-names>O.</given-names></name><name><surname>Rodriguez</surname><given-names>M.E.</given-names></name></person-group><article-title>Adenylate cyclase influences filamentous haemagglutinin-mediated attachment of Bordetella pertussis to epithelial alveolar cells</article-title><source>FEMS Immunol Med Microbiol</source><volume>48</volume><issue>1</issue><year>2006</year><fpage>140</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">16965362</pub-id></element-citation></ref><ref id="bib198"><label>198</label><element-citation publication-type="journal" id="ref0985"><person-group person-group-type="author"><name><surname>McGuirk</surname><given-names>P.</given-names></name><name><surname>McCann</surname><given-names>C.</given-names></name><name><surname>Mills</surname><given-names>K.H.</given-names></name></person-group><article-title>Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis</article-title><source>J&#x000a0;Exp Med</source><volume>195</volume><issue>2</issue><year>2002</year><fpage>221</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">11805149</pub-id></element-citation></ref><ref id="bib199"><label>199</label><element-citation publication-type="journal" id="ref0990"><person-group person-group-type="author"><name><surname>Mobberley-Schuman</surname><given-names>P.S.</given-names></name><name><surname>Connelly</surname><given-names>B.</given-names></name><name><surname>Weiss</surname><given-names>A.A.</given-names></name></person-group><article-title>Phagocytosis of Bordetella pertussis incubated with convalescent serum</article-title><source>J&#x000a0;Infect Dis</source><volume>187</volume><issue>10</issue><year>2003</year><fpage>1646</fpage><lpage>1653</lpage><pub-id pub-id-type="pmid">12721945</pub-id></element-citation></ref><ref id="bib200"><label>200</label><element-citation publication-type="journal" id="ref0995"><person-group person-group-type="author"><name><surname>Vojtova</surname><given-names>J.</given-names></name><name><surname>Kamanova</surname><given-names>J.</given-names></name><name><surname>Sebo</surname><given-names>P.</given-names></name></person-group><article-title>Bordetella adenylate cyclase toxin: a swift saboteur of host defense</article-title><source>Curr Opin Microbiol</source><volume>9</volume><issue>1</issue><year>2006</year><fpage>69</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">16406775</pub-id></element-citation></ref><ref id="bib201"><label>201</label><element-citation publication-type="journal" id="ref1000"><person-group person-group-type="author"><name><surname>Basler</surname><given-names>M.</given-names></name><name><surname>Masin</surname><given-names>J.</given-names></name><name><surname>Osicka</surname><given-names>R.</given-names></name><name><surname>Sebo</surname><given-names>P.</given-names></name></person-group><article-title>Pore-forming and enzymatic activities of Bordetella pertussis adenylate cyclase toxin synergize in promoting lysis of monocytes</article-title><source>Infect Immun</source><volume>74</volume><issue>4</issue><year>2006</year><fpage>2207</fpage><lpage>2214</lpage><pub-id pub-id-type="pmid">16552051</pub-id></element-citation></ref><ref id="bib202"><label>202</label><element-citation publication-type="journal" id="ref1005"><person-group person-group-type="author"><name><surname>Mobberley-Schuman</surname><given-names>P.S.</given-names></name><name><surname>Weiss</surname><given-names>A.A.</given-names></name></person-group><article-title>Influence of CR3 (CD11b/CD18) expression on phagocytosis of Bordetella pertussis by human neutrophils</article-title><source>Infect Immun</source><volume>73</volume><issue>11</issue><year>2005</year><fpage>7317</fpage><lpage>7323</lpage><pub-id pub-id-type="pmid">16239529</pub-id></element-citation></ref><ref id="bib203"><label>203</label><element-citation publication-type="journal" id="ref1010"><person-group person-group-type="author"><name><surname>Carbonetti</surname><given-names>N.H.</given-names></name><name><surname>Artamonova</surname><given-names>G.V.</given-names></name><name><surname>Andreasen</surname><given-names>C.</given-names></name><name><surname>Bushar</surname><given-names>N.</given-names></name></person-group><article-title>Pertussis toxin and adenylate cyclase toxin provide a one-two punch for establishment of Bordetella pertussis infection of the respiratory tract</article-title><source>Infect Immun</source><volume>73</volume><issue>5</issue><year>2005</year><fpage>2698</fpage><lpage>2703</lpage><pub-id pub-id-type="pmid">15845471</pub-id></element-citation></ref><ref id="bib204"><label>204</label><element-citation publication-type="journal" id="ref1015"><person-group person-group-type="author"><name><surname>Bagley</surname><given-names>K.C.</given-names></name><name><surname>Abdelwahab</surname><given-names>S.F.</given-names></name><name><surname>Tuskan</surname><given-names>R.G.</given-names></name><name><surname>Fouts</surname><given-names>T.R.</given-names></name><name><surname>Lewis</surname><given-names>G.K.</given-names></name></person-group><article-title>Pertussis toxin and the adenylate cyclase toxin from Bordetella pertussis activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cAMP-dependent pathway</article-title><source>J&#x000a0;Leukoc Biol</source><volume>72</volume><issue>5</issue><year>2002</year><fpage>962</fpage><lpage>969</lpage><pub-id pub-id-type="pmid">12429718</pub-id></element-citation></ref><ref id="bib205"><label>205</label><element-citation publication-type="journal" id="ref1020"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>P.J.</given-names></name><name><surname>Lavelle</surname><given-names>E.C.</given-names></name><name><surname>Mills</surname><given-names>K.H.</given-names></name><name><surname>Boyd</surname><given-names>A.P.</given-names></name></person-group><article-title>Adenylate cyclase toxin from Bordetella pertussis synergizes with lipopolysaccharide to promote innate interleukin-10 production and enhances the induction of Th2 and regulatory T&#x000a0;cells</article-title><source>Infect Immun</source><volume>72</volume><issue>3</issue><year>2004</year><fpage>1568</fpage><lpage>1579</lpage><pub-id pub-id-type="pmid">14977963</pub-id></element-citation></ref><ref id="bib206"><label>206</label><element-citation publication-type="journal" id="ref1025"><person-group person-group-type="author"><name><surname>Skinner</surname><given-names>J.A.</given-names></name><name><surname>Reissinger</surname><given-names>A.</given-names></name><name><surname>Shen</surname><given-names>H.</given-names></name><name><surname>Yuk</surname><given-names>M.H.</given-names></name></person-group><article-title>Bordetella type III secretion and adenylate cyclase toxin synergize to drive dendritic cells into a semimature state</article-title><source>J&#x000a0;Immunol</source><volume>173</volume><issue>3</issue><year>2004</year><comment>1934-40</comment></element-citation></ref><ref id="bib207"><label>207</label><element-citation publication-type="journal" id="ref1030"><person-group person-group-type="author"><name><surname>Flak</surname><given-names>T.A.</given-names></name><name><surname>Heiss</surname><given-names>L.N.</given-names></name><name><surname>Engle</surname><given-names>J.T.</given-names></name><name><surname>Goldman</surname><given-names>W.E.</given-names></name></person-group><article-title>Synergistic epithelial responses to endotoxin and a naturally occurring muramyl peptide</article-title><source>Infect Immun</source><volume>68</volume><issue>3</issue><year>2000</year><fpage>1235</fpage><lpage>1242</lpage><pub-id pub-id-type="pmid">10678932</pub-id></element-citation></ref><ref id="bib208"><label>208</label><element-citation publication-type="journal" id="ref1035"><person-group person-group-type="author"><name><surname>Cundell</surname><given-names>D.R.</given-names></name><name><surname>Kanthakumar</surname><given-names>K.</given-names></name><name><surname>Taylor</surname><given-names>G.W.</given-names></name></person-group><article-title>Effect of tracheal cytotoxin from Bordetella pertussis on human neutrophil function in&#x000a0;vitro</article-title><source>Infect Immun</source><volume>62</volume><issue>2</issue><year>1994</year><fpage>639</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">8300220</pub-id></element-citation></ref><ref id="bib209"><label>209</label><element-citation publication-type="journal" id="ref1040"><person-group person-group-type="author"><name><surname>Reisine</surname><given-names>T.</given-names></name></person-group><article-title>Pertussis toxin in the analysis of receptor mechanisms</article-title><source>Biochem Pharmacol</source><volume>39</volume><issue>10</issue><year>1990</year><fpage>1499</fpage><lpage>1504</lpage><pub-id pub-id-type="pmid">2159759</pub-id></element-citation></ref><ref id="bib210"><label>210</label><element-citation publication-type="journal" id="ref1045"><person-group person-group-type="author"><name><surname>Munoz</surname><given-names>J.J.</given-names></name><name><surname>Arai</surname><given-names>H.</given-names></name><name><surname>Bergman</surname><given-names>R.K.</given-names></name><name><surname>Sadowski</surname><given-names>P.L.</given-names></name></person-group><article-title>Biological activities of crystalline pertussigen from Bordetella pertussis</article-title><source>Infect Immun</source><volume>33</volume><issue>3</issue><year>1981</year><fpage>820</fpage><lpage>826</lpage><pub-id pub-id-type="pmid">6269999</pub-id></element-citation></ref><ref id="bib211"><label>211</label><element-citation publication-type="journal" id="ref1050"><person-group person-group-type="author"><name><surname>Kirimanjeswara</surname><given-names>G.S.</given-names></name><name><surname>Agosto</surname><given-names>L.M.</given-names></name><name><surname>Kennett</surname><given-names>M.J.</given-names></name><name><surname>Bjornstad</surname><given-names>O.N.</given-names></name><name><surname>Harvill</surname><given-names>E.T.</given-names></name></person-group><article-title>Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis</article-title><source>J&#x000a0;Clin Investig</source><volume>115</volume><issue>12</issue><year>2005</year><fpage>3594</fpage><lpage>3601</lpage><pub-id pub-id-type="pmid">16294220</pub-id></element-citation></ref><ref id="bib212"><label>212</label><element-citation publication-type="journal" id="ref1055"><person-group person-group-type="author"><name><surname>Carbonetti</surname><given-names>N.H.</given-names></name><name><surname>Artamonova</surname><given-names>G.V.</given-names></name><name><surname>Mays</surname><given-names>R.M.</given-names></name><name><surname>Worthington</surname><given-names>Z.E.</given-names></name></person-group><article-title>Pertussis toxin plays an early role in respiratory tract colonization by</article-title><source>Infect Immun</source><volume>71</volume><issue>11</issue><year>2003</year><fpage>6358</fpage><lpage>6366</lpage><pub-id pub-id-type="pmid">14573656</pub-id></element-citation></ref><ref id="bib213"><label>213</label><element-citation publication-type="journal" id="ref1060"><person-group person-group-type="author"><name><surname>Van Rooijen</surname><given-names>N.</given-names></name><name><surname>Sanders</surname><given-names>A.</given-names></name></person-group><article-title>Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications</article-title><source>J&#x000a0;Immunol Methods</source><volume>174</volume><issue>1&#x02013;2</issue><year>1994</year><fpage>83</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">8083541</pub-id></element-citation></ref><ref id="bib214"><label>214</label><element-citation publication-type="journal" id="ref1065"><person-group person-group-type="author"><name><surname>Carbonetti</surname><given-names>N.H.</given-names></name><name><surname>Artamonova</surname><given-names>G.V.</given-names></name><name><surname>Van Rooijen</surname><given-names>N.</given-names></name><name><surname>Ayala</surname><given-names>V.I.</given-names></name></person-group><article-title>Pertussis toxin targets airway macrophages to promote Bordetella pertussis infection of the respiratory tract</article-title><source>Infect Immun</source><volume>75</volume><issue>4</issue><year>2007</year><fpage>1713</fpage><lpage>1720</lpage><pub-id pub-id-type="pmid">17242062</pub-id></element-citation></ref><ref id="bib215"><label>215</label><element-citation publication-type="journal" id="ref1070"><person-group person-group-type="author"><name><surname>Carbonetti</surname><given-names>N.H.</given-names></name><name><surname>Artamonova</surname><given-names>G.V.</given-names></name><name><surname>Andreasen</surname><given-names>C.</given-names></name><name><surname>Dudley</surname><given-names>E.</given-names></name><name><surname>Mays</surname><given-names>R.M.</given-names></name><name><surname>Worthington</surname><given-names>Z.E.</given-names></name></person-group><article-title>Suppression of serum antibody responses by pertussis toxin after respiratory tract colonization by Bordetella pertussis and identification of an immunodominant lipoprotein</article-title><source>Infect Immun</source><volume>72</volume><issue>6</issue><year>2004</year><fpage>3350</fpage><lpage>3358</lpage><pub-id pub-id-type="pmid">15155640</pub-id></element-citation></ref><ref id="bib216"><label>216</label><element-citation publication-type="journal" id="ref1075"><person-group person-group-type="author"><name><surname>Mielcarek</surname><given-names>N.</given-names></name><name><surname>Riveau</surname><given-names>G.</given-names></name><name><surname>Remou&#x000e9;</surname><given-names>F.</given-names></name><name><surname>Antoine</surname><given-names>R.</given-names></name><name><surname>Capron</surname><given-names>A.</given-names></name><name><surname>Locht</surname><given-names>C.</given-names></name></person-group><article-title>Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis</article-title><source>Nat Biotechnol</source><volume>16</volume><issue>5</issue><year>1998</year><fpage>454</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">9592394</pub-id></element-citation></ref><ref id="bib217"><label>217</label><element-citation publication-type="journal" id="ref1080"><person-group person-group-type="author"><name><surname>Shumilla</surname><given-names>J.A.</given-names></name><name><surname>Lacaille</surname><given-names>V.</given-names></name><name><surname>Hornell</surname><given-names>T.M.</given-names></name></person-group><article-title>Bordetella pertussis infection of primary human monocytes alters HLA-DR</article-title><source>Infect Immun</source><volume>72</volume><issue>3</issue><year>2004</year><fpage>1450</fpage><lpage>1462</lpage><pub-id pub-id-type="pmid">14977950</pub-id></element-citation></ref><ref id="bib218"><label>218</label><element-citation publication-type="journal" id="ref1085"><person-group person-group-type="author"><name><surname>Martino</surname><given-names>A.</given-names></name><name><surname>Volpe</surname><given-names>E.</given-names></name><name><surname>Auricchio</surname><given-names>G.</given-names></name><name><surname>Colizzi</surname><given-names>V.</given-names></name><name><surname>Baldini</surname><given-names>P.M.</given-names></name></person-group><article-title>Influence of pertussis toxin on CD1a isoform expression in human dendritic cells</article-title><source>J&#x000a0;Clin Immunol</source><volume>26</volume><issue>2</issue><year>2006</year><fpage>153</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">16598657</pub-id></element-citation></ref><ref id="bib219"><label>219</label><element-citation publication-type="journal" id="ref1090"><person-group person-group-type="author"><name><surname>Akira</surname><given-names>S.</given-names></name></person-group><article-title>TLR signaling</article-title><source>Curr Top Microbiol Immunol</source><volume>311</volume><year>2006</year><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">17048703</pub-id></element-citation></ref><ref id="bib220"><label>220</label><element-citation publication-type="journal" id="ref1095"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>S.C.</given-names></name><name><surname>Lavelle</surname><given-names>E.C.</given-names></name><name><surname>McCann</surname><given-names>C.</given-names></name></person-group><article-title>Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T&#x000a0;cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology</article-title><source>J&#x000a0;Immunol</source><volume>171</volume><issue>6</issue><year>2003</year><fpage>3119</fpage><lpage>3127</lpage><pub-id pub-id-type="pmid">12960338</pub-id></element-citation></ref><ref id="bib221"><label>221</label><element-citation publication-type="journal" id="ref1100"><person-group person-group-type="author"><name><surname>Banus</surname><given-names>H.A.</given-names></name><name><surname>Vandebriel</surname><given-names>R.J.</given-names></name><name><surname>de Ruiter</surname><given-names>H.</given-names></name></person-group><article-title>Host genetics of Bordetella pertussis infection in mice: significance of Toll-like receptor 4 in genetic susceptibility and pathobiology</article-title><source>Infect Immun</source><volume>74</volume><issue>5</issue><year>2006</year><fpage>2596</fpage><lpage>2605</lpage><pub-id pub-id-type="pmid">16622195</pub-id></element-citation></ref><ref id="bib222"><label>222</label><element-citation publication-type="journal" id="ref1105"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>P.B.</given-names></name><name><surname>Wolfe</surname><given-names>D.</given-names></name><name><surname>Latz</surname><given-names>E.</given-names></name><name><surname>Golenbock</surname><given-names>D.</given-names></name><name><surname>Preston</surname><given-names>A.</given-names></name><name><surname>Harvill</surname><given-names>E.T.</given-names></name></person-group><article-title>Comparative toll-like receptor 4-mediated innate host defense to Bordetella infection</article-title><source>Infect Immun</source><volume>73</volume><issue>12</issue><year>2005</year><fpage>8144</fpage><lpage>8152</lpage><pub-id pub-id-type="pmid">16299309</pub-id></element-citation></ref><ref id="bib223"><label>223</label><element-citation publication-type="book" id="ref1110"><person-group person-group-type="author"><name><surname>CDC</surname></name></person-group><chapter-title>Pertussis</chapter-title><year>2013</year><ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/pert.pdf" id="interref5">http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/pert.pdf</ext-link></element-citation></ref><ref id="bib224"><label>224</label><element-citation publication-type="journal" id="ref1115"><person-group person-group-type="author"><name><surname>Teijaro</surname><given-names>J.R.</given-names></name></person-group><article-title>Cytokine storms in infectious diseases</article-title><source>Semin Immunopathol</source><volume>39</volume><issue>5</issue><year>2017</year><fpage>501</fpage><lpage>503</lpage><pub-id pub-id-type="pmid">28674818</pub-id></element-citation></ref><ref id="bib225"><label>225</label><element-citation publication-type="journal" id="ref1120"><person-group person-group-type="author"><name><surname>Channappanavar</surname><given-names>R.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name></person-group><article-title>Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology</article-title><source>Semin Immunopathol</source><volume>39</volume><issue>5</issue><year>2017</year><fpage>529</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">28466096</pub-id></element-citation></ref><ref id="bib226"><label>226</label><element-citation publication-type="journal" id="ref1125"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>X.J.</given-names></name><name><surname>Thomas</surname><given-names>P.G.</given-names></name></person-group><article-title>New fronts emerge in the influenza cytokine storm</article-title><source>Semin Immunopathol</source><volume>39</volume><issue>5</issue><year>2017</year><fpage>541</fpage><lpage>550</lpage><pub-id pub-id-type="pmid">28555383</pub-id></element-citation></ref><ref id="bib227"><label>227</label><element-citation publication-type="journal" id="ref1130"><person-group person-group-type="author"><name><surname>Basler</surname><given-names>C.F.</given-names></name></person-group><article-title>Molecular pathogenesis of viral hemorrhagic fever</article-title><source>Semin Immunopathol</source><volume>39</volume><issue>5</issue><year>2017</year><fpage>551</fpage><lpage>561</lpage><pub-id pub-id-type="pmid">28555386</pub-id></element-citation></ref><ref id="bib228"><label>228</label><element-citation publication-type="journal" id="ref1135"><person-group person-group-type="author"><name><surname>Srikiatkhachorn</surname><given-names>A.</given-names></name><name><surname>Mathew</surname><given-names>A.</given-names></name><name><surname>Rothman</surname><given-names>A.L.</given-names></name></person-group><article-title>Immune-mediated cytokine storm and its role in severe dengue</article-title><source>Semin Immunopathol</source><volume>39</volume><issue>5</issue><year>2017</year><fpage>563</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">28401256</pub-id></element-citation></ref><ref id="bib229"><label>229</label><element-citation publication-type="journal" id="ref1140"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W.H.</given-names></name><name><surname>Erazo</surname><given-names>E.M.</given-names></name><name><surname>Ishcol</surname><given-names>M.R.C.</given-names></name></person-group><article-title>Virus-induced pathogenesis, vaccine development, and diagnosis of novel H7N9 avian influenza A virus in humans: a systemic literature review</article-title><source>J&#x000a0;Int Med Res</source><year>2019</year><pub-id pub-id-type="doi">10.1177/0300060519845488</pub-id></element-citation></ref><ref id="bib230"><label>230</label><element-citation publication-type="journal" id="ref1145"><person-group person-group-type="author"><name><surname>Garanina</surname><given-names>E.</given-names></name><name><surname>Martynova</surname><given-names>E.</given-names></name><name><surname>Davidyuk</surname><given-names>Y.</given-names></name></person-group><article-title>Cytokine storm combined with humoral immune response defect in fatal hemorrhagic fever with renal syndrome case, tatarstan, Russia</article-title><source>Viruses</source><volume>11</volume><issue>7</issue><year>2019</year></element-citation></ref><ref id="bib231"><label>231</label><element-citation publication-type="journal" id="ref1150"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>A.</given-names></name><name><surname>Rahman</surname><given-names>T.</given-names></name><name><surname>Bartiss</surname><given-names>R.</given-names></name></person-group><article-title>Lipoxin A4, a 5-lipoxygenase pathway metabolite, modulates immune response during acute respiratory tularemia</article-title><source>J&#x000a0;Leukoc Biol</source><volume>101</volume><issue>2</issue><year>2017</year><fpage>531</fpage><lpage>542</lpage><pub-id pub-id-type="pmid">27630217</pub-id></element-citation></ref><ref id="bib232"><label>232</label><element-citation publication-type="journal" id="ref1155"><person-group person-group-type="author"><name><surname>Rikihisa</surname><given-names>Y.</given-names></name></person-group><article-title>Molecular pathogenesis of Ehrlichia chaffeensis infection</article-title><source>Annu Rev Microbiol</source><volume>69</volume><year>2015</year><fpage>283</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">26488275</pub-id></element-citation></ref><ref id="bib233"><label>233</label><element-citation publication-type="journal" id="ref1160"><person-group person-group-type="author"><name><surname>Santos-Oliveira</surname><given-names>J.R.</given-names></name><name><surname>Regis</surname><given-names>E.G.</given-names></name><name><surname>Leal</surname><given-names>C.R.</given-names></name><name><surname>Cunha</surname><given-names>R.V.</given-names></name><name><surname>Bozza</surname><given-names>P.T.</given-names></name><name><surname>Da-Cruz</surname><given-names>A.M.</given-names></name></person-group><article-title>Evidence that lipopolisaccharide may contribute to the cytokine storm and cellular activation in patients with visceral leishmaniasis</article-title><source>PLoS Neglected Trop Dis</source><volume>5</volume><issue>7</issue><year>2011</year><fpage>e1198</fpage></element-citation></ref></ref-list></back></article>